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Cardiac Tissue Regeneration; The Use of Stem Cells
Chavy Friedlander
1. Introduction
Cardiovascular disease is the leading cause of illness and fatality. Diseases such as
coronary artery disease, myocardial infarction and subsequent congestive heart failure pose a
serious problem to much of the population in the Unites States and all over the world. The
heart’s compromised function that results from the above conditions is so influential as the heart
has little capacity to repair its lost tissue; once the cardiac myocytes are destroyed its effects are
amplified by a drastic decrease in cardiac function.
Until recently with the advent of stem cell technology, researchers believed that once
cardiac myocytes are destroyed they could never be regenerated and thus little could be done to
reverse the adverse effects of cardiac muscle atrophy (Laflamme and Murry 2005). This dogma,
that the heart is a post mitotic non-regenerating organ and that cardiac myocytes are terminally
differentiated cells that participate in cardiac function all throughout life, introduced more than
60 years ago, is being challenged as the results of different experimental and clinical work are
showing capacity for cardiac tissue hyperplasia This paper will explore the various kinds of stem
cells used in an attempt to regenerate cardiac tissue.
2. Stem Cells

Stem Cells are self renewing cells that characteristically can differentiate into other types
of cells. Hematopoietic stem cells, adipose-derived stem cells, muscle-derived stem cells, cardiac
stem cells and embryonic stem cells are some kinds of stem cells currently being studied in their
use as cellular therapy for myocardial regeneration.
A. Hematopoietic Stem Cells

Hematopoietic stem cells (HSCs) are bone marrow derived stem cells. These cells have
been the target of tissue engineering and cellular therapy as they are self renewing cells that can
differentiate into multiple cell lineages (Wu et al 2006). HSCs exhibit great potential in
developing into cardiomyocyte-like cells as blood and cardiac tissues originate in adjacent areas
in embryonic development. In early development, blood cells originate in the mesoderm: the
hematopoietic precursor cells accumulate in the blood until it finally reaches the bone marrow.
The heart muscle is generated within the anterior lateral mesoderm. Originating from adjacent
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regions of the mesoderm in the developing embryo is what contributes to these stem cells
potency (Leri et al 2005).
Clinical work with the importation of bone marrow cells to the infarcted heart to
regenerate cardiac cells has yielded varying results. Orlic and colleagues (2001a) transplanted
bone marrow cells into the infarcted hearts of mice to see if the dead myocardium would be
restored. The researchers sorted Lineage -, ckit+ bone marrow cells from mice and implanted
them into the contracting wall bordering the infarct shortly after coronary ligation. Indeed the
Lineage-, ckit+ cells differentiated into myocytes and formed vascular structures occupying 68%
of the infarcted portion of the ventricle nine days after transplantation.
Similar to Orlic, Balsam et al (2004) also studied the effects of implanting Lineage - c
kit+ hematopoietic stem cells expressing green fluorescent protein (GFP+), isolated from mice
into the ischameic myocardium of wild type mice. Abundant GFP+ cells were detected in the
myocardium ten days after the implantation, but by 30 days post implantation few GFP+ cells
were detected. Balsam’s work suggests that the HSCs remain in the infarcted region of the heart
for a limited amount of time. Unlike Orlic’s findings, Balsam discovered that the GFP+ cells did
not express cardiac tissue specific markers, but rather, most of them expressed the hematopoietic
specific cell marker CD45, indicating that these cells never differentiated into cardiomyoctes.
Murry et al (2004), in his work tracked the fate of hematopoietic stem cells with 145 HSC
transplants into normal and injured adult mouse hearts and found that transdifferentiation into
cardiomyocytes was undetectable.
Researchers have also been investigating the mechanism for the therapeutic effects of
HSC transplantation – primarily via the paracrine and cytokine signaling. Korf-Klingebiel et al‘s
(2008) work with bone marrow stem cells sheds lights on the paracrine signaling between
transplanted bone marrow stem cells and resident cardiomyocytes in the hosts’s cardiac tissue. In
their experiment, this research group shows that HSCs secrete proangiogenic, cytoprotective
growth factors and cytokines thus promoting angiogenesis and cardiomyocyte survival via
paracrine effects. Orlic et al on a search to find a noninvasive method implementing HSCs, to
recover the injured heart found that transdifferentiation of primitive bone marrow stem cells is
dependent on tissue damage and the level of pluripotent cells. He suggests that HSCs, mobilized
by stem cell factor and granulocyte-colony stimulating factor, would home to the infarcted
region, replicate, differentiate and promote myocardial repair. In his experiment, cytokine
mediated translocation of bone marrow stem cells resulted in a significant degree of tissue
regeneration. Cytokine induced cardiac repair decreased mortality by 68%, infarct size by 40%
and diastolic stress by 70%. Cardiac ejection fraction also increased as the consequences of the
formation of new myocytes with arterioles and capillaries connected with the circulation of the
unaffected ventricles (2001- b).
Jackson et al (2001) tested a side population of CD34- bone marrow stem cells for their
capacity to regenerate cardiac myofibrils in ischemically injured cardiac tissue. In his study, the
side population cells and their progeny became incorporated into both cardiac muscle and vessel
structures where they displayed the characteristics of differentiated cardiomyocytes, suggesting
that the stem cells do differentiate into cardiomyocytes. While Jackson’s study seems interesting,
it cannot be taken as evidence that hematopoietic stem cells take on the cardiac cell phenotype
after engraftment as his method used for isolating the side population CD34- bone marrow cells
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appears to be lacking and thus there is much possibility that contaminating non hematopoietic
stem cells in his experiment is what contributed to the cardiac cell engraftment.
The findings of Orlic and his counterparts have motivated researchers to investigate the
effects of HSC injections in the post infarcted human heart. Several clinical trials have explored
the hypothesis that an intracoronary infusion of these bona marrow cells may enhance recovery
of Left Ventricular (LV) systolic function following Acute Myocardial Infarction (AMI). Meyer
et al (2006) studied the specific effects of bone marrow cells on the recovery of left ventricular
(LV) function in patients after AMI. His group learned that hematopoietic bone marrow cells did
not significantly increase the long term systolic ventricular function of the post infarcted heart.
He administered a single dose of HSCs to 30 of 60 patients undergoing post infarction therapy.
In the control group LV ejection fraction increased by .7- 3.1 percentage points after 6 and 18
month respectively; LV ejection fraction in the bone marrow cell transfer group increased by 6.7
and 5.9 percentage points. Meyer noted that the difference in LV ejection fraction improvement
was significant after six months but not after 18 months. While the single dose of HSCs did not
provide long term benefit to left ventricular systolic function, the accelerated ejection fraction
recovery rate after AMI due to HSC therapy was beneficial to the patient recovery.
Schaninger et al (2006) has obtained similar results to Meyer’s in his clinical work. His
group found that the recovery of left ventricular systolic function in patients after AMI is
enhanced by an infusion of bone marrow stem cells into the reperfused coronary artery. Clinical
data obtained by Janssen et al (2006), in their controlled experiment of 67 patients, indicate that
HSC transfer when applied early after coronary reperfusion may lead to a reduction in infarct
size and a better recovery of regional systolic function. Other studies, however, indicate that
improvement in left ventricular function after intracoronary injection of bone marrow cells in the
AMI is not seen (Lunde et al 2006).
Although the ability for hematopoietic stem cells to differentiate into cardiomyocytes is
debated by different researchers, the use of these stem cells for myocardial regeneration
nevertheless seems promising. Varying results have been obtained when injecting HSCs into the
hearts of humans, yet most studies indicated a short term improvement in systolic function post
cardiac trauma. The mechanism for these stem cells, primarily through a cytokine/paracrine
signaling pathway can have great implications in the world of non invasive stem cell therapy.
B. Adipose- derived stem cells
These stem cells, derived from mammalian adipose tissue, recently displayed their ability
to differentiate in to multiple lineages. In 2001, investigators from UCLA and University of
Pittsburg demonstrated that a population of cells derived from collagenase digested human
adipose tissue could be induced into multiple cell lineages including cardiomyocyte lineage (Zuk
et al 2001). The ease of access to fat and its abundance makes adipose tissue a potentially useful
source of stem cells for cardiac tissue regeneration.
Interestingly, adipose -derived stem cells exhibit close associations with bone marrow derived stem cells. The cell surface phenotype of adipose -derived stem cells is almost identical
to that of bone marrow -derived stem cells and thus their patterns of differentiation should
seemingly be similar, yet the data of Winter et al (2003) suggests that in vitro differentiation of
adipose- derived stem cells in mice is less than observed in bone marrow derived stem cells.
According to these findings, the rate of differentiation of adipose- derived stem cells is much
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slower than in hematopoietic stem cells. In absolute incongruity to these finding, a comparative
study of marrow and adipose derived cells obtained from the same donors, performed by De
Ugarte et al (2003) demonstrates that the adipose derived cells require approximately 5% the cell
number used for marrow cells in order to reach initial confluence by one week. De Ugarte’s
work suggests that the proliferative capacity for adipose derived stem cells far exceeds that of
hematopoietic stem cells. Their seemingly high proliferative capacity and their similarities to
bone marrow derived stem cells signify the potential for adipose tissue to act as an alternate,
perhaps preferred cell source for clinical application.
To date there hasn’t been much clinical work in the area of using adipose derived stem
cells to regenerate myocardium in vivo, yet some studies on the cardiomyocyte differentiation
capacity for adipose derived stem cells have been published. Planat-Benard et al (2004)
investigated the emergence of cardiomycyte phenotype from adipose derived cells and found that
beating cells with cardiomyocyte features were identified after culture of the adipose cells. The
cardiomycoyte phenotype was identified with expression of specific cardiac markers,
immunocytochemistry staining, and ultrastructural anaylsis. The early culture also displayed a
pacemaker activity in the cells. This study is important as it shows that functional
cardiomyocyte-like cells could be directly obtained from adipose tissue. The potential for
adipose tissue to function as a reservoir of stem cells that can differentiate into cardiomyocytelike cells must further be investigated.
C. Skeletal muscle- derived stem cells

Skeletal muscle derived stem cells, also known as myoblast or satellite cells are being
investigated in their potential to enhance cardiac function post acute myocardial infarction(AMI).
These cells that lie under the basal membrane of skeletal muscle fibers, seem promising in the
area of cell based therapy due to their preclinical efficacy, availability, ability to be amplified in
vitro and their relatively good survival after implantation (Menasche et al 2003). Unlike other
stem cells, satellite cells retain their specific characteristics and do not transdifferentiate into
cardiomyocyte cells when transplanted into cardiac tissue (Reineke et al 1999). Still the
myoblast’s inherent contractile ability can be a great asset in improving the contractile capacity
of scar tissue formed after cardiac injury. Several groups of researchers have investigated the
effects of muscle derived stem cells injected into a post injury cardiac scar.
Murry et al (1996) tested the functionality of skeletal myoblasts in injured cardiac tissue
via the injection of neonatal skeletal muscle cells into the the hearts of rats directly after coronary
injury. At day three after implantation, myotubes expressing fast fiber, easily fatiguable MHCs
were present in the injected cells. By week seven, the grafts began to express beta MHCs – a
hallmark of the fatigue resistant, slow fiber phenotype. This continued until three months, yet all
the while the grafts never expressed cardiomyocyte specific alpha MHCs. Murry reports that
even though the grafts did not express a cardiomyocyte phenotype, they were able to contract;
upon stimulation ex vivo; wounds containing two week old myoblast grafts contracted. Further,
the myoblast grafts could perform a cardiac duty like cycle for six minutes, alternating between
relaxation and contraction. Murry’s experiment on how myoblast grafts convert to fatigue
resistant slow twitch mature myofibrils are one of many such studies and supports the idea that
fully developed myofibrils within the cardiac infarct retain their skeletal lineage and do not
differentiate into cardiac cells with intercalated discs and other cardiac features.
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Taylor et al (1998), in their study found that skeletal myoblasts can differentiate into
striated muscle cells within damaged myocardium and these cells augment both systolic and
diastolic myocardial performance after transplantation in the damaged myocardium. Taylor’s
group transplanted skeletal myoblasts into the infarcted myocardium of rabbits, monitored
cardiac function in vivo for two to six weeks and examined serial sections of the hearts by light
and electron microscopy. Islands of different sizes comprising elongated, striated cells that
retained characteristics of both skeletal and cardiac cells were found in the cardiac infarct.
Taylor’s findings support Murry’s claim that the skeletal muscle stem cells retain their skeletal
muscle lineage. His study further indicates that in rabbits in which myoblasts were incorporated,
myocardial performance was improved.
Similar to Taylor et al, Ghostine et al (2002) studied the effect of skeletal myoblast
transplantation on a scar in the infarcted heart of a sheep. Ghostine’s group injected myoblasts
into the scar and studied subsequent cardiac function at 4 months and 12 months after the
injection. His findings show that for up to one year the skeletal myoblast implantation limits post
infarction ejection fraction deterioration, and improves systolic scar function by colonization of
skeletal muscle cells in the fibrotic tissue. Although Ghostine’s results are promising, they can‘t
be validated as this clinical trial involves only one sheep and thus the indicated improvement in
cardiac function can stem from various different sources. The true relationship between the
skeletal myoblast transfer and greater ejection fraction must be further investigated.
The question of whether skeletal muscles beat in vivo in humans is a newly researched
area that is currently being explored. Menasche et al (2008) began a phase I clinical study on the
implantation of autologous skeletal myoblasts in post infarction scars in humans. Menasche and
his group, veterans in the field of skeletal myoblast implantation, have previously found a linear
relationship between the improvement in ejection fraction and the number of injected skeletal
myoblasts after transplantation. In 2001, they reported the first human case study of implanting
autologous skeletal myoblasts into a post infarction scar during coronary artery bypass grafting.
Five months after the implantation, evidence of contraction and viability in the grafted scar by
echocardiography and positron emission topography were obtained. (Menasche et al 2001) Later,
in 2003, Menasche tested the safety and efficacy of skeletal myoblast implantation in patients
with severe ischemic heart disease. Of the ten patients included in his trial, four developed
ventricular tachycardia and were implanted with an automatic internal cardioverter- defibrillator,
a device to regulate their heart beat (Menasche et al 2003). This could have been predicted with
Murry’s finding that the satellite cells have an inherent contractile ability While Menasche
concludes that his clinical trial demonstrates the feasibility and safety of skeletal myoblast
transplantation as his patients had an uncomplicated post operative course, this cannot be viewed
uncritically. Although three of the four patients that developed cardiac arrhythmias had
preoperative ventricular hyperexcitability the numbers seem very high; almost half the patients
involved in this clinical trial developed this severe side effect.
Although in Ghostine et al’s experiment (2002), myoblast transplantation has been found
to limit post infarction ventricular dilation this was not seen in the Menasche’s patients. The
probable reason for this is that Menasche’s patients that had previous old infarctions had already
enlarged ventricular dimensions. In his clinical follow up in 2008, Menasche gathered 98
patients, with either left ventricular dysfunction, or myocardial infarction and an indication for
coronary surgery. Each patient received an injection of either 400, or 800 million cells grown
from a skeletal muscle biopsy or a placebo solution in and around the cardiac scar. The myoblast
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injections did not improve echocardiogroahic heart function. In addition to its failure to improve
cardiac function, the myoblast graft increased the number of post operative arrhythmic events
(Menasche et al 2008).
Muscle- derived stem cells are readily available, easy to amplify and have a good
survival rate after implantation. Myoblasts have the potential to enhance the heart’s contractile
function as they retain their skeletal muscle cell’s contractibility. In humans, the risk vs. benefit
ratio of myoblast implantation to increase cardiac function of injured hearts has yet to be
determined and must further be investigated.
D. Cardiac Stem Cells
1. Identifying Cardiac Stem Cells
The question of whether there are stem cells derived from cardiac tissue has been
thoroughly investigated. Until recently, it was commonly believed that the adult mammalian
heart is lacking in the ability to generate new cardiomyocytes: cardiomyocytes do not proliferate.
This view is supported in part by clinical observation as primary myocardial tumors are rarely
observed in adults (Soonpa and Field 1998). However, recent efforts looking for evidence of
cardiomyocyte turnover in the adult mammalian heart have led to varying results.
Studies by Beltrami and colleagues (2001) challenging the dogma that the adult heart is a
postmitotic organ, suggest that the human adult heart may have the endogenous capacity to
regenerate. By staining the human heart tissue with an antibody specific for Ki-67, a protein
closely associated with the cell cycle and cell proliferation, they concluded that there is extensive
cardiomyocyte proliferation during normal aging and that the number of cardiomyocyte
proliferation is markedly up regulated in and after myocardial infarction. Compared with the
number of Ki-67 cells in a series of control hearts from patients who died of noncardiac causes,
the number of Ki-67 cells in hearts from patients that have experienced AMI was 84 times higher
in regions that bordered the infarct zone, and 24 times higher in regions of the heart distant from
the scar. Based on this data, Beltrami calculated myocyte mitotic indexes of .08 and .03 percent
in zones adjacent to and distant from the infarcts and suggests that the billions of cardiomyocytes
lost in a heart attack are replaced in about 18 days.
Like Beltrami, Bergmann et al (2009), studied the rate of cardiomyocyte turnover in
humans. In a search for using an effective method to study cell turnover, Bergmann used a novel
approach utilizing a disturbing chapter in the history of nuclear weapons to track cardiomyocyte
proliferation. Bergmann took advantage of Spalding et al’s (2005) study describing that testing
for the radioactive isotope Carbon 14 in cells can reveal the cells age. Bergmann’s predecessor
discusses how testing of nuclear weapons during the Cold War resulted in a dramatic global
increase in the levels of the isotope Carbon 14 in the atmosphere, followed by an exponential
decrease after 1963. His work indicates that Carbon 14 in genomic DNA closely parallels
atmospheric levels and can be used to establish the time point when the DNA was synthesized
and cells were born, thereby measuring the rate of cell turnover. With this effective
cardiomyocyte dating method, Bergman’ s group determined the age of cardiomyocytes in
humans and discovered that cardiomyocytes do indeed renew over the human lifespan albeit at
the very slow rate of 1% turning over annually at the age of 25, decreasing to .45% at the age of
75.
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Bergman and Beltrami’s findings indicate a large discrepancy in the rate of cardiac cell
turnover. This may be due to the fact that Bertrami’s method of reporting dividing
cardiomyocytes with the Ki-67 antigen may have produced drastically exaggerated numbers of
reproducing cardiomyocytes. The number of cells with the Ki-67 antigen may be representative
of all cells in cardiac tissue in mitosis, not only the cardiomyocytes, and thus Beltrami obtained
such a large number in his study on cardiac cells replication. Also, it has been pointed out by
Soonpa and Field (1998) that Ki- 67 staining in the heart does not unequivocally establish that
cell division has occurred, since a substantial amount of cardiomyocytes are binucleated or
polyploidy and in the context of AMI, polyploidy may precede cell death and thus the elevated
number of Ki-67 cells during infarction is accounted for.
Research by Kajstura et al (1998) indicates proof of myocyte proliferation. Using
confocal microscopy, this investigative group reports that 14 myocytes per million were in
mitosis in control human hearts, and a nearly 10- fold increase of this parameter was measured in
end stage ischemic heart disease (152 myocytes per million). They also suggest that large
numbers of myocytes can be formed with time as mitosis only lasts one hour. Urbanek et al’s
study (2003)on the myocyte formation from cardiac stem cells in human cardiac hypertrophy
indicate that the human heart contains a population of cardiac stem cells that can divide and
differentiate into myocytes and that this cardiac stem cell pool is enhanced acutely after
infarction.
Although these findings are novel in that never before was mitosis seen in cardiac
myocytes and that cardiac cells were believed to be incapable of dividing, according to one
research group these reports don’t provide much clinical use. Leri et al (2005) describes that the
problem of compromised cardiac function following an ischemic event isn’t the lack of
myocytes, it is the accumulation of old poorly contracting cells and the extensive myocardial
scarring that occurs following AMI. Leri describes that 12-72 hours following an ischemic
induced myocardial necrosis there is an infiltration of neutrophils and an accumulation of
macrophages which initiate the removal of necrotic myocardial tissue. Within seven days,
scarring, that starts with the deposition of granulation tissue, is initiated and increases over a
period of several weeks. It is this scarring that albeit protects the heart form aneurismal dilation
contributes to reduced ventricular function in the most ischemic heart. In addition, the non
contractile nature of the scar will lead to compensatory ventricular remodeling of nonischaemic
myocardium and eventually heart failure.
Leri explains that contrary to the general belief that the heart’s restricted regenerative
ability is representative of the initial event of impaired cardiac function, it is the newly formed
non contractile cells that are responsible for the impaired cardiac function post AMI. The
inevitable scar formation that results from cardiac cell aplasia decreases the heart’s contractile
capacity. The need to surpass the fibrosis had led researchers to develop strategies to replace
dead cells with viable cells. Bone marrow derived cells, adipose derived cells, skeletal
myoblasts, cardiac cells and embryonic cells are being used experimentally to replace the rigid
scar forming tissue in the heart as we are learning. The implanted stem cells most likely form a
passive graft thereby decreasing the stiffness of the scarred portion of the ventricular and thus
enhancing the heart’s contractile function. According to Leri it is the elastic qualities of the new
cells that contribute most to enhanced heart function.
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2. Cardiac Stem Cells used for therapy

Adult cardiac stem cells(CSCs), isolated on the basis of various stem cells markers such
as stem cell antigen c-Kit (Bearzi et al 2007 and Bertrami et al 2003) are believed to be involved
in maintaining myocardial homeostasis throughout life but seem to be incapable of counteracting
massive degenerative events such as AMI themselves. Application of ex vivo human cardiac
stem cells seems to be a promising approach to bolster the hearts inherent repair capacity. Unlike
other stem cells, cardiac stem cells should be more effective in making new myocardium as
CSCs are programmed to create heart muscle and upon activation can rapidly engender
parenchymal cells and coronary vessels possibly rescuing the failing heart (Quaini et al 2002,
and Urbanek et al 2005).
Dawn et al (2005) injected CSCs into the coronary arteries of rats four hours after
coronary occlusion. Echocardiographical analysis showed that the CSCs attenuated the increase
in LV end diastolic dimensions and impairment in LV systolic performance at five weeks after
infarction. The CSCs induced myocardial regeneration decreasing the infarct size by 29%.
Dawn’s study establishes CSC as a possible candidate for cardiac regeneration and indicates that
the hearts own stem cells could be collected and stored for therapeutic purposes. Studies by
Beltrami et al (2003), Oh et al (2003) and Matsuura et al (2004) support Dawn’s findings and
reveal that the injection of CSCs locally promotes myocardial regeneration after infarction in rats
and mice. Bearzi et al (2007) similarly studied the effect of injecting human cardiac stem cells in
the infarcted myocardium of immunodeficient mice and rats and found that the human CSC
generate a chimeric heart, which contains human myocardium composed of myocytes , coronary
resistance arterioles and capillaries. After isolating the ckit + CSC from eight patients and
injecting them into the infarcted myocardium of rats, Bearzi found that the human cardiac cells
were structurally and functionally integrated with the rodent myocardium and contributed to the
enhanced performance of the infarcted heart.
Aside from transplanting CSCs into infarcted myocardium, some researchers have
studied the possibility of activating resident stem cells in cardiac tissue to repair the infarcted
heart. Linke et al (2005) studied the dog heart to see if it contains resident cardiac progenitor
cells that can be stimulated by the Hepatocyte Growth Factor (HGF)-Insulin like Growth Factor
1 (IGF1) receptor system to regenerate myocardium after infarction. Linke proposed that cardiac
stem cells can be activated by this growth factor signaling system. Linke based his clinical trial
on a study that describes how HGF enhances vessel growth and favors cell- extracellular matrix
interaction, which may be critical during myocardial regeneration. The study further indicates
that stimulation on IGF1 receptors prevents cell death and induces differentiation of
cardiomyocytes (Reiss et al 1996). Linke’s findings were that the dog heart possess a reservoir
for cardiac stem cells characterized by undifferentiated cells that are self renewing, and able to
differentiate into other cell lineages. In accordance with the previous findings of other
researchers, Linke’s results are expected. More importantly however, Linke confirmed the idea
that the cardiac stem cells posses an HGF and IGF 1 receptor system that when activated induces
their migration, proliferation and survival. Linke’s group injected HGF and IGF1
intramyocardially to stimulate resident cardiac progenitor cells after infarction. Indeed, the
formation of myocytes and coronary vessels within the infarct was stimulated and the newly
generated myocytes expressed nuclear and cytoplasmic proteins specific to cardiomyocytes.
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With all these findings, we learn that the presence of cardiac stem cells in myocardium
seems to be undeniable, yet the origins of the stem cells still remain debatable. The question of
whether CSCs are generated within the myocardium or as Urbanek et al (2003) suggests are
continuously being supplied to the heart by the bone marrow through the systemic circulation is
being investigated, yet for the purpose of this review directed on the implications of stem cells in
cardiac injury, this question will not be addressed.
E. Embryonic Stem Cells
These stem cells, derived from the inner mass of the blastocyst, posses unique properties.
Embryonic stem cells (ESCs) can be grown in vitro and reproduce indefinitely in their
undifferentiated state. They also maintain the property of multilineage commitment having the
capacity to differentiate into cells originating from any of the three germ layers of the embryo.
Because of their enormous potential, human ESCs have been obtained with the expectation for a
future successful application of their broad therapeutic potential to patients. The uses for ESCs
can be significant as adult stem cells have certain limitations. In addition to their limited
proliferative capacity, the plasticity of adult stem cells has recently been challenged (Amit et al
2000). Recent studies by Terada et al (2002) and Ying et al (2002) indicate that the assumed
capacity of transdifferentiation of adult stem cells into other lineages in vivo may simply be the
fusing of implanted cells with existing cell types rather than a direct conversion into
cardiomyocytes. The aforementioned limitations to adult stem cells and the inherent
electrophysiological, structural and contractile properties of ESC derived cardiomyocytes make
ESCs an ideal donor cell type for cardiac tissue regeneration.
Still, while ESCs seem to be the ideal cell type for implantation in the injured heart, the
utilization of ESCs in clinical practice is hardly existent because their adult stem cell
counterparts present fewer dangers than ESCs. The primary risk associated with the utilization of
ESCs is its potential to form tumors, a dangerous side effect stemming from the ESC’s capacity
to proliferate indefinitely. Human ESCs cultured in suspension form spontaneous cellular
aggregates called Embryoid Bodies. These tumors- like structures are found both in vitro and in
vivo after ESC implantation (Reubinoff et al 2000, and Thomson et al 1998).
Because of the risks associated with ECS therapy, only several sporadic studies have
employed these cells in their uncommitted state to repair the damaged heart. These reports, while
indicating an improved ventricular function in the heart, also reveal dramatic side effects
including the formation of benign tumors and the engrafting and colonizing of all organs with the
possible development of neoplastic regions by the intravenously injected ESCs. In an attempt to
avoid these serious complications associated with ESC implantation, researchers utilizing ESC,
use methods to partially differentiate the ESCs in vitro before their implantation into the injured
heart. This degree of cardiomyogenic commitment enhances the engraftment of cells in the
myocardium and attenuates the probability of ESC acquiring undesired cell lineages thereby
reducing the risk of tumor formation. To date most studies on the use of ESC exploit this method
of differentiation.
Although due to certain ethical issues, there aren’t any clinical studies on the
implantation of human ESC in the human myocardium, other studies on the cardiomyocyte
differentiation capacity of ESCs have been explored. Kehat et al (2001) cultivated human ESCs
and plated them to form Embryoid Bodies. Kehat’s group found that 8.1% of the cellular
aggregates displayed contracting areas and the cells within these spontaneously contracting areas
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stained positive for anti-cardiac myosin heavy chain, anti-cardiac troponin and various other
cardiac specific features. Under electron microscopy, the areas also displayed varying degrees of
myofibril organization consistent with early stage cardiomyocytes.
Clinical trials by Hodgson et al (2004), Min et al (2002) and Min et al (2003) study the
effects of transplanting ESC derived cardiomyocytes into the hearts of rats. Hodgson injected
infarcted rat hearts with ESCs preexamined for cardiogenicity. The trial found that stem cell
delivery generated new cardiomyocytes that integrated into host myocardium and was associated
with normalized ventricular architectures, little scar, and decrease in signs of myocardial
necrosis. Hodgson’s study points out that the ESCs injected were well accepted by the rats as no
evidence of graft rejection, or tumor formation was observed. Hodgson’s findings conclude that
ESCs through differentiation within the host myocardium, can contribute to a stable beneficial
outcome on contractile function and ventricular remodeling in the infarcted rat heart
Min et al (2001, injected ESCs into the infarcted hearts of rats intramyocardially.
Compared with a control group injected with the equivalent volume of cell free medium, the
experimental rat’s cardiac function was significantly improved six weeks after cell
transplantation. Min’s study indicates that embryonic stem cells can be implanted and survive in
injured rat myocardium and that these cells improve myocardial function. In a later analysis, Min
et al (2003) studied the prolonged effects of ESC transplantation in the infarcted heart. His group
injected rats with ESCs stained with GFP and studied the heart and its function 32 weeks after
infarction and subsequent injection. After 32 weeks, tissue positive for GFP was found in the
myocardium suggesting that the engrafted cells were still present. Echocardiographic data also
showed that ESC transplantation significantly improved ventricular function relative to the
control group even after four months.
In contrast to the findings of Hodgson and Min, Fijnvandraat’s study on embryonic stem
cells reveal that ESCs are not capable of restoring cardiac function in the infarcted heart. In
2003, FIjnvandraat in his study on in vitro differentiated embryonic stem cells and its
subsequent cardiogenesis in vivo and in vitro found that ESC derived cardiomyocytes maintain a
phenotype of the primary heart tube, and not of the chamber myocardium. Fijnvandraat, with
very specific regulation of gene expression discovered that the ESC derived cardiomyocytes do
not develop into fully mature chamber myocardium, and rather show a phenotype comparable to
young embryonic cardiomyocytes in vivo and thus would not be of great importance in the area
of restoring cardiac function(Fijnvandraat et al 2003).
The clinical implications of these findings seem somewhat promising as rat ESCs display
the potential to restore damaged rat myocardium. Due to certain ethical concerns that lead to
complications in obtaining human ESC it may seem plausible to use rat ESC to restore human
myocardium. Yet Mcdevitt et al (2005) and Kehat et al (2001)’s studies display that rat and
human ESC are very different and thus cannot be used interchangably. Mcdeviit studied
proliferation patterns in human and mouse embryonic stem cell derived cardiomyocytes. The
study revealed that cardiomyocytes differentiating from human ESCs exhibit a high level of
proliferation which progressively decreases as the cells mature in culture. In stark contrast to the
cardiomyocytes derived from human ESCs, cardiomyocytes derived from mouse ES cells
appeared to be non proliferative using similar experimental techniques.
Kehat, in his work notes that there are some major differences in human and murine ES
cell differentiation because there are significant differences in human and murine development.
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Kehat compares his results in the differentiation of human ESCs with the rate of differentiation
in mouse ESC. He explains that differentiation of human of ES cells proceed at a much slower
rate than in mouse ESCs. In mouse cells, cells are grown in suspension for five days and
spontaneously contracting areas appear one day after plating and within two- ten days 80-90% of
EBs reveals pulsating areas. In contrast to this, human ESCs are grown in suspension for ten
days and the spontaneous contracting areas did not appear until day four after plating; and the
percentage of pulsating areas is a mere 8.1% Thus to have any really benefit for human
myocardial regeneration clinical trials focusing specifically on human ESCs must be utilized .
Min et al (2002), in their experiment also spotted a group of growth factor proteins that
seems to be involved in cardiac organogenesis in the early embryonic stages. They noted that
different growth factors like vascular endothelial growth factor (VEGF) seem to enhance the
functional improvement of post infarcted mouse hearts with transplantation of ESCs. To test
whether specific growth factors would assist the ESCs in differentiating into functional cardiac
tissue, Kofidis et al (2005) injected undifferentiated and labeled ESC into the infarcted mouse
myocardium, added growth factors, and comparatively evaluated the restorative effect of their
transplantation. Kofidis’s group injected rat hearts with ESC supplemented with fibroblast
growth factor (FGF), and ESC supplemented with transforming growth factor (TGF) and
compared the subsequent cardiac function to a control group of rats injected only with the
growth factors and not the ESC. Each group of growth factors had different effects on the
capacity for regeneration. Kofidis found that TGF administration, compared with FGF and
VEGF displayed the most restorative and differentiation potential. To further test the effect of
supplementing growth factors with ESC, Yang et al (2002) studied VEGF to examine if an
improvement in blood flow to ischemic regions can be found. Yang injected ESCs over
expressing VEGF into the hearts of mice post infarction and compared the cardiac function to
group of mice injected with normal ESCs. The effects of the ESCs and the ESC over expressing
VEGF on neovascularization in ischemic were evaluated and compared. Improvement in left
ventricular systolic function was significantly greater in post AMI mice transplanted with ESC
plus VEGF. In addition, Yang found that the ESC themselves expressed certain amounts of
VEGF and thus were able to stimulate the growth of new blood vessels in injured myocardium.
Earlier on, Kofidis et al (2004) administered a study on growth factors and explicitly
studied the effects of Insulin- like growth factor -1 (IGF-1) in enhancing the proliferative
capacity of ESC. His group implanted ECSs with IGF- 1 in an attempt to enhance the restorative
capability of ESC on injured myocardium. They found that IGF -1 promoted expression of
cardiomyocyte phenotype in ESCs in vivo. Their findings indicate that supplementation with
IGF -1 enhances a- sarcomeric actin expression, and expression of MHC 1 thus indicating a
stronger differentiation potential in the stem cells supplemented with IGF- 1. A trend in better
myocardial fractional shortening in the group of mice treated with ESC and IGF-1 was also
noted. These studies are significant as they suggest that growth factors may be supplemented
with pluripotent cells to drive their differentiation to the desired phenotype and enhance their
engraftment, leading to more efficient use of stem cells in cardiac therapy.
Kofidis further describes that contrary to the notion that embryonic stem cell are not
susceptible to a host’s immune response, ESC transplantation may face similar issues of
allorecognition as solid organs transplantation. The idea that ESCs express only small amounts
of MHC I, a cell marker foreign to cardiac tissue, in culture and thus are not susceptible to
immunorejection (Kaufman and Thomspon 2002)is refuted in Kofidis’s experiment as he found
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nearly 70% of the injected ESCs in vivo expressing MHC I. In a series of immunological
experiments in their lab, Kofidis’s group obtained evidence of a humoral response in donor cells.
They detected an increased production of Interferon- gamma, Interleukin -2 (IL-2), IL-4, and IL5 by activated splenocytes of the host in response to ESC injection into the heart. Even so, many
clinical trials including that of Hodgson’s involving the injection of ESC in the hearts of rats in
vivo have displayed no real signs of immunorejection.
Embryonic stem cells posses certain advantageous characteristics in their use for stem
cell therapy. Their unlimited proliferative capacity, coupled with their ability to differentiate into
any type of cell make them a model contestant for stem cell therapy. In contrast to their adult
stem cell counterparts, studies with ESCs have yielded mostly unvarying results in their ability to
differentiate into cardiac myocytes and their contribution to improved myocardial performance
post myocardial infarction. The dangers associated with transplanting ESC can be circumvented
by plating the ESC in vitro to start their cardiomyogenic differentiation before being implanted
in vitro. Due to certain human ethical concerns and the subsequent lack of funding, current
studies on the implantation of ESC and their functional benefit in damaged human myocardium
are lacking. Hopefully this will soon change and therapeutic effects of these stem cells will be
taken advantage of.
3. Conclusion
Cellular therapy is the latest in a series of strategies applied in an effort to mitigate the
progressive and otherwise irreversible loss of cardiac function that frequently follows a heart
attack. The need for an effective therapy to restore cardiac function following a cardiac event in
which cardiomyocytes atrophy is essential. Heart failure, the condition that occurs when the
heart’s contractile reserve is depleted below a critical threshold, is already the most common
cause of hospitalization in US citizens over 65, and, as our population ages, some have predicted
epidemic proportions of this diseases (Laflamme and Murry 2005). The proposal that heart
failure could be reversed or prevented if new myocardium could be grown in diseased hearts is
excitedly being explored. This idea has gained widespread attention recently, leading to
numerous reports and multiple early stage clinical trials in this field. In this review a summary of
current data arising from clinical applications involving hematopoietic, adipose-derived, skeletal
muscle-derived, cardiac and embryonic stem cells in cellular therapy for acute myocardial
infarction is presented. While studies of cardiac regeneration utilizing these stem cells seem
promising and are advancing at a quick rate, perfecting our interventions to repair the heart will
take continuous effort and many years.
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Cardiac Regeneration
Sara Leah Abraham
Introduction
Cardiovascular disease is a generic term that refers to any illness or disorder that involves
the heart and its vessels or the blood vessels of the body. Cardiovascular disease has been
accepted as the leading cause of death worldwide. According to the Centers for Disease
Control’s National Vital Statistics Reports, twenty six percent of deaths in 2006, 631,636 in
total, were caused by diseases of the heart (Heron et al. 2009).
One of the most common of all cardiovascular diseases is Ischaemic Heart Disease. This
coronary artery disease often leads to Acute Myocardial Infarction, more commonly known as a
heart attack. An ischemia occurs when an organ is receiving an insufficient supply of blood,
often caused by a clogged artery (De Milto 2006). Atherosclerosis and blood clots in some of
the larger coronary arteries are the most common condition to block coronary circulation.
Coronary arteries take rise from the root of the aorta and spread out over the epicardium. These
arteries branch out into energy hungry cardiac muscle, the myocardium, to supply it with oxygen
and nutrients. The blockage of these deep arteries is known as myocardial ischemia. When
ischemia to a specific region is severe, injury occurs (American Heart Association 2008). When
blockage results in cell death, the condition is called an infarction.
Myocardial infarction is characterized by necrosis, cellular death in an isolated region of
the heart. Cellular death stimulates the migration of macrophages to the infarct zone. They
remove the necrotic tissue, and the area is refilled with a dense collagen scar, leading to a
decrease in muscle thickness. The scar tissue, by and large, is acellular, and does not have the
biochemical properties of myocardial cells. This can lead to electrical inconsistencies, loss of
structural integrity, and mechanical dysfunction, such as arrhythmias. Together, these
abnormalities can lead to complete heart failure (Joggerst and Hatzopoulos 2009).
Current treatments for post myocardial infarction patients aim to assist in the healing
process and prevent further heart attacks, such as cholesterol-lowering medications and
angiotensin inhibitors. A rehabilitation plan that includes blood pressure and cholesterol
management may be set up. Diet and exercise regimes may change (Mayo Clinic 2010).
Ultimately, though, once an area of the myocardium is dead, it’s irreversible. It is because of this
that scientists are looking for ways to alleviate the effects of myocardial ischemia and infarction
by means of cardiac regeneration.
Cell Therapy
The basic concept of cell therapy is that exogenous, or possibly even autologous cells
implanted into diseased tissue can recover and improve its function by substituting for the
resident cells that have died. The improved neurologic function of Parkinson’s patients that
underwent the grafting of intracerebral dopaminergic cells and the prospect of weaning a number
of diabetics off insulin after Langerhan islet transplants provide a good indication that cell
therapy can be clinically effective. Transplanted cells must be engrafted in very specific
quantities, and they must be able to integrate into normal host tissue without excess reproduction
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and other adverse effects. When attempts to ameliorate the effects of myocardial infarction by
converting the infarct zone into contractile tissue with the use of viral vectors encoded with
muscle specific master genes failed, cell therapy became an increasingly attractive method of
attempted cardiac regeneration (Menasche 2004).
Stem Cells:
Stem cells can be defined by two significant characteristics. First and foremost, they
must be able to self-renew. They must be able to go through many cycles of mitosis and still
remain in their undifferentiated state. Secondly, a stem cell must have the capability to
differentiate into various specialized cell types. The effectiveness and value of stem cells are
often based on their potential to do this. Pluripotent stem cells are able to differentiate into
specialized mature cells from the three germ layers. The embryonic stem cell is the classic
example of a pluripotent stem cell. Multipotent stem cells, alternatively, are limited to
differentiating into mature cells of directly related lineages, generally from the same germ layer.
Adult stem cells, sometimes called somatic stem cells, that are derived from postnatal, or even
fully mature tissue are generally multipotent. Some adult stem cells sometimes have a more
limited capacity for self-renewal, and are committed to differentiation into specific lineages.
These cells are called adult progenitor cells (Cook et al. 2009). Until very recently, the
myocardium has been labeled and viewed as an end-differentiated organ – one without any
potential for regeneration. Certain types of stem cells are currently being tested as sources for
regenerative potential for the heart. There is a new availability for hope in the possibility of
reconstructing the infracted, failing ventricle (Loscalzo et al. 2008).
Mesenchymal Stem Cells:
Mesenchymal stem cells (MSCs) were first identified by their ability to form fibroblast
like populations, and have been recognized for their plasticity. In the past, they have been
known to help normal bone regenerate in vivo. They were initially discovered in the stroma of
bone marrow. It has been established that by secreting growth factors important for proliferation
and colony stimulating factors, MSCs provide support for hematopoiesis. While generally
harvested from bone marrow, MSCs have recently been found in and isolated from the placenta,
adipose tissue, the liver, and umbilical cord blood. MSCs, an integral part of the composition of
endothelium (perivascular cells), are now seen as ubiquitous. No single, specific marker for
MSCs has been discovered yet, though they are characteristically lacking typical hematopoietic
antigens, such as CD 34, CD 44 an45, and more. MSCs produce a large number of cytokines
and growth factors, including the important vascular endothelial growth factor . The hallmark
and most distinctive feature of the mesenchymal stem cell is its inherent ability to differentiate
into anything of mesodermal lineage, such as bone, cartilage, tendon, muscle, and adipose tissue.
The main advantage of MSCs in cell therapy is their unique immunological properties. They can
be transplanted across major histocompatibility barriers; recipients will not need to take
immunosuppressants. They can be taken from any healthy donor, even an unrelated one, and
cryopreserved until needed. With their ability to self-renew and differentiate, MSCs can be
induced to differentiate into cardiomyocytes, and there is evidence that MSCs migrate primarily
to sites of inflammation. These factors together suggest their potential for treatment for ischemic
myocardial infarction. A disadvantage of MSCs is that they are perhaps too heterogenic, and
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there are concerns that they may provide unexpected results, such as ossification (Cook et al.
2009).
Intracoronary injections of autologous bone marrow have led to moderate recovery of
cardiac function, but clinical findings show that bone marrow cells don’t actually engraft in the
infarct zone, nor do they reduce infarct size. A placebo controlled study was therefore done to
increase the evidence that MSCs have reparative properties. To ensure that mesenchymal stem
cell grafts were allogeneic, donor pigs were of a different strain than recipient pigs. The bone
marrow was obtained from the iliac crests of male swine. MSCs were identified and isolated by
density, and were plated to expand in culture, and were then cryopreserved. They were
magnetically stained in order to be later identified under MRI. Recipient pigs underwent a
surgically induced myocardial infarction via balloon occlusion of the left anterior descending
coronary artery for sixty minutes, followed by reperfusion; left ventricular performance and
cardiac oxygen consumption was measured. After three days, animals were randomly chosen to
receive intramyocardial infusions of allogeneic porcine MSCs or a placebo through a needle
tipped injection catheter. Contractility of the myocardium was measured by the maximal rate of
isovolumetric contraction and ventricular elastance, and the ratio of left ventricular systolic
pressure to stroke dimension. At day three post injection, no animal had died or shown signs of
arrhythmias, or shown signs of cardiac perforation, thus indicating that the method of delivery
was safe. The animals were euthanized after eight weeks. Their hearts were analyzed in gross
and microscopic levels. Tissue samples were taken from the infarct zone, the infarct border, and
remote tissue. Immunostaining revealed the presence of α-actinin, troponin-T, and myosin heavy
chains. Histologic evaluation demonstrated that MSCs were found present throughout the infarct
and border regions, and they expressed muscle specific proteins that weren’t found while they
were still in culture plates. They were also found in vascular structures, where they had
incorporated into vascular smooth muscle and endothelium. Myocardial infarction normally
begins at the subendocardial area of the myocardium and moves out through the midmyocardium
out towards the subepicardia
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region. In animals that received a mesenchymal stem cell transplant, the infarct region was
confined to the midmyocardium. When measured, the subendocardial rim was thicker in the
mesenchymal stem cell-treated group than in control groups. MSCs probably caused this
cardiac regeneration of the subendocardium. The effects of the transplant on cardiac function are
as follows (see table 1).
The animals exhibited recovery to almost normal levels of both systolic and diastolic function.
Myocardial efficiency increased, almost bringing stroke work back to a normal level. Cardiac
energy metabolism was nearly recovered (Amado et al 2005).
Hematopoietic Progenitor Cells /Bone Marrow Mononuclear Cells:
Hematopoietic progenitor cells are the only stem or progenitor cell that are routine in
clinical use today, due in part to the fact that they are easy to isolate and feasible to implant
(Joggerst and Hatzopoulos 2009). They reside in bone marrow, and are responsible for making
all blood cells, constantly repopulating the hematopoietic and immune systems. They are used in
bone marrow transplants to treat many disorders, including leukemia and aplastic anemia. In
humans, hematopoietic progenitor cells are identified by the CD 34 marker (a surface
gylocoprotein). Hematopoietic progenitor cells home to bone marrow in healthy mammals,
where they adhere firmly to the endothelium. Whether or not hematopoietic progenitor cells
actively participate in the repair of cardiomyocytes after an infarction is a matter of debate,
though they have been known to differentiate into skeletal muscle fibers. It is generally
accepted, though, that hematopoietic progenitor cells are responsible for the inflammatory
wound healing process (Cook et al. 2009). Experimental studies have suggested that
intramyocardial or intravascular administration of bone marrow derived hematopoietic
(Amado et al. 2005)
progenitor cells may play a part in the functional regeneration of infarcted cardiac muscle by
enhancing neovasculogenesis of an ischemic myocardium (Schachinger et al. 2006).
Patients, aged eighteen to eighty, were eligible for the REPAIR-AMI (Reinfusion of
Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial if they’d
had an ST-elevation myocardial infarction with residual left ventricular wall motion abnormality
and a significantly decreased left ventricular ejection fraction (Schachinger et al. 2006). (A
normal resting ejection fraction, the fraction of blood pushed out of the heart by the ventricles
per beat, is 62.3±6.1% [Pfisterer and Battler 1985].) This placebo controlled, double blind
randomized trial was performed in seventeen different centers, at a median of 4 days after AMI
reperfusion therapy. Bone marrow biopsies were done on 204 patients and the aspirate was sent
to a single cell-processing laboratory, where patients were randomized to receive either an
intravascular infusion of bone marrow derived hematopoietic progenitor cells (101 patients) or a
placebo medium (103 patients). This infusion was done using a stop-flow technique via balloon
positioned in the infarct-related coronary artery. After four months, the BMC (bone marrow
cells, and alternate name for hematopoietic progenitor cells) group showed enhanced contractile
recovery of left ventricular function. One year later, the results of the experiment were
measured. A total of eight deaths occurred in the year, six in the placebo group and 2 in the
BMC group. None of the patients in the BMC group experienced a second myocardial
infarction, while six patients in the placebo group suffered a total of eight myocardial infarctions,
six of which were located to the target blood vessel. While on paper these numbers may seem
small, statistically, the difference is significant. Similarly, additional revascularization
procedures were needed less frequently in the BMC group than in the placebo group. Thirty22

eight revascularizations were needed in thirty seven patients of the placebo group, while only
twenty five were needed in twenty two patients of the BMC group (Schachinger et al. 2006).
The BMC group can be seen as a predictor of a reduced cardiovascular event rate. It is
reassuring that in every endpoint, be it death, another myocardial infarction, or rehospitalization
due to heart failure, there was a trend, albeit a statistically insignificant one, in favor of the BMC
group. This data suggests that the contractile recovery seen at four months may possibly
translate into a better clinical outcome one year post BMC infusion (Schachinger et al. 2006).
Cardiac Stem Cells:
The steps that have been made towards cardiac regeneration through the various stem cell
types prompted further research into any natural regenerative properties and mechanisms that
cardiac tissue might have. The heart has always been viewed as a postmitotic organ because
mature cardiomyocytes don’t reproduce or propagate. Contradictory facts seemed to accumulate
as cardiomyocytes were discovered proliferating and reentering the cell cycle in certain
pathological conditions such as ischemia and hypertension (Joggerst and Hatzopoulos
2009). After a female heart was transplanted into a man, male cardiomyocytes and endothelial
cells were found growing within the heart. Y-chromosome positive cells must have migrated
from the recipient’s atrial stump or bone marrow into the donated heart, and differentiated into
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(Schachinger et al. 2006)

functional cardiomyocytes (Quaini et al. 2002). Since then, several types of cells have been
discovered in the adult heart that have stem cell characteristics. One stem cell characteristic is a
cytoplasmic exclusion of certain vital dyes, like Hoechst 33342 and Rhodamine
123. Populations of these cells, sometimes called side population cells, have been found in
various organs, such as skeletal muscle, bone marrow, and adipose tissue. These cells have
recently been found in cardiac tissue as well, concentrated in the deep tissue of atria and
apex. Cardiac side population cells have been seen to differentiate into cardiomyocytes,
suggesting that they may in fact be cardiac progenitor cells. After cardiac injury, such as
ischemia, these cardiac side population cells are mobilized and move to the injury site. The
apparent conflict between the existence of cardiac progenitor cells and the heart’s lack of
regenerative ability is still puzzling to researchers, though two theories have been developed.
The first is that these cells, along with mature cardiomyocytes, cannot survive the hypoxic
conditions of ischemia. The second is that the pool of cardiac stem cells diminishes with age,
which can possibly contribute to lack of regeneration in the elderly (Joggerst and Hatzopoulos
2009).
Studies have found what have been loosely termed human cardiac stem cells in small
niches in the heart. These small clusters of human cardiac stem cells are closely connected to
myocytes and fibroblasts by gap junctions and adherans junctions. The myocytes and fibroblasts
form supporting walls that contain the cardiac stem cells. These cells are very obviously
committed to myocyte lineage. Stem cell antigen C-kitPOS, sarcomeric proteins, and myocyte
transcription factors are co-expressed consistently, though they sometimes also expressed
transcription factors for endothelial cells and smooth muscle cells. Myocardial samples were
enzymatically dissociated, and C-kitPOS cells sorted out and plated; multicellular clones were
formed successfully in eight out of twelve cases. These clones were, in turn, plated again, or
placed in individual wells. Doubling time was approximated at 29 hours. These cells
differentiated into cardiomyocytes, smooth muscle cells, and endothelial cells. Developing
myocytes had sarcomeric units, were striated, and showed contractile activity after electrical
stimulation (Bearzi and Rota 2007).
Human cardiac stem cells were collected from eight patients and injected into infarcted
mouse or rat heart, forming chimeric organs that contained human myocytes and coronary
vessels. Cell therapy led to regeneration in the infarct zone. The new cells tested positive for αsarcomeric actin and human DNA sequences were found in seventeen out of twenty five treated
mice and fourteen out of nineteen rats. Of the new tissue, ≈84% was myocardial and ≈8%
consisted of new microvasculature, making an approximate ration of one capillary to eight
cardiomyocytes. Two different lentiviruses were injected into the cardiac stem cells and the
infarcted rat and mice hearts to promote different dye production, and the results showed that
there had been no cell fusion. The new cardiomyocytes were all human, and that animal
cardiomyocytes did not contribute to the regeneration or repair. An examination of ECG done
on injected hearts showed that tissue regeneration had partially restored contractile function in
the infarct, resulting in an increased ejection fraction and a general improvement of ventricular
function. When examined, the synchronicity of calcium tracings in both human and rat
cardiomyocytes proved their functional integration. An occasional protein was even found
linking human and rodent cardiomyocytes. Together, these observations all prove the role of
transplanted human cardiac stem cells in cardiac homeostasis and myocardial regeneration
(Bearzi and Rota 2007).
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Skeletal Myoblasts:
While the regenerative ability of cardiac muscle cells is a relatively new development, it
has been known for a while that skeletal myoblasts retain the potential to regenerate. This is due
in large part to the presence of stem cells, sometimes called satellite cells, in this case, because of
their location in the periphery of mature, multinucleated muscle tubules. A billion or more
myoblasts can be easily cultured in the laboratory from a single small piece of muscle tissue.
Myoblast therapy was developed originally as a possible treatment for muscular dystrophy,
because myoblasts from a normal donor would fuse with the muscle of the recipient to provide
normal proteins absent from dystrophic patient. In 1992, scientists realized the potential use of
skeletal myoblasts in cardiac regeneration. Over time, experiments proved that myoblast
transplantation could repair a damaged myocardium when cells engraft and integrate, adding
new contractile muscle to the heart, and by promoting cardiac repair, including rejuvenation of
blood supply, and therefore oxygen and nutrients, to previously damaged areas (Dinsmore and
Nabil 2006).
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Of one the wonderful things about myoblast therapy is that it can be autologus. In
preparation for transplant, a skeletal muscle biopsy about five grams is done. The muscle is
trimmed of all connective tissue and minced. It then goes through several cycles of digestion
with trypsin and collagenase. The resulting cells are plated and grown in a medium developed
primarily for supporting myoblast growth. The actual number of cells used for transplant can be
anywhere from three hundred million to eight hundred million. Animal studies done with
transplantation of skeletal myoblasts into ischemically damaged myocardium have demonstrated
good results. They show that skeletal myoblasts engraft and contribute to improved heart
function; they have survived long term without manifesting adverse affects, such as arrhythmias.
Autologus rat myoblasts grafted into ischemic myocardium survived both inside and out of the
infarct zone, and fused, forming myotubes in close contact with myocytes at the border of the
infarct zone. Myocardial contractility and cardiac output increased in comparison to the control
group. Ventricular volume and remodeling were minimal. In sheep, progressive heart failure
halted short term , and was functionally reversed in the long term. Skeletal muscle fibers formed
organized bundles that co-aligned with adjoining cardiac muscle. Muscle density in areas of
ischemic collagen scars was almost restored to normal. Clinical studies have been done in both
the USA and Europe, and direct evidence for skeletal myoblast survival had been provided.
Autologus myoblasts formed myofibers that survived in the human myocardium and aligned

Autologous human myoblast transplantation in a
human patient as an adjunct to coronary artery
bypass surgery on a beating heart (Haider et al.
2004).
parallel to host cardiac muscle fibers, showing potential for synchronized contraction. This in
turn, can contribute to improvements in systolic and diastolic functioning. Left ventricular
ejection fraction increased. Tissue viability scanning of the scarred region of the myocardium
six months post transplant showed improved metabolic activity (Dinsmore and Nabil 2006).
While the theory shows great promise, a few problems with myoblast transplantation were
exhibited in some trials. Ten patients that received myoblast transplants reported severe left
ventricular dysfunction. Their ejection fraction dropped significantly to below 35%. In the
MAGIC (Myoblast Autologuous Grafting in Ischemic Cardiomyopathy) trial, four out of sixty
four patients developed ventricular tachycardia after receiving skeletal myoblast injections in
coronary artery bypass grafting, and twenty four more were expected to. Therefore, clinicians
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must proceed with caution in regard to arrhythmias in pursuing myoblast therapy. Furthermore,
many myocardial infarction patients are not surgical candidates, and a less invasive method of
delivery must be devised (Dinsmore and Nabil 2006).
Of all the various studies done to investigate the effects of cell therapy on myocardial
infarction, few have taken timing into account, and as of yet, the optimal time for cell
transplantation in heart attack patients remains unclear. One such study was done in 2009 using
human umbilical cord blood cells (HUCBC), which are rich in mesenchymal progenitor cells and
contain endothelial cell precursors with huge in vitro proliferation capabilities. Myocardial
infarction was identified in eighty male Wistar rats by elevated ST segments in a transthoracic
ECG. Equal volumes of either HUCBCs or a phosphate buffered saline placebo were injected
into the rats through a caudal vein at days one, five, ten, and thirty after myocardial infarction.
The rats were all sacrificed four weeks post infusion, after a hemodynamic assessment and an
ECG. Mortality in rats transfused on day one post infarction was 40%, most deaths occurring
within one week. Rats infused on day five and day ten both hard mortality rates of 10%, and
those injected thirty days after the myocardial infarction had a mortality rate of 30%, usually at
three weeks post infarction. Before injection, all rats had a similar left ventricular ejection
fraction of about 45%. After four weeks, the left ventricular ejection fraction in five-day
transplantation group had moved up to about 50% and the ten-day group reached almost 60%,
doing significantly better than the control groups. Left ventricle wall thickening also improved
significantly in the 10-day group, as opposed to the others. While scar formation was extremely
noticeable in hearts injected with buffered solution, scar size was smaller in groups that received
the HUCBC injection, more so in the five and ten day groups than the others. When injected
cells were immunostained with anti-human leukocyte antigen, it was observed that only cells
delivered in the ten-day group had settled in the infarct zone in the myocardium enough to make
a difference. New angiogensis was due to the endothelial progenitors found in HUCBC.
Microvasculature density was significantly greater in the five-day and ten-day groups than in
their controls, and was altogether greater in the ten-day group. Myocardial infarction is a time
dependent process, based on the loss of effective cardiomyocytes and the formation of scar
tissue. The process begins with an inflammation of the infarct zone, and this reaction is nearly
complete at ten days post myocardial infarction. It can be concluded that this is the best
environment for stem cell homing and survival (Xing, Yun-li et al. 2009).
Tissue Engineering
Cardiac muscle tissue has a very quick and active metabolism. It therefore requires a lot
of oxygen and nutrition. In natural cardiac tissue, almost every cardiomyocyte can be found in
close proximity to a capillary vessel, ensuring that each cell is properly perfused and taken care
of. Cardiac cell density is much higher than most other tissues. In a normal heart, noncardiomyocyte cells such as vascular endothelial cells, smooth muscle cells, and fibroblasts make
up 70% of the tissue. These non-cardiac cells are integral to normal heart functioning. All these
factors together make it very difficult to artificially create cardiac muscle (Guo et al. 2009).
One study investigated the effects of co-seeding rat mesenchymal stem cells with
embryonic cardiomyocytes. The scientists conducting the study believed that the only way to
attempt to engineer cardiac muscle is in three dimensions, so they constructed a three
dimensional tubular scaffold called a myotubule. They fed liquid collagen between two rotating
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cones, resulting in a cylindrical tube of collagen fibrils with a hollow, inner central lumen. To
isolate the mesenchymal stem cells, they anesthetized 300 rats and removed the femoral and
tibial bones. The marrow cavities were flushed and the marrow was combined. The bone
marrow was passed through thin needles to break up clumps, and the single cell suspensions that
resulted were centrifuged for five minutes at 200g. Cells were trypsinized three times, and
replated. Only bone marrow stromal cells remained. Cells were labeled with green fluorescent
protein for lineage tracing, and were replated for subculturing. Embryonic cardiac myocytes
were collected from rat embryos. Upon the dissection of their hearts, the atria were discarded.
The ventricles were minced and incubated, and centrifuged, until ventricular primary cells could
be isolated. The embryonic ventricular cardiomyocytes (ECMs) were planted in a medium
filled collagen tube alone, and a combination of ECMs were seeded together with mesenchymal
stem cells. The results of both experiments were studied at seven, fourteen, twenty one, and
twenty eight days. Gene expression of the tissue in both myotubules was studied in order to
analyze cardiogenic differentiation. In order to validate findings of cardiac myocyte markers in
these collagen tube cultures, cardiac specific markers were immunocytochemically stained. This
was done using antibodies directed against specific cardiac transcription factors, hormones,
contractile and structural filaments, and junctional proteins. Through staining and lasers, it was
established that the cells located in the myotubes tested positive for many cardiomyocyte
markers, including myosin heavy chains, sarcomeric myosin heavy chains (a contractile protein),
cardiac troponin, cardiac actinin and desmin, GATA binding proteins, peptide hormones ANP
and BNP, and others (Valarmathi et al. 2010).
At 21 days, ECM tube cultures showed the presence of myocytes mainly on the luminal
and outer surfaces of the construct. External to the tubule, ECMs aligned and overlapped in an
orderly manner, but cells on the inner luminal surface showed cord like cellular arrangement that
resembles that of in-vivo myocytes. These cells showed signs of developing sarcomeric units,
and tested positive for actin and myosin. They indicated progressive differentiation towards invivo neonatal-like ventricular cardiac muscle cells. In MSC/ ECM co-cultures, the
differentiating cells appeared organized into many layers of intercalated bundles and branches
throughout the myotubule. Cross bridges and specialized cell junctions were evident. The
maturing cardiomyocytes showed evidence of evolving into Z-disks and into cardiac specific
sarcomeric arrangements, and showed promise for cardiac biosynthetic activities. The MSCs
that had been immunostained showed markers associated with cardiomyocytes, including myosin
heavy chains and other aforementioned characteristic, proving that it wasn’t only the ECMs
affecting the expression of cardiac properties. In comparison to the ECM only construct,
hormone secretion levels of the MSCs/ECMs stayed strong and constant. The cells were
metabolically active. When tested under electron microscope, the nuclei of ECMs were typical
of underdeveloped embryonic cardiac muscle cells. The MSCs/ECMs co-culture revealed the
typical appearance of developing cardiomyocytes. Cells were elongated, multilayered, and
orderly. Myofilaments were present, if randomly dispersed throughout. Plus, the cells showed
developing mitochondria and vescicles of the active cardiomyocyte. MSCs/ECMs combination
expressed cardiac specific genes, proteins, ion channels, receptors. In addition spontaneous,
synchronized contraction of the culture was evident through the transparent myotubule
(Valarmathi et al. 2010).
Previous successes in the implantation of engineered cardiac tissue have failed due to
necrosis at the core of the transplanted tissue and poor survival related to ischemic injury.
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Bioengineers have long sought a solution to this problem. Human embryonic stem cells were
differentiated into cardiomyocytes and suspended in a rotating orbital shaker, resulting in human
cardiac tissue patches, composed of enriched cardiomyocytes. These patches, however, did not
survive transplantation in-vivo. Scientists tried heat shocking the patches a day before
implantation and bathing them in prosurvival cocktail before implanting them into skeletal
muscle of nude rats. At one week, they found only rare, isolated human cardiac muscle cells. The
peripheral edges of the tissue were viable, but the entire inner core was dead. They deduced that
the problem was in large part due to the ischemic injury at the infarct zone, and that the patches
were too thick for nutrients to diffuse into the core, and that in order for the procedure to be
successful, the tissue needed to be vascularized. The tissue patches died before host
angiogenesis could provide them with a normal blood supply (Stevens et al. 2009).
Tri-cell cardiac patches were scientists’ next attempt. Human embryonic stem cell
derived cardiomyocytes were combined with human umbilical vein endothelial cells (HUVEC)
and mouse embryonic fibroblasts in a 1:1:0.5 ratio in a medium of human embryoid bodies (a
cluster of heterogeneous embryonic stem cells that are set to differentiate to a specific lineage
[Itskovitz-Eldor et al. 1999]). The newly created tissue had endothelial cell networks that
resembled a vascular plexus. The next logical step was to test the contractility of the new tissue.
Patches were stimulated using square waves of frequency and contraction was monitored via
video edge detection. Cardio-HUVEC-MEF patches were cultured for 2-3 days before testing.
They routinely contracted when stimulated by 2 Hz of electricity (120 beats/minute), but
couldn’t keep pace with 5 Hz of stimulation. When stimulated at higher frequencies, the patches
never fully relaxed, and a decrease in contractile ability resulted. Another important
consideration for scientists to take into account are the passive mechanical properties of cardiac
tissue, especially in relation to diastolic filling. The passive stiffness of Cardio-HUVEC-MEF
patches were tested in comparison to cardio only patches by using strips cut from each patch.
They were stretched in increasing length increments. At 7.9 mN/mm2, cardio-HUVEC-MEF
constructs were closer to the stiffness of neonatal pig myocardium than cardio-only patches.
When tested, scientists saw that the cardio-HUVEC-MEF constructs produced more connective
tissue and collagen fibrils per area, making their stiffness more physiologically appropriate.
These patches were a thousand times less stiff than the collagen scar that forms as a result of
myocardial infarction, suggesting that they would impede much less on diastolic filling (Stevens
et al 2009).
The next step for scientists was to test whether or not these vascularized human cardiac
tissue patches could survive implantion in vivo. Prior to their implantation into the gluteus
muscle of nude rats, cardio-only and cardio-HUVEC-MEF patches were heat shocked and
bathed in pro-survival cocktail. At one week post implantation, the rats were killed. Human
cardiomyocytes and endothelial cells were indentified through the immunohistochemical staining
of β-myosin heavy chain and human complement proteins. In cardio-only patches, only the
occasional, isolated human cardiomyocytes were detected. Comparably, cardio-HUVEC-MEF
patches formed much larger grafts of human myocardial tissue. The cardiac muscle cells showed
small, sarcomeric arrangements. Many human endothelial cells could be found among the
patches, some of them even containing traces of red blood cells. Despite the fact that cardio-only
patches were produced from 50% more cardiomyocytes, implanted cardio-HUVEC-MEF patches
grew to be 11 times larger. Next, the cardio-HUVEC-MEF constructs were sutured into the
hearts of nude rats. The patches had attached to the hearts of all test subjects. The microvessels
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that had formed contained red blood cells and white blood cells, indicated that the new vessels
had anastomosed with the normal rat blood vessels, creating a much more ideal environment for
tissue survival. (Stevens et al. 2009).
In the ten years that scientists have been experimenting with tissue engineering, much
progress had been made. Nevertheless, there are still many obstacles that need to be overcome
before newly synthesized cardiac tissue can be used to alleviate the effects of myocardial
infarction. One of the largest problems facing bioengineers is constructing tissue the proper size
and shape to fit into human myocardium. So far, no three dimensional tissue construct has been
thick enough or large enough. Three to four cardiomyocyte monolayers have been successfully
stacked one on top of the other, but the thickness hasn’t come close to that of human cardiac
tissue. As for shape, researchers have been able to construct tissue in rings, strips, and squares.
While each of those shapes has its own advantage, none of them come close to the shape of a
natural human heart. Of course, another large issue is immunorejection. None of the methods
developed thus far have used or yielded autologus material. All implantation studies have used
immunosuppressants. Another commonly overlooked problem is that most media supplements
used to grow the tissue are xenogenic, resulting in several issues including infection. New, nonxenogenic growth media must be developed before engineered tissue can successfully be
transplanted into humans (Xing, Yu-jie et al. 2009 b). Until this tissue has been successfully
transplanted, studies cannot be done to test how this tissue affects the functionality of the
working heart.

Conclusion
Because myocardial infarction and the death of cardiac muscle has always been
seen as irreversible, researchers have been working on many different ways to reverse the
process and regenerate cardiac muscle. In most studies, heart function was partially, if not
mostly restored, even if cardiac muscle itself was not actually produced. The reperfusion of
existing muscle and the prevention of scar formation definitely played a part in reestablishing
cardiac function and preventing further heart complications. Researchers discovered the
existence of cardiac progenitor cells and have begun to experiment with them. Tissue has been
engineered and successfully transplanted into rats. Much progress has been made in the field,
though there are still obstacles that need to be overcome. Many studies featured embryonic cells,
the use of which is still extremely controversial, and may lead to tumor formation in the long run
(Joggerst and Hatzopoulos 2009). Finally, more human trials need to be done to prove the safety
and benefits of cell therapy and tissue transplantation.
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Benefits of Breastfeeding
Renee Chill
AbstractWhen a child is born, a mother can choose to breastfeed her infant or to use an alternative
source of nutrition such as formula. To choose properly, the mother must be informed about the
pros and cons of each method of feeding. This paper will elaborate on the process of
breastfeeding and present some of the benefits that are conferred to both infant and mother
through the act of breastfeeding, benefits that formula does not provide. Breastfeeding positively
affects infants in both the short- and long-term by providing protection from infectious diseases,
fostering the psychological bond with their mothers, and increasing cognitive development later
in life. In addition, mothers benefit from choosing to breastfeed their infants by having a quicker
delivery of the placenta, retaining less weight postpartum, and having a decreased risk of breast
cancer. In conclusion, this paper will show that while formula does contain essential nutrients
for infants, it does not provide the protective and curative benefits that breast milk does.
IntroductionLactation is a fundamental part of the reproductive cycle of all mammals, including
humans. After intrauterine and parenteral nourishment has terminated, and before individuals
can independently sustain themselves, mothers can naturally provide their newly born children
with necessary nutrition through breastfeeding. In the early twentieth century, statistics reveal a
decrease in the percentage of infants who were breastfed, most likely due to a lack of knowledge
of the health benefits that are associated with breastfeeding. However, as science continues to
improve and more studies are conducted, it is becoming increasingly clear that human milk is the
ideal source of nutrition for infants. Early scientific literature, generally from countries other
than the United States, claimed that breastfeeding was better than bottle-feeding, as evidenced in
mortality charts comparing the risk of death in both groups, but no reasons could be given to
explain this assertion (Grulee et al., 1934,1935). Refinements in the analysis of food constituents
have allowed for further studies of breast milk, revealing how it is physiologically suited for
newborns. Developments in the study of infections have also identified the anti-infectious
properties of breast milk, offering protection for the infant until weaning. Still other studies
acknowledge various other health benefits of breastfeeding to both mother and infant. Recent
statistics show an increased trend toward breastfeeding in the Western world, due to increased
education of the benefits of human lactation. The objective of this paper is to show why breast
milk is better for infants than alternative sources of nutrition, whether milk from animals or
formula.
DiscussionAnatomy and Physiology of breastfeeding-
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Mammary glands begin to develop embryologically at six weeks, maintaining growth
until milk ducts are developed by the time of birth. At puberty of a female, the breasts expand to
their adult size, the left usually being slightly bigger than the right. During lactation, the breast
weighs between 600 and 800 grams, compared to the roughly 200 grams in a nonpregnant
woman and 400-600 grams in a pregnant woman (Lawrence, 1989).
The breast is made up of many different independent glands. The stroma and the
parenchyma are two divisions that make up the corpus mammae. The stroma includes the
connective tissue, fat tissue, blood vessels, nerves, and lymphatics. The parenchyma is
comprised of the alveolar gland with ductular branching alveoli. Each gland opens into a
lactiferous duct, whose distal end is dilated to form the lactiferous sinus. There is a slight
constriction before opening onto the surface of the nipple (Lawrence, 1989).
The nipple, or papilla mammae, contains 15 to 25 lactiferous ducts, as well as smooth
muscle fibers, sensory nerve endings, and sweat glands. The areola, which surrounds the nipple,
contains Montgomery glands that become enlarged during pregnancy and lactation. They secrete
a substance that lubricates and protects the nipples and areolae during lactation (Lawrence,
1989).
The lactating mammary gland is characterized by a large number of alveoli. Its
functioning depends on the interplay of numerous intricate nervous and endocrine factors. Some
are involved in mammogenesis, preparing the glands for lactation; others in lactogenesis, and
others are responsible for the maintenance of lactation, or galactopoeisis. During pregnancy, a
complex sequence of events, involving the hormone prolactin being synthesized by the
adenohypophysis and released into circulation, as well as other hormones, prepares the breast for
lactation. At delivery, with the ejection of the placenta, there is an abrupt decline in estrogens
and progesterone. Since estrogens have an inhibiting effect on the secretion of milk by prolactin,
their withdrawal triggers the onset of lactation. Suckling stimulates the release of prolactin, as
well as oxytocin from the neurohypophysis. Prolactin stimulates milk synthesis, while oxytocin
is involved in milk secretion (Mader, 2000).
Human breast milk is comprised of many different molecules, such as carbohydrates,
proteins, and lipids, as well as minerals and vitamins. However, the composition varies with
time of day, stage of lactation, maternal nutrition, and several other factors. Colostrum, the
yellowish, thick fluid produced in the first few days following delivery, has a higher protein and
lower fat content than mature milk, but energy and carbohydrate content are similar in both. It is
rich in fat-soluble vitamin A, carotenoids, and vitamin E. This distribution reflects the needs and
reserves of the newborn child (Sarkar, 2004). From approximately 7 -10 days to two weeks
postpartum, the content of breast milk gradually changes to become mature milk. Mature milk is
mainly made of water; all other constituents are dissolved or suspended in the water. Because
25% of the newborn’s heat loss is from evaporation of water from the skin and lungs, water from
breast milk helps regulate the infant’s body temperature. Lipids represent the second largest
percentage of the total breast milk composition. Proteins constitute about .9% of breast milk
contents, with eight out of the twenty amino acids present being essential. The most prevalent
carbohydrate in breast milk is lactose, or milk sugar, which is synthesized by the mammary
gland. A number of other carbohydrates are present in the milk as well. Vitamins, minerals,
enzymes, and hormones make up the rest of the components of breast milk (Lawrence, 1989).
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The World Health Organization (WHO) recommends exclusive breastfeeding until the
infant is six months of age because it protects against infectious morbidity, mortality, and
promotes adequate growth and development (Kramer and Kakuma, 2001). The most important
short-term immunological benefit of breastfeeding is the protection against infectious diseases.
When the infant is first born, the immune system is in its nascent stage, placing the child at risk
of infection. Colostrum, the specialized milk produced for the first few days following delivery,
is much richer in immunoglobulins, antimicrobial peptides, and growth factors than mature milk
(Playford, 2001). These components allow colostrum to be an important immune modulator,
inducing maturation and differentiation of thymocytes, promoting peripheral blood leukocyte
proliferation, and inducing cytokine production (Boldogh et al., 2008). Boldogh et al. (2008)
conducted a study to investigate whether colostrum causes allergies and what its impact is on
allergic sensitivity. The researchers found that colostrum does not increase IgE or IgG levels,
which are the antibodies that cause the majority of allergic reactions. They also found that
colostrum significantly decreased IgE and IgG production, airway eosinophilia, mucin
production, and hypersensitivity to common allergens. These findings show the importance of
feeding colostrum to newborn babies, as it is the best form of nutrition for the immature immune
system. No other animal’s milk or formula can provide for the precise physiological needs of the
newborn human as well.
Mature human milk also contains numerous immune-related compounds, including
oligosaccharides, cytokines, and interferons. Several of these components of milk offer passive
protection in the upper respiratory system and gastrointestinal tract, preventing adherence of
pathogens to the mucosa, and thereby protect the infant against invasive infections (SchackNeilson and Michaelsen, 2007). One liter of human milk contains about five to ten grams of
unbound oligosaccharides, which represents a major component of human milk, exceeding the
amount of lipids. More than 130 different human milk oligosaccharides have been identified,
both neutral and acidic, as well as combinations of the two. Compared with human milk, the
concentration of oligosaccharides in the milk of domestic animals that is usually fed to infants is
smaller by a factor of ten to a hundred. Infant formula contains only trace amounts of less
complex oligosaccharides (Bode, 2006). The neutral fraction of human milk oligosaccharides
appears to be the most relevant factor for the development of the intestinal flora typical for
breastfed infants (Boehm and Stahl, 2007). Human milk oligosaccharides withstand the low pH
of the stomach and resist degradation by enzymes from the pancreas and brush border
membrane. Because of this resistance, these oligosaccharides are able to rinse the infant’s
esophagus, stomach, and small intestine, finally serving as nutrients for colon bacteria (Bode,
2006).
Most pathogenic microorganisms (e.g. Campylobacter jejuni, Escherichia coli, Vibrio
cholera, and strains of Shigella and Salmonella) are only virulent with adhesion to the host’s
epithelial surface. Acidic oligosaccharides have been found to play an important role in the
prevention of adhesion of these bacteria on the intestinal epithelial surface (Boehm and Stahl,
2007). Human milk oligosaccharides rinse the laryngopharyngeal region and may also reduce
pathogen adhesion at the entry to the upper respiratory tract. Adhesion of Streptococcus
pneumonia and Hemophilus influenza to pharyngeal epithelial cells, the most common cause of
oritis media and respiratory tract infections in infants, is also inhibited by human milk (Bode,
2006). Acidic oligosaccharides are also involved in immune reactions, such as interacting with
selectins in inflammation processes. Sialization of oligosaccharides can interfere with binding of
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certain selectins and affect important regulators of the immune system (Boehm and Stahl, 2007).
These effects of human milk oligosaccharides combine to provide extremely effective protection
against intestinal infection and postnatal stimulation of the immune system. Because the
quantity and diversity of oligosaccharides in human milk are distinct compared to those of other
species, the use of other forms of nutrition aside from breast milk cannot offer the same
oligosaccharide absorption, metabolism, function, and beneficial effects.
As stated previously, exclusive breastfeeding protects against gastrointestinal morbidity
(Schack-Nielsen and Michaelsen, 2007). However, because iron concentration in human milk is
low, breastfeeding may increase the risk for iron deficiency in some infants. Although ironfortified formula may provide the necessary iron, the infant will be placed at risk for
gastrointestinal infection. This is the case especially for infants of low-income households and
communities where hygienic preparation of foods may be compromised, leading to more
gastrointestinal infections and malnutrition. Monterrosa et al. (2008) conducted a study of
infants born to low-income women in Guadalajara, Mexico. The researchers sought to
investigate whether infants in this setting who were predominantly breastfed through the first six
months of life would experience fewer gastrointestinal infections but be more likely to be iron
deficient compared with infants who were fed iron-fortified formula on a regular basis. One
hundred and fifty four mother-child pairs were recruited from the Hospital Civil Dr. Juan
Menchaca, a certified Baby Friendly Hospital, where most of the patients are low income.
Baseline data were collected while the mother and infant pairs were in the hospital, and followup visits on the infants’ monthly birthdays were conducted as well. The study found that the
non-predominantly breastfed infants (55 partially breastfed and 50 exclusively formula-fed) were
almost twice as likely to have a gastrointestinal infection compared with the 49 predominantly
breastfed infants. Mean iron concentration, however, was lower in the predominantly breastfed
infants than in partially breastfed and formula-fed infants. The researchers concluded that even
with the risk of iron deficiency, it is better for mothers to primarily breastfeed their infants until
age six months. Iron deficiencies can be prevented by iron supplementation in pregnancy and by
feeding the infant iron-rich foods at six months of age, but gastrointestinal infections can cause
morbidity and mortality in infants (Monterrosa et al., 2008).
Another important aspect of breastfeeding is the close psychological relationship it
fosters between mother and child because of the increased bonding opportunities. Research
shows that breastfeeding mothers touch their infants more often both during feeding and while
playing together. Mothers who breastfeed commonly exhibit more physiological and social
responsiveness toward their infants. Infants who are breastfed are also generally more alert and
responsive (Jones et al., 2004). Many women experience some kind of emotional imbalance in
the first week after delivery, due to the enormous change in hormonal levels after the delivery of
the placenta. However, some women become clinically depressed, suffering from post-partum
depression. Depression can occur in all women, regardless of whether they are breastfeeding or
not (Lawrence, 1989). Newborns of depressed mothers are found to demonstrate less left frontal
brain activity, lower heart rate variability, and abnormal biochemical patterns, such as lower
levels of dopamine and serotonin and higher levels of norepinephrine and cortisol, compared to
newborns of mothers who are not depressed (Jones et al., 2004). One study (Jones et al., 2004)
suggests that breastfeeding may protect newborns against some of the negative effects of
maternal depression. The researchers compared infants of depressed mothers who were
predominantly breastfed to those who were fully formula-fed by three months of age. In a
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measurement of electroencephalographic activity, the breastfed infants displayed the same left
frontal brain activity patterns as those demonstrated by infants of non-depressed mothers.
Conversely, the formula-fed infants of depressed mothers showed less left frontal brain activity,
indicating deficits in approach motivation. The study thus effectively demonstrates that “a stable
breastfeeding relationship protects infants from some of the negative psychological and
physiological effects in an environment of maternal depression” (Jones et al., 2004). Expectedly,
though, depressed mothers are less likely to breastfeed and they breastfeed for shorter periods of
time than non-depressed mothers. It is possible that if depressed mothers were to be informed of
the significant benefits of breastfeeding and its protective factors for their infants, they would
choose to continue breastfeeding.
Long-Term Health Benefits to InfantAside from offering short-term protection from several diseases and infections, studies
show that breast milk influences the child’s own immune system. Infants are born with their
immune systems not fully developed, dominated by subtype-2 helper T cells. Breastfeeding,
through human milk oligosaccharides, speeds up the maturation of the immune system by
stimulating the development of subtype-1 helper T cells. In fact, ultrasound measures of the
thymus, an important structure necessary for T cell development and maturation, reveals that the
thymus of breastfed infants at four months of age is twice the size of that in formula-fed infants
(Schack-Nielsen and Michaelsen, 2007). Because breast milk contains immunomodulatory
properties, breastfeeding has been found to protect against the later development of many
immune-mediated diseases such as bronchial asthma, atopic dermatitis, type I diabetes,
ulcerative colitis and Crohn disease (Klement et al., 2004, Schack-Nielsen and Michaelsen,
2007).
Another one of the most consistent findings of breastfeeding is a positive effect on later
intelligence tests with a few test points advantage for breastfed infants (Uauy and De Andraca,
1995; Gomez-Sanchiz et al., 2003, 2004; Schack-Nielsen and Michaelsen, 2007). A metaanalysis of several studies by Anderson et al. (1997), as quoted by Schack-Nielsen and
Michaelsen (2007) found that breastfeeding conferred a benefit of 5.3 points in cognitive
function between six months and 16 years of age compared with formula-feeding and a benefit
of 3.2 after adjusting for relevant variables like sociodemographic, environmental, and
biomedical factors. The authors noted that the longer the infant was breastfed, the better the
scores in cognitive function. Two studies conducted by Gomez-Sanchiz et al. (2003, 2004) that
measured the difference in mental capabilities in breastfed versus formula-fed children at ages 18
and 24 months, respectively, confirmed these findings. In both studies, the authors found that
breastfeeding for more than four months had a beneficial effect on cognitive development at the
ages measured. They do add that parental intelligence clearly influences cognitive development
as well. To limit familial covariant factors, Schack-Nielsen and Michaelsen (2007) cite a study
comparing breastfeeding and intelligence that was conducted among 2734 adolescent sibling
pairs in 2005. The children who were breastfed scored 1.7 and 2.4 points higher in intelligence
within and between families, respectively. Furthermore, the longer the child was breastfed, the
higher he or she scored, as the study’s results showed increased scores of 0.2 points per month of
breastfeeding.
A possible hypothesis for the disparities observed in cognitive development in breastfed
and formula-fed infants lies in the essential and nonessential long-chain fatty acid content in each
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source of nutrition. In particular, docosahexaenoic acid (DHA) present in human milk has been
shown to be necessary for retinal and brain development, as it can be incorporated into cell
membranes in the central nervous system (Uauy and De Andraca, 1995; Schack-Nielsen and
Michaelsen, 2007). Since plasma DHA concentrations of breastfed infants are higher than that
of infants who are fed formula, present formulas are thought not to provide adequate alphalinolenic acid to support DHA accumulation in tissues. A study of full-term infants fed either
human milk or cow milk formula containing 12-18% linoleic and 0.5-1.0% alpha-linolenic acids
showed that at four months of age, indexes of visual acuity were more mature in the breastfed
infants (Uauy and De Andraca, 1995). Additionally, psychomotor indexes are found to be higher
in breastfed infants whose mothers had been supplemented with DHA in order to increase DHA
content of milk, when measured at 30 months, reinforcing the suggestion that the DHA
concentration in human milk increases cognitive development (Schack-Nielsen and Michaelsen,
2007).
Aside from the composition of breast milk, other factors involved in breastfeeding could
be responsible for the stimulated cognitive development. Physical and psychological behavior
by the mother during breastfeeding could promote cognitive development as well. Some suggest
that hormones triggered in the mother through breastfeeding, such as oxytocin and prolactin, or
the actual bonding experience, could influence the mother to focus more on the infant, to use
more affectionate touch, and to lessen the likelihood of maternal depression, all of which could
foster cognitive development in the child (Schack-Nielsen and Michaelsen, 2007).
Health Benefits to MotherBreastfeeding does not only provide numerous benefits to the infant, but the mother also
gains several benefits. The most immediate benefit is apparent within the first thirty minutes
after delivery, the time that the infant is highly alert and can therefore successfully latch on to the
breast (Lawrence, 1989). Breastfeeding in this interval is beneficial to the mother because it
allows for a quick expulsion of the placenta, a physiological process that must occur within the
first thirty minutes after birth. As explained previously (Mader, 2000), suckling by the infant
stimulates the release of the hormones oxytocin and prolactin, which begin the process of breast
milk production and secretion. The hormone oxytocin, though, also performs a vital function for
delivery. While the smooth walls of the uterus are relatively insensitive to oxytocin during
pregnancy, sensitivity increases when the fetus is fully developed. Sudden increased levels of
oxytocin in the uterus stimulate the contraction of the uterine wall, triggering labor and delivery.
Therefore, as the newborn infant suckles at the breast immediately following delivery, the
oxytocin that is released by the neurohypophysis in response to that stimulus will also continue
to contract the uterus. These increased contractions will speed up the process of the tearing of
the connections between the endometrium and the placenta, resulting in the ejection of the
placenta. If this placenta expulsion does not occur within the first thirty minutes of birth, a
complication termed retained placenta, the mother will be in danger of excessive bleeding.
Therefore, when a mother puts the newborn to her breast during the first thirty minutes after
birth, a time when the infant is highly alert and receptive to touch (Lawrence, 1989), she
decreases the catastrophe of a postpartum hemorrhage (Ladewig, et al., 2010).
One of the most commonly reported benefits of breastfeeding for the mother is maternal
weight loss. A large prospective cohort study conducted by Baker et al. (2008) sought to answer
many questions, such as how quickly a woman can return to her pre-pregnancy weight while
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breastfeeding and if the amount of weight gained during pregnancy affects one’s ability to lose
weight while breastfeeding. The researchers collected data on pregnant Danish women during
the first trimester of pregnancy, and interviewed them by phone at two prenatal (12 and 26 weeks
of gestation) and at two postpartum (6 and 18 months postpartum) time points. Based on selfreported data on pre-pregnancy weight and height, the researchers categorized the ~36,000
women by body mass index (BMI) value as underweight, normal weight, overweight, obese I,
and obese II and III. During each of the interviews, the women reported their weight gain or
loss. At the postpartum interviews, the women also related the method of infant feeding. The
authors observed that the more the women breastfed, the lower the amounts of weight retention
were at both postpartum interviews. They conclude that at six months postpartum, normalweight women who have exclusively breastfed their infants are predicted to retain 2 kg less than
women who gained a similar amount during pregnancy but breastfed for less than a week. Obese
women are also expected to return to pre-pregnancy weight at six months postpartum. This
study is significant because of it has several strengths: a very large cohort, prospective data
collection, careful collection of infant feeding data, and others. The results are also noteworthy
since they show the relationship between breastfeeding, gestational weight gain, and postpartum
weight retention. Similar results were also found in a study, conducted by Kac et al. (2004), of a
cohort of Brazilian women. Although the studies are somewhat limited because they do not take
into account the mothers’ eating and exercise habits, the significant difference in weight
retention in breastfeeding and non-breastfeeding women in such a large cohort still reveals an
association between breastfeeding and postpartum weight loss. In a society where obesity has
become an epidemic, especially among women, research indicating a method to reduce
postpartum weight retention may help decrease the number of overweight women.
Perhaps the most major benefit that mothers may receive from breastfeeding is a reduced
risk of developing breast cancer. In an extremely large international study analyzing data of
many different smaller studies (Collaborative Group on Hormonal Factors in Breast Cancer,
2002), results indicate that the risk of breast cancer is reduced by 4.3% for women who breastfed
for a cumulative total of 12 months and by 27% for women who breastfed for a cumulative total
of 55 months or more. In one hospital-based case-control study in Shandong Province, China,
Zheng et al. (2008) investigated the relationship between lactation and breast cancer risk. Four
hundred and four women with histologically confirmed incident breast cancer cases, along with
an equal number of controls, were included. The women were all interviewed by blind
interviewers and were asked whether they had ever been pregnant and how many live births they
had, at what ages did they give birth, and whether they had only breastfed or gave their children
formula since birth. If the respondents had breastfed, they were asked to report how many
months on average they had breastfed each child. After calculating results, the authors found “a
significant inverse association between lactation and breast cancer risk”. They found that the
mean duration of lactation per child was significantly associated with reduced risk of breast
cancer for women who breastfed for more than two years per child compared to women who
breastfed for less time. This reduced risk is associated with a longer duration of breast-feeding
for both pre- and post-menopausal women, although the risk was generally lower for premenopausal women. The protective effect of breastfeeding noted in post-menopausal women
implies that the benefits of breastfeeding are maintained for years after women wean their
youngest children. This is significant because breast cancer risk increases with increasing age
(Shema et al. 2007), so breastfeeding may reduce the risk of cancer even in the period of high
occurrence. A similar study conducted by Shema et al. (2007) of ~800 Israeli Jewish women
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produced comparable results. This group of authors added that the decrease in breast cancer risk
with longer lifetime duration of breastfeeding is not linear, as most of the protective effect of
breastfeeding is gained during the first year of breastfeeding. Additional length of breastfeeding
did confer some benefit in terms of decreasing breast cancer risk. Mechanisms that have been
proposed to explain the observed association between breastfeeding and breast cancer risk
(Zheng et al., 2000, Shema et al., 2007) are: (1) a reduced exposure of breast cells to cyclic
hormones of reproductive life because of ovulatory suppression that occurs with prolonged
breastfeeding, (2) direct physical changes in the breast that accompany milk production, (3) a
reduction in the concentrations of toxic organochlorines in the breast, and (4) an expression of
change in growth factor beta during lactation, a negative growth factor in human breast cancer
cells.
However, not all results of studies on the relationship between various lactative factors,
such as number of children breastfed, mean duration of lactation for each child breastfed, and
lifetime duration of lactation, and breast cancer risk have been consistent. As referenced in
Shema et al. (2007), some studies suggest that the inverse relationship between breastfeeding and
breast cancer risk only exists among pre-menopausal women, especially with long durations of
breastfeeding and early age at first breastfeeding. Others imply that breastfeeding only confers
the benefit of a reduced breast cancer risk in post-menopausal women. Still others find no
association at all. Nonetheless, the overwhelming majority of studies do indicate that
breastfeeding does reduce the risk of breast cancer.
Whereas studies conducted in China and Japan have all shown that breastfeeding and
breast cancer risk are inversely associated, it is the results from studies of western populations
that have been conflicting (Zheng et al., 2000). This could be due to the fact that studies
investigating breastfeeding in western populations are usually rather limited. Most women in
western cultures have two or less children, and breast-feed for an average of four months per
child, usually with formula supplementation. Interestingly, a study conducted of Nigerian
women (Huo et al., 2008), also investigating the association between breastfeeding and breast
cancer risk and finding an inverse relationship between the two, noted that younger women in
their study had an increased risk of developing breast cancer. The authors hypothesized that
because the majority of older Nigerian women almost always breastfed their babies, usually for
12 months or longer per child, breast cancer did not used to be so prevalent in Nigeria.
However, the younger women have begun to adopt a more western lifestyle, changing their
reproductive factors to have less children and breastfeed for less amount of time per child, and
therefore the protective effects of breastfeeding have diminished.
Conclusion and SummaryWhile this paper has shown the many salubrious effects of breastfeeding for both infants
and mothers, using formula or alternative sources of nutrition is not necessarily unhealthy for
infants. Most infant formulas available in the market today are nutritionally adequate, however,
as this paper has elucidated, do not provide any remedial or preventive benefits as breastfeeding
does (Sarkar, 2004). For example, while formula does contain necessary nutritional contents
mimicking breast milk as much as possible, human milk oligosaccharides are impossible to
replicate exactly because of their diversity and complexity. Consequently, infants who are
exclusively fed formula will not receive the health benefits that oligosaccharides in breast milk
provide. Also, infants who are not breastfed do not have the same bonding opportunities with
their mothers as infants who are breastfed do, and thus will not experience the same
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psychological closeness to their mothers. Finally, mothers who choose not to breastfeed are
missing out on the numerous benefits for them that come from the act of breastfeeding. In
conclusion, breastfeeding is considered a superior source of nutrition over other modified milk
formulas because of its many intrinsic nutritional and salutary properties, and because no
formula can duplicate breast milk completely. However, in the case of absence or insufficient
production of breast milk, infant formula is a suitable and convenient substitute, as long as one is
careful to prepare it properly, sterilizing the feeding equipment to avoid contamination.
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Pompe’s Disease and the Effects ofAlpha-Glucosidase Deficiency
Aaron Richler
Overview:
The energy that the body needs in order to function is obtained from carbohydrates that
we get through our diet. These carbohydrates are monosacharides, disaccharides and
polysacharides. The polysaccharides and disaccharides are hydrolyzed to monosaccharide’s such
glucose (which comprises roughly 80%) fructose and galactose. Most cells convert the fructose
and galactose to glucose. The body can use the glucose or store it. If energy is needed, glucose
can be oxidized through the many reactions of glycolysis which gives a net production of 2 ATP
and 2 NADH from one molecule of glucose. In the presence of oxygen the product of glycolysis
pyruvic acid will be decarboxilated to Acetyl Coenzyme A (Acetyl COA) in the mitochondrial
matrix forming carbon dioxide and 2 NADH in the process. The acetyl COA subsequently enters
the citric acid cycle (the Krebs cycle) where after a series of reactions, 2 molecules of ATP, 4
molecules of carbon dioxide, 6 NADH and 2 FADH2 are produced. The NADH’s enter the
electron transport chain and over a series of reactions with the proteins in the mitochondrial
matrix form 3 ATP per molecule of NADH and 2 ATP per molecule of FADH2. (Murray)
In accordance with homeostasis, the presence of high energy will cause the body to
balance energy levels by forming storage molecules of energy for use in times of need. This
storage form of glucose is called glycogen; the synthesis is called glycogenesis. This glycogen
can later be degraded into is monomer units for the use in oxidative phosphorylation. (Champe)

Glycogen is a branched chain
of alpha-D-glucose. Most of the
glucose molecules are attached to each
other via a carbon to oxygen to carbon
bond known as a glycosidic bond. In
the linear portions of glycogen the
glycosidic bond is known as the 1,4
linkage this is a bond between the
carbon labeled 1 and the carbon
labeled 4 on the next glucose. Every 810 glucose molecules there is a 1, 6
glycosidic bond causing the above
mentioned characteristic branching of
glycogen. (Murray) [Figure 1]

Figure 1 1,4 and 1,6 Glycosidic Bonds in Glycogen (Brooklyn College, 2009)

Glycogen is mainly stored in the skeletal muscle and the liver while it has been found in
almost every cell in the body in trace amounts. The liver cell has the most glycogen consisting of
up to 6% of its total weight. Alternatively in muscle cells glycogen is never more than 1% its
total mass. However, because the total mass of muscle in the body is larger than that of the liver,
overall, muscle contains more glycogen than the liver. (Murray)
Muscle contains glycogen for its own use. When in need of energy it will break down the
glycogen via glycolysis in order to synthesize ATP for muscle contraction. Muscle will replenish
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its reserves of glycogen after exercise for example and will not be affected during short periods
of fasting. Yet, the liver stores glycogen in order to maintain blood glucose between meals;
higher levels of glycogen are found after meals and lower levels during fasting. (Murray)
There are five enzymes that catalyze the reactions of glycogenesis. The first enzyme
glucokinase which is found in liver cells and beta cells of the pancreas phosphorylates glucose.
Additionally, hexokinase, a similar enzyme phosphorylates glucose in most of the other cells of
the body. This phosphorylation creates Glucose 6-PO4 which is the substrate for the enzyme
phosphoglucomutase which transfers the phosphate group to the 1st carbon. Next, uridine
triphosphate (UTP) a high energy molecule reacts with glucose 1 PO4 and the enzyme UDPpyrophosporylase forming UDP-glucose. Being that glucose cannot be added to other single
molecules of glucose UDP glucose attaches to glycogenin a molecule with a tyrosine side chain
to form the primer for additional glucoses to be attached. After adding two molecules of glucose
to this base stand, the enzyme glycogen synthase continuously acts with UDP-glucose to form a
long linear chain of glucose attached via alpha-1,4-glycosidic bonds. The ends of the chain to
which this enzyme attaches to are
called nonreducing ends. Branches
are formed in the chain in order to
increase solubility and to increase
nonreducing ends. By increasing non
reducing ends enzymes can easily
remove and attach glucose molecules
thereby increasing the rate of
synthesis as well as degradation of
the chain. (Champe)
The branches are formed by
the enzyme glucosyl 4:6 transferase.
The enzyme breaks a 1,4 bond in the
linear portion of the chain usually
forming 5-8 glycosyl chains and
attaches this small chain to another
spot on the chain via a 1,6 linkage.
This results in two more nonreducing
ends.
Figure 2 Glycogen
Degradation
(Champe, 1994,
Modified)

The new reducing ends can
then be elongated by glycogen
synthase and glucosyl 4:6 transferase
usually removing 5-8 terminal
molecules and adding them to
another point in the chain by 1, 6
linkage and so on forming branched
glycogen.(Champe) The remaining
branched chain of glycogen after the
action of glycogen phosphorylase is
called the limit dextrin. Next, the
enzyme glucosyl (4:4) transferase
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removes 3 of the four remaining glucose units before the branch point and adds them to the
remaining linear chain via a 1,4 linkage. Then the enzyme amylo-alpha-(1,6)-glucosidase cleaves
the one remaining glucose molecule attached via 1,6 linkage before the branch point to which the
cycle starts again with the glycogen phosphorylase removing linear portions of the chain and so
on until the glycogen molecule is completely degraded. (Champe)
In response to low blood glucose glycogenolysis is initiated. First the enzyme glycogen
phosphorylase cleaves the alpha-1,4 glycosidic bonds of the linear portions of the chain of
glycogen. This enzyme stops when there are four glucose units left before a branching point. The
enzyme Alpha-1, 4-glucosidase (lysosomal enzyme) is another enzyme that cleaves the alpha-1,
4-glycosyidc bonds until there are four glucose units left in that chain before the branch point.
(Champe)
The remaining branched chain of glycogen after the action of glycogen phosphorylase is
called the limit dextrin. Next, the enzyme glucosyl (4:4) transferase removes 3 of the four
remaining glucose units before the branch point and adds them to the remaining linear chain via
a 1,4 linkage. Then the enzyme amylo-alpha-(1,6)-glucosidase cleaves the one remaining glucose
molecule attached via 1,6 linkage before the branch point to which the cycle starts again with the
glycogen phosphorylase removing linear portions of the chain and so on until the glycogen
molecule is completely degraded. (Champe) [Figure 2]
The products of glycogenolysis are Glucose-1-phosphate and glucose. Glucose-1phosphate is converted to glucose -6-phosphate by phosphoglucomutase. In the liver Glucose-6
po4 is converted to glucose by glucose-6-phophotase and then released into the blood. In skeletal
muscle Glucose-6-po4 is converted to glucose which is used for energy in the form of ATP from
glycolysis.(Murray)
Regulation of Glycogen synthesis and degradation in the body occurs through allosteric
regulation. This is charachterized by the inhibition of enzyme pathways by changing the shape of
a molecule so that it cannot work or activation of a protein to make it work.
Glycogenesis will be initiated when an increased concentration of glucose 6-PO4 is in the
cytosol of the cell. The enzyme Glycogen synthase is allosterically activated via positive
feedback. This causes the enzyme to synthesize glycogen via pathway mentioned above.
With increased concentration of glucose, glucose 6-PO4, and ATP the enzyme glycogen
phosphorylase is inhibited via negative feedback which stops the degradation of glycogen.
(Champe)

Glycogen degradation
In order to break down glycogen in a particular cell the glycogen synthesis pathway must
be inhibited. This inhibition is carried out by cAMP pathway/ Adenylate cyclase pathway.
In response to hormone such as glucagon attaching to it the membrane receptor couples
with the G-protein in the membrane and activates adenylate cyclase enzyme in the membrane.
When activated the enzyme catalyzes the reaction of ATP to form 3,5, Adenosine
monophosphate (cAMP). CAMP then activates a protein kinase which then phosphorylates a
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particular protein substrate in the particular pathway that is occurring. This phosphorylated
protein can then act on other substrates. (Champe)
Another process that uses the cAMP pathway is the inhibition of glycogen synthesis. In
response to glucagon, epinephrine, or low levels of energy glycogen synthesis will to be stopped.
Glucagon or epinephrine activates adenylate cyclase and eventually the cAMP activates a kinase
that inactivates glycogen synthase by phosphorylating it. This inactivated enzyme is now
referred to as Glycogen synthase b. In the phosphorylated form the glycogen synthase b cannot
synthesize more glycogen. (Champe)
Activation of Glycogen degradation is also carried out by cAMP pathway by the binding
of glucagon or epinephrine. Activated cAMP dependent kinase phosphorylates and activates
phosphorylase kinase. Phosphorylase kinase then phosphorylates the enzyme glycogen
phosphorylase b to glycogen phosphorylase a which starts hydrolyzing glycogen. (Champe)

GSD
The first known diagnosis of GSD occurred in 1928 by the physicians Snappes and Van
Crefald. The case involved was a 7 year old presenting with hepatomegaly or liver tumor and the
patient had a very low fasting glucose yet very high acetone and beta-hydroxybuterate in the
urine. After various tests the term “insufficient mobilization of glycogen” was used and the
disease was defined as a debranching enzyme deficiency. Later, this disease was termed GSD III
or Cori’s disease. Over the next few years more cases of GSD were found by various physicians
and chemists that found increased amounts of glycogen in patients’ organs. (Fernandes)
There are more than 14 known glycogen storage diseases. All of these diseases are
genetic and characterized by an abnormal type or quantity of glycogen in tissues, usually caused
by a missing or defunct enzyme in the pathway. Nearly all of the proteins involved in
glycogenolysis and glycogenesis have been the cause of a particular GSD. The defunct or
missing enzyme can affect the liver function or muscle function or both. The diseases are
diagnosed acc. to types of symptoms that are evident in the patient. (Chen).
Glycogen storage diseases have three general groups hepatic, myopathic and
miscellaneous. Clinically, the diseases are numbered but only the first through seventh are
traditionally used; the others are described according to enzyme affected (Harrsisons).
Hepatic types are diseases that are grouped acc. to their hepatic hypoglycemic
pathophysiology in that those diseases that affect the liver affect sugar levels too because the
liver is mainly responsible for carbohydrate metabolism (Chen). These are Von Gierke’s disease
(Type I) a glucose-6-phosphotase deficiency affects liver, kidney and intestine because of
increased glycogen storage which causes severe hypoglycemia, fatty liver and
hyperlacticacidemia, Cori’s Disease (Type III) which is a debranching enzyme deficiency
causing accumulation of branched polysaccharide with symptoms such as hepatomegaly,
hypoglycemia and hypotonia and Hers’ disease (Type VI) which also has high liver glycogen
content and hypoglycemia. Others include Andersen’s disease (Type IV) which is caused by a
lack of branching enzyme as well as Type IX which is caused by a phosphorylase kinase
deficiency. These diseases have characteristic symptoms of expected liver and sugar diseases
such as hypoglycemia, hepatomegaly (Chen)
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The myopathic type is a group of muscle-energy pathophysiology related diseases. These
diseases are McArdle’s disease (Type V) a skeletal` muscle glycogen phosphorylase deficiency
with symptoms such as myglobinuria, muscle pain, muscle cramps and muscle enzymes in serum
after exercise., Tarui’s disease (Type VII) which is to type V but also can have symptom of
hemolytic anemia. The miscellaneous group includes of Anderson’s (Type IV) a branching
enzyme deficiency and Pompe’s (Type XI). These are different in that their symptoms and
causes are not specifically related to any group (Chen). There are other GSD’s that are
characterized by deficiencies of cAMP dependent protein kinase or adenlyl cyclase.
The overall frequency of glycogen storage disease in populations of European decent is
around 1 in 23,000 births with types I,II,III,VI, and IX the most common comprising of
approximately 90% of all cases. Inheritance patterns of disease are generally autosomal
recessive. However, there are forms that have been found to show x-linked patterns. (Chen)

GSD Type 2 – Pompe’s

Glycogen storage disease type ll was discovered by Pompe in 1932 when a 7 year old girl
was found with massive accumulation of glycogen in her tissues. The discovery made Pompe the
third physician to discover a GSD. In that same year and in the years to come many more cases
of cardiomegaly, hypotonia and death before the age of 1 were found with physicians reporting
additional symptoms associated. (Hirschorn)
The disease is known as Glycogen storage disease type 2, Pompe’s Disease, acid maltase
deficiency, acid α-glucosidase deficiency or lysosomal enzyme deficiency. Initially the disease
was only referred to as idio cardiomegaly but in 1963 with new biochemical discoveries in cell
biology and metabolic pathways it was termed as a glycogen storage disease (Chen).
Additionally, it was termed a lysosomal storage disease when Hers eventually defined a
lysosomal storage disease as having 1) lysosomal enzyme deficiency 2) deposit build up present
in vacuoles (Chen). The discovery by Pompe also led to the startup of research into lysosomal
storage diseases with over 40 known today.
The lysosome was first discovered by Christian de Duve in 1955 as a membrane bound
vacuole in human cells containing hydrolytic enzymes all active at acid pH (de Duve). These
enzymes he postulated were able to break down macromolecules one of which is glycogen.
(Campell)
Pompe’s disease is caused by a genetic deficiency of the enzyme alpha-1,4-glucosidase
(lysosomal enzyme) which is found in the lysosome and primary and secondary vacuoles of
cells. Normally this enzyme as well as glycogen phosphorylase cleaves the alpha 1,4 glycosidic
bonds of the branched chains of glycogen until there are 4 glucose molecules left before the
branching point where the enzyme glycosyl 4,4 transferase cleaves the glucose molecules until
the branch point. But a deficiency in the lysosomal enzyme will cause a build up in the glycogen
branches because of the inability of glycosyl 4,4 transferase to function on the glycogen. This
leads to a build up of partially branched glycogen in the cell cytoplasm as well as glycogen
accumulation in the primary and secondary vacuoles of the cells. (Chen)
47

A postulated mechanism of action that causes the symptoms of the disease is that the
deficiency of alpha-glucosidase causes a build up in the lysosomes of the cell. After reaching a
capacity as well as with mechanical action of muscle the lysosomes rupture spilling their
contents into the cytosol. (Griffin) An increase in protein breakdown has been seen in various
studies by both radioactive isotope and stable tracers. This breakdown occurs because of the
cells’ low levels of energy which initiates a cellular response by harvesting energy from the
muscle protein and thus the wasting away of muscle and the subsequent symptoms such as
muscle pain and hypotonia as well as respiratory problems are seen. (Bodamer)
The clinical representation of Pompe’s shows a broad range of phenotypes all of them
include myopathy but differ in other symptoms. There are three general groups of GDS 2
infantile onset, juvenile onset and adult onset. The groups differ in their progression
characteristics but all are
characteristically confirmed
by the absence or lack of the
alpha-glucosidase. Yet,
studies have shown that
severities of disease are in
correlation with the lack of
alpha-glucosidase, with
infants and children usually
having the worst forms.
Additionally, symptoms
seem to develop when there
Figure 3 Model Depicting that signs of Pompe’s
is less than 30% enzyme activity and increase in
emerge when enzyme activity is below 30% (van
severity with the lessoning of activity. (van der
der Ploeg, 2008, modified)
Ploeg)

Infantile Onset:
Infantile onset, otherwise known as the classic
Pompe disease is the most common and the most severe of
the three types of GDS2, causing cardio-respiratory death
before the age of two years old. Most frequently it is
reported in infants in the first months of life. Symptoms are
generally severe cardiomegaly and hypotonia as well as
macroglossia and rapid progressive weakness. Upon EKG
testing as well as during autopsy it was found that both of
the ventricles of the heart have increased thickness caused
by the excess glycogen. (Chen) [Figure 4]

Childhood-Juvenile Onset:
The childhood juvenile onset group is characterized
by symptoms occurring after the age of two years old (Chen).

Figure 4 Severe Cardiomegaly in 9 month
old child (Johnson, 2009).
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The symptoms usually present are skeletal muscle involved without any major cardiomegaly.
The disease progresses more slowly than that of the first type and patients usually die of
respiratory failure before thirty years of age. (Chen)

Adult Onset:
Adult onset GSD2 presents as a slowly progressive disease. The disease is usually found
in patients in their mid 20’s to 60’s. In all cases known so far the disease does not cause
cardiomegaly but affects other skeletal muscles as well as the diaphragm. Weakness is usually
first followed by lower back pain and loss of deep tendon reflexes. Other symptoms include
somnolence, orthopnea, exertional dyspnea, and morning headache. (Chen) Death usually occurs
from respiratory failure but being that the disease affects the respiratory muscles death may be
caused by pulmonary hypertension and cardiac failure.
Documented cases of patients that were athletically active, shows that patients can have
completely normal lives before the onset of this disease.

GSD 2b: Danon’s disease
First discovered in 1981 in two boys by Morris J. Dannon, this subtype is characterized
by patients with GSD2 symptoms such as cardiomyopathy with vacuolar storage of glycogen yet,
interestingly, normal alpha-glucosidase activity. Other clinical symptoms are arrhythmias,
mental retardation and a Creatine kinase rise to tenfold in some cases. Yet, the hallmark finding
is that the vacuoles contained autophagy material with glycogen in skeletal and cardiac muscle.
The disease has been shown to be caused by a deficiency of a major lysosomal membrane
glycoprotein called lysosomal-associated membrane protein 2 (LAMP-2) with studies mapping
the deficiency as originating from the X chromosome and showing x-linked heritability patterns.
(Piotrowska-Kownacka)

Genetic causes
The gene that codes for the enzyme alpha-glucosidase is located on chromosome 17
(q21-23) and is designated GAA on the human gene map and has 20 exons, 19 introns and is
approximately 20 kb long. There are over 180 mutations that exist with that number increasing.
The mutations that are occurring are missense, nonsense, splice site mutations, and small
deletions and insertions. However, around half of all the mutations found are due to missense
mutations. (Hirschorn)
In 1990 the gene was first cloned and cDNA strands were isolated. It was found that the
enzyme created from the cDNA showed the same characteristics as the endogenous enzyme.
(Hoefsloot)
Interestingly, carriers of the disease show codominance in that they will have 50%
functioning enzyme. Therefore they will not have symptoms of the disease as mentioned above
that patients with more than 30% functioning enzyme are not affected. (van der Pleug)
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The three clinical manifestations of the disease prompted investigators to conclude that
the various phenotypes of the disease are caused by different locations of the various mutations.
For instance, in 75% of the patients that had the slow progressive type of Pompe’s (which would
include child and adult onset) were found to have the particular chromosomal mutation c.-3213T>G. Yet the other more severe forms were found to have other mutations such as c.1935C>A
and c.2560C>T which are found in patients with no enzyme activity at all. (van der Pleug)
Additionally, researchers found that the symptoms of the other 25% of the patients with the c.32-13T>G mutation showed varying amounts of functional enzyme leading to the possible
theory that there are modulating factors involved such as diet and exercise. (van der Pleug)

Testing:
Being that in all cases of Pompe’s disease there is a deficiency of enzyme prenatal
diagnosis is possible in groups that are at risk. Testing of the chorionic villi cells either cultured
or uncultured during pregnancy with the artificial substrate 4-methlyumbelliferyl-alpha-Dglucopyranoside (4MUG) will give a probable diagnosis for infantile onset GSD2. This testing is
advantageous because it allows for the diagnosis with only 12 weeks into pregnancy and one day
to actually diagnose. (Chen) Additionally, a study in Thailand successfully tested an infant with
electron microscopy of chorionic villi. Also, amniocenteses as well cordocenteses is possible.
(Phupong)
The artificial substrate 4MUG is also used in testing cultured skin fibroblasts. Skin
fibroblasts contain large amounts of enzyme so if there is a deficiency it will be noted in
accordance with strict standards. This test is advantageous in order to be able to use the same
specimen over long periods of time. (van der Plaug)
This same artificial substrate can be used in muscle biopsies. Muscle biopsies can
differentiate between the infantile onset and adult onset.
Additional testing includes the periodic acid Schiff (PAS) which tests for glycogen. The
mechanism occurs through the reaction of periodic acid and glycogen which gives aldehyde
products which then react with the Schiff reagent which gives off a purple color. (Kiernan)

Treatments:
The first study on the treatment of Pompe’s was done in a Japanese lab. They
subsequently showed that they can restore some activity of the acid alpha glucosidase in a mouse
model (Kikuchi). Five years later in 2003 the company Genzyme created cloned enzyme
recombinant human acid alpha glucosidase (rhGAA) from transgenic rabbit milk or CHO cells
and have shown great results. When either of these was given in high doses of 10mg/kg there
was a significant diminishing of glycogen in the cells of skeletal and smooth muscle as well as
heart and other organs. These results made it possible to apply for FDA testing. (Koeberl)
Studies show that there is a critical threshold of about 30% of the average enzyme
activity needed to prevent the symptoms of the disease. Enzyme therapy and replacement are in
order to bring the patient up to the threshold but it seems that diet and exercise might lower this
threshold. (van der Ploeg)
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In 1983 Slonim and coworkers used a high protein diet to cure and raise the muscle
function of a child with GSD 2. (Bodamer) This diet relied on the fact that the cell was utilizing
energy from the breakdown of protein which is discussed above. Since then however, there is
dispute whether such a diet would work, with recent reports showing that only 25% of patients
show slight improvement of muscle function. Yet, even if this diet would work it is hard to get
patients to eat a 30% protein diet. Furthurmore even if the patients can handle such a diet the
patients gain considerable amount of wait which decreases their respiratory function thus
removing any positive reasons for the diet.
A recent study was done on the efficacy of rhGAA type called Myzozyme® in the
treatment of infantile onset. The study showed that the younger the patients were when the
therapy started the better their conditions would be. Infants younger than 6 months showed the
best results with all of the patients surviving past 18 months and 83% ventilator free. On the
other hand the group of infants that was 6-36 months old when the treatment started did not fair
as well. But both groups did show thinning of the cardiac ventricular index, changes in growth
and motor development. This study also established that doses 20 mg/kg cause less adverse
events than 40 mg/kg of the enzyme. (Koeberl)
There are problems with the treatment of the enzyme just like other synthetic protein
therapies. The main problem that impeded the approval of Myzozyme® was the fact that when
patients with no GAA activity were treat4ed with Myzozyme® they developed anti-rhGAA
antibodies with fatal consequences.
Yet a recent study showed the possibility of elimination of the antibodies with strict
immune-modulation therapy and had successful results. Although there are various other
reactions to this drug this therapy greatly increases the chance of survival of many of the patients
even at later stages. (Mendelsohn) This drug is now being prescribed to Pompe’s disease patients
of all ages with approval from the European commission and is in the final stages of FDA
approval.
There has been promising research regarding the neural deficits in Pompe’s patients that
was documented just weeks ago. Researchers found that in comparison to a control group mice
without the GAA gene have significant glycogen accumulation in the cervical spinal cord and
other parts of the CNS. The study also included phrenic nerve monitoring which showed that
mice without the GAA gene had deficient neural output. (DeRuisseau) This led to the conclusion
that medications should be made to affect the nervous system as well as the musculatory system.

Conclusion
GSD 2 is an inherited autosomal recessive disorder that causes various mutations on the
gene that codes for the enzyme acid-alpha glucosidase. The mutation will cause a decrease or
stop in enzyme activity leading to a buildup of glycogen in the lysosomes of the cells. Due to the
accumulation of the glycogen, severe complications such as cardiomegaly, hepatomegaly,
hypotonia and others are seen. However, there is much hope for patients with this disease with
the recent approval of the medication Myzozyme® as well as the continuing research into other
antidotes that is currently underway.
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Role of genetics in prediction of coronary artery disease.
Andrey Yuabov
Introduction:
Coronary arteries disease (CAD) is a leading cause of death in United States and rest of
the world. It mostly involves atherogenic formation within the walls of the coronary arteries,
which in turn restricts the adequate perfusion to the heart muscle. This leads to myocardial
infarction and sudden death. In the past few decades the theories of coronary arteries disease
pathogenesis have changed. The facts reveal that the onset of the disease can develop as early as
childhood. The degree of the disease gradually progresses in stages and it is regarded as a
complex, ongoing inflammatory process that begins with initial endothelial dysfunction. There
are multiple risk factors that directly and indirectly impacts the development and progression of
CAD such as hypercholesterolemia, smoking, hypertension, diabetes, stress , high fat meals, lack
of exercise, alcohol abuse, obesity and recently chronic infections were added to the list as well.
Moreover, we realize now that coronary artery disease runs in the family and there are some risk
factors that can not be altered or controlled such as age, sex and heredity. We know that the firstdegree relatives of people who suffers from coronary artery disease at the early age are at much
greater risk that others. Coronary artery disease is considered to be highly complex
heterogeneous disease that results from blended effect of multiple genes. In recent years,
researchers have identified the involvement of about 400 genes that might contribute to or to
protect against development of disease.(Dzau and Liew 2007). Although, the definite
conformation that even half of those is actually involved is still a long way from determination.
The bigger question arises from all this information. Can we take an individual genomic profile
and translate it into something that’s clinically useful? Rather, than discuss all 400 genes that
have been implicated, this paper will focus on several of the best-understood genes in order to
find their practical application. Among them are disease-causing genes, susceptibility genes and
disease-linked genes. It is important to keep in mind that this situation is rapidly changing and
hopefully in future genetic approaches will shape the practice of medicine in fundamental ways.
Normal structure and physiology
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The heart functions as a pump that delivers blood to the rest of the body. It consists of the
three main layers: endocardium, myocardium and epicardium which surrounds by pericardium.
Just like all other organs it has its own blood supply which delivered via two coronary arteries
that branches of the aorta. The right coronary artery (RCA) lies in the coronary sulcus and
supplies blood to the right ventricle, right
atrium, and some portion of posterior wall of
the
left ventricle as well as sinoatrial (SA) and
atrioventricular (AV) node. The left coronary
artery
(LCA) immediately branches into the left
anterior descending artery (LAD) and the
circumflex artery (Cx). The LAD primarily
supplies blood to the wall of the left ventricle
and
ventricular septum as well as to the anterior
wall
of the right ventricle. The Cx encircles the heart
and
lies in the anterior interventricular sulcus and
supplies blood to left atrium, lateral wall of the
left
ventricle and partially supplies SA node and posterior wall of the left ventricle (Fig 1). Delivery
of blood to myocardium is complicated by compression of intramyocardial vessels during
systole, which results in the retrograde blood flow in coronary arteries during diastole. Therefore,
subendocardial layer of the myocardium is more susceptible to hypoperfusion because
ventricular diastolic pressure opposes the driving pressure for flow. Development of CAD will
further complicate myocardial perfusion.
Coronary arteries consist of three layers: the innermost tunica intima, tunica
media, and the outermost tunica adventitia. The tunica intima forms an inner lining of a artery
and is in direct contact with blood. It is comprised of single layer of squamous epithelial cells,
called endothelium that is embedded in an
extracellular matrix. The internal elastic lamina
Figure 1.coronary circularion
separates the tunica intima from the tunica media
(Fig 2
www.cvphysiology.com/Blood%20
).
Flow/BF001.htm

Figure 1. cross-sectional view of
coronary artery
www.chelationtherapyonline.com/article
s/p169.htm

Endothelial cells secret locally acting chemical mediators that influence the contractile state of
the overlying smooth muscle that play a major role in the control of the vascular tone. These
molecules include vasodilators such as prostacyclin, endothelial-derived relaxing and
hyperpolarizing factors (EDRF), (EDHF). It also produces vasoconstrictor substances, such as
endothelin and prostanoids. In addition, endothelial cells synthesize and secrete heparans and
growth factor that regulates smooth muscle cell proliferation. Endothelium remains healthy by
secreting different substances that prevent it from platelets aggregation or adhesion of other
molecules. The media is relatively thick layer comprised mainly of smooth muscle cells and
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elastic fibers. It’s primary role to control the diameter of the lumen by smooth muscle cell
contraction or relaxation. Tunica externa is the most outer layer and consists of elastic and
collagen fibers. It contains numerous nerve ending and tiny vessels that supply tissue of the cell
wall itself as well as connects the artery to the surrounding tissue. This layer separates from
media by network of elastic fibers, called external elastic lamina.
Pathophysiology of CAD Atherosclerosis is the major cause of CAD. Theories of the
pathophysiology of atherosclerosis underwent big changes over time. Few decades ago it was
looked as mostly disorder of lipid storage, and later it was considered to be disorder of lipid
metabolism. Further, CAD was looked as disease of the smooth muscle proliferation. With the
discovery of inflammatory cells and molecule in plaques led to conclusion that disease might be
inflammatory in nature. Current views on pathogenesis of atherosclerosis are as follows. The
development of an atherosclerotic plaque is a multi step process. The presence of risk factors for
CAD, such as hypercholesterolemia, cigarette smoking, hypertention, diabetes mellitus and shear
stress are associated with endothelial dysfunction. These conditions gradually damage healthy
and smooth lining of endothelium. This is the first step in development of atherosclerosis and it
results in increased permeability of endothelium (fig 3).
Figure (3)
Atherogenesis
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Once the layer is damaged, the excess low density lipoproteins and other cellular waste product
can easily get into the inner layer of an artery wall. While entrapped low density lipoprotein is
progressively accumulates and undergo oxidation. This initiates inflammatory response and
stimulates smooth muscle cells proliferation. In response to invasion, endothelium and smooth
muscle cells release mediators to initiate recruitment of leukocytes, T-cells and monocytes into
the developing lesion. Furthermore, intralesional monocytes become macrophages. They eat and
digest large amounts of surrounding oxidized low density lipoprotein. As of the result of this
process, these lipid filled macrophages are becoming foam cells, due to their foamy appearance.
Together with T cells and monocytes, they form the bulk of “fatty streaks”. ”. The next stage in
development of atherosclerosis is a formation of “intermediate or fibrofatty lesion” which is
more complex in composition. The combination of fatty streaks growth and ongoing
inflammation, stimulate smooth muscle cells to multiply and migrate to an injury site. As these
cells become noncontractile and fibrous they migrate to the top of the atherosclerotic plaque,
forming a cap over it. These lesions might not be immediately harmful and may be viewed as
protective response to injury. As this plaque continues to grow, the coronary arteries gets thicker,
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harder and looses its elasticity. Calcium ions binding to the site of the plaque formation might
contribute to lack of elasticity as well. As plaque expands into the lumen of a coronary artery,
blood flow is greatly reduced through that artery. At this stage physical symptoms such as chest
pains and shortness of breath may occur which associates with angina pectoris. However, it is the
physical disruption of the plaque exhibits an acute coronary event such as myocardial infarction.
The rupture of the plaque usually occurs due to increased pressure in a narrow artery. It might
cause the complete occlusion due to blood clot formation cascade and manifest MI or sudden
death.
Genomic approach to CAD
The biggest challenge for scientists of a new era of genetics is to identify the genes and
gene expression changes that are responsible for pathological process of CAD. Two main
projects: human genome project and international hapmap project provided a crucial data for
genetic analysis in a complex heterogenic disease such as atherosclerosis and coronary artery
disease. To study such as complex diseases, scientists recently have been using two general
categories of study designs such as association studies and linkage studies. In Linkage studies,
the goal is to identify the inheritance of the disease in large families throughout few generations.
It is possible if we are able to identify single nucleotide polymorphism (SNP) on the fragment of
the chromosome that is inherited by family who is affected by a disease but not those who is
disease free. Furthermore in this design, we concentrate on identifying the gene variation of our
interest after narrowing down the section of a chromosome. This methodology is found to be
helpful especially in identifying diseased genes that inherited in a Mendelian fashion. Gene
disease associated study was introduced in 1996. It is designed to identify genetic variation of
available genome in associations with specific trait or disease of interest. Two independent
groups are usually participate in these studies. Those groups are, “cases” which are those
individuals who has been diagnosed with a disease and “control” are those who are similar
people within same parameters that are disease free. After carefully calculated results, if
frequencies of genetic variation are greater in individuals who are affected by a disease then it
said to be associated with a disease. Positive association cannot be interpreted as causation, but
only statistical association for the most part. Both of these methods have their advantages and
disadvantages just like any other studies.
Throughout years of genetic study, molecular biologists have identified several diseasecausing genes for disorders in lipid metabolism. They are directly related to development of
coronary artery disease. In order to understand dyslipidemia disorders, it’s important to
understand the physiology of lipid metabolism. Lipids are hydrophobic and therefore have to be
transported by lipoproteins in blood. Different lipoproteins have variety of integrated and
peripheral apoproteins that perform a different functions such as structural integrity, receptor
binding, and enzyme activation. Lipoproteins are categorized by their density of protein content.
They divide into two major groups high density lipoproteins (HDL) and non-high density
lipoproteins. Non-high density lipoproteins are further subdivided into chylomicrons, very-low
density lipoprotein, intermediate density lipoproteins and low-density lipoproteins. They
transport lipids from sites of absorption or synthesis to sites of their utilization. High-density
lipoproteins are considered as “good cholesterol”. They are responsible for transport of excess
lipids in circulation back to the liver.
For example Apoprotein B mostly found on non-high density lipoprotein and involves
in assembly and packaging of ingested triglycerides and cholesterol into non-high density
lipoproteins. Apoprotein E involves in receptor binding to hepatocytes via (LDL receptor).
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Through this mechanism, liver uptakes the necessary lipid contents from non-high density
lipoprotein. Apoprotein C binds to adipocytes and skeletal muscle cell via lipoprotein lipase,
which acts as the receptor to facilitate lipid absorption.
Disease-causing genes have been identified for disorders in lipid metabolism such as
familial hypercholesterolemia, familial defective Apolipoprotein B, Apolipoprotein A
deficiency, Tangier disease, Autosomal recessive hypercholesterolemia, Sitosterolemia ect.
Familial hypercholesterolemia (LDL)receptor
Familial hypercholesterolemia is an autosomal dominant disease defined by the presence
of mutation in the low-density lipoprotein receptor gene. It characterized by severely elevated
plasma level of low density lipoprotein (Saint-Jore B et al., 2000) Heterozygouse familial
hypercholesterolemia is the most prevalent and affect about 1 in 500 people. Affected
heterozygous individual exhibit plasma cholesterol levels in the range of 300-400 mg/dl.
Clinically, patients develop severe atherosclerosis involving multiple vascular territories but
especially in coronary arteries. This leads to premature coronary atherosclerosis in fourth decade
of life and often requiring bypass surgery early in life. Familial hypercholesterolemia patients
were found to have one copy of mutated low density lipoprotein gene, which normally is located
on chromosome 19p13. A variety of point, deletion and splice mutation have been described.
Effect of this mutation leads to loss of its function. The mutant low density lipoprotein receptor
has reduced affinity for removal of apolipoprotein B and E from the circulation. (Marian
Ali,2000) Because Familial hypercholesterolemia is not only relatively common and associated
with a high risk of early coronary artery disease but is treatable with LDL-C-lowering strategies,
this genetic disorder meets the World Health Organization criteria for systematic screening. It
has been estimated that familial hypercholesterolemia is properly diagnosed in only 15% of
affected Canadians and as many as 30% of the patients do not survive their first myocardial
infarction. Therefore, early detection of the disease has the potential to save life and prevent
morbidities (Yuan et al.,2006)
Apolipoproteins are important components of lipoprotein particles. Current data shows
that measurements of various apoliportroteins may help to predict the risks of coronary artery
disease ( Walldius & Jungner, 2004).Their involvement in synthesis and metabolism of
lipoproteins are gradually being defined. In addition to stabilizing lipoprotein structure, some of
lipoproteins act as ligands to tissue receptors, while others activate or inhibit enzymes involved
in metabolic steps in circulation or tissues.
Apolipoprotein A deficiency.
Apolipoprotein A has two major forms A1 and A2. Apolipoprotein A1 is associated with high
density lipoprotein cholesterol, and may be largely responsible for determining the plasma level
of it. In addition apolipoprotein A1is the ligand for ATP-binding cassette protein and hence is
involved in the docking procedure by which excess cholesterol in peripheral cells is externalized
to high density liporprotein (Walldus & Jungner,2004). Its been reported that deficiency of
apolipoprotein A1and low levels of high density liporprotein cholesterol were significantly
related to an increased risk of cardiac mortality in patients with coronary artery disease(Walldus
& Jungner,2004). Gene coding for apolipoprotein A1is located on the long arm of chromosome
11. Two polymorphism of apolipoprotein A1gene namely G to A substitution at -75bp of
transcription start site and C to T substitution at +83 bp have been implicated in susceptibility to
coronary artery disease and shown to influence plasma lipid levels (Taranjit et al.,2008) Many
studies are controversial about the effect of particular gene polymorphism on pathogenesis of
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atherosclerosis and coronary artery disease, but in combination with other polymorphic variants
may be better predictor of disease risk in future.
Familial Defective Apolipoprotein B
Plasma lipoproteins are important determinants of atherosclerosis. Apolipoprotein B is a
large amphipathic glycoprotein that exists in two forms and plays an important role in lipid
metabolism. Both forms are produced by the same apolipoprotein gene: apolipoprotein b-48,
which is required for chylomicron production in the small intestine and apolipoprotein; b-100,
which is required for very low density lipoprotein production in the liver. In addition,
apolipoprotein b-100 is the ligand for low density lipoprotein-receptor-mediated endocytosis of
low density lipoprotein particles.(Whilfield et al.,2004) Mutation in apolipoprotein b-100 is
characterized by increased plasma low density lipoproteins and very low density lipoprotein
levels and has clinical features of hypercholesterolemia and premature coronary artery
disease(Marian.Ali.2000). Familial defective apolipoprotein b-100 is a second relatively
common cause of severe autosomal dominant hypercholesterolemia (Dzau. 2007). It is relatively
common, with estimated frequency of 1 out of 500 in normal population and clinically not
possible to distinguished from heterozygous familial hypercholesterolemia (Whilfield et
al.,2004). The most common mutation is R3500Q which involves in substitution of a glutamine
for arginine at the position 3500 (Whilfield et al.,2004). Other point mutation, R3500W and
R3500C are rare cause of familial defective apolipoprotein b-100 (Real et al.,2003). Low density
lipoproteins of affected individual will have a 90% decrease in affinity for low density
lipoprotein receptor and low density lipoproteins clearance will be markedly impaired. Therefore
routine screening is feasible and should be performed not only in subjects with clinical
phenotypes but also in asymptomatic subjects with elevated low density lipoprotein
levels.[Ali.2000] Treatment is similar to that of familial hypercholesterolemia with reliance on
statin therapy, which both decrease very low density lipoprotein production and enhances
clearance of very low density lipoprotein remnants[Dzau.2007]
Other mutations of Apolipoprotein b-100 may cause familial hypobetalipoprotenimia,
which is characterized by hypocholesterolemia and resistance to atherosclerosis and coronary
artery disease (Whitfield et al 2004).
Autosomal recessive hypercholesterolemia is caused by mutation in a putative adaptor
receptor protein called ARH, that function in the internalization of low density lipoprotein
receptor and cargo. This recessive disorder is characterized by severe hypercholesterolemia,
xanthomatosis and premature coronary artery disease (Arca et al., 2002). Autosomal recessive
hypercholesterolemia did not associated with the low density lipoprotein receptor or
apoliporpotein b genes and exhibited an autosomal recessive inheritance, with the parents of the
affected subjects having normal low density lipoprotein cholesterol values [Dzau.2007].
Interestingly, the function of low density lipoprotein receptor is near to normal in their cultured
fibroblast but is impaired in lymphocytes, macrophages and hepatocytes. Low density
lipoprotein receptor protein is present in these cells within normal limits but dispersed unevenly
with most of the receptor residing on the plasma membrane, where it binds to low density
lipoprotein but fails to internalize and degrade its cargo [Dzau.2007]. This specific disorder is
rare and prevalent in Sardinia, Italy. Two ARH mutation were present in all 17 unrelated
Sardinians families with ARH: a frameshift mutation (C432insA) in exon 4( ARH1) and
nonsense mutation (C65G->A) in exon 1(ARH2) (Arca et al., 2002) . Screening of the coding
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regions of ARH with similar phenotype in other random parts of the world revealed that only
four out of 40 of them were positive for ARH1 mutation and all happened to be Italian.
Low circulating serum levels of high density lipoprotein cholesterol seem to be a frequent
lipoprotein disorder in coronary artery disease and can be caused by either genetic or lifestyle
factors. Many gene abnormalities can cause this lipid disorder.
Tangier disease is a rare disorder of lipid metabolism, characterized by extremely low
levels of high density lipoprotein cholesterol. It is caused by mutation in the adenosine
triphosphate-binding cassette transporter A1 (ABCA 1), also known as the cholesterol efflux
regulatory protein (Kolovou et al.,2006). ABCA1 is a member of ATP-binding cassette
transporter family. These integral proteins use ATP as a source of energy to transport variety of
molecules including ions, vitamins, lipids, peptides proteins and number of hydrophobic
compounds across intracellular and plasma membranes (Kolovou et al.,2006). Complete loss of
ABCA1 function leads to severely decreased cellular cholesterol efflux and cholesterol ester
accumulation in macrophages and other cells of the reticuloendothelial systems (Rust et
al.,1999). Due to impaired ability to transport cholesterol out of the peripheral cells, it
accumulates in body tissues. Therefore clinically, Tangier disease patients present with
hepatosplenomegaly, enlarged tonsils, neurapathy and most important in our case atherosclerotic
lesions. Studies suggested that carriers of defective adenosine triphosphate–binding cassette
transporter A1 bear a moderately increased risk for coronary artery disease.
Sitosterolemia is a rare autosomal recessive disorder. It characterizes by markedly increased
intestinal absorption of all sterols including cholesterol, shellfish and plant sterols and impaired
resecretion of those sterols into bile. Affected individual have expanded body pools of
cholesterol and very elevated plant-sterol levels. Affected individual will frequently develop
accelerated atherosclerosis and premature coronary artery disease (Lu et al.,2001) In the studies,
it has been mapped that this condition results from over 25 mutation in either ABCG5 or ABCG8
genes which located on chromosome 2 in band 2p21. These genes encode for adenosine
triphosphate-binding cassette transporter protein (ABC) transporters, steroline-1 and steroline -2.
Their functions are to limit intestinal absorption and stimulate excretion of noncholesterol sterols
by liver into bile. Mutation of these transporters predispose to sterol accumulation and early
artherosclerosis. Sitosterolemia can clinically present similar to homozygous familiar
hypercholesterolemia in terms of elevated LDL-cholesterol especially in childhood around 300
mg/dl or 8 mmol/l. Therefore, it a possibility that sitosterolemia is frequently misdiagnosed with
hyperlipidemia.
Although, all mentioned above lipid metabolism disorders are rare, they are high risk
factors and directly related to incidence of coronary artery disease. Studies of these disorders
gave researches a better understanding of lipoprotein and cholesterol metabolism. Whether
hypercholesterolemia is caused by mutation in one gene or cumulative effect of several genes
defects, early diagnosis is essential to start appropriate therapy. Most notable was development
of Statins drugs which is a class of medications that was developed to lower plasma low density
lipoprotein cholesterol levels.
MEF2A
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Recently, the first non-lipid related disease causing gene was identified and proposed to be
responsible for an autosomal dominant form of coronary artery disease (adCAD). However,
when association is detected, it is still difficult to prove direct causality. False positive
association may arise due to differences in ethnicity, age or sex [Dzau, 2007]. Several studies
were performed to identify the role of human myocyte enhancer factor-2A (MEF2A) and its
mutation in early coronary artery disease development .MEF2A is a protein that is coded by
MEF2A gene which is located on chromosome 15q26. The seven-amino acid deletion of the
human transcriptional myocyte enhancer factor-2A was reported to be a functional mutation. It
disrupted nuclear localization of MEF2A, reduced MEF2A-medieted transcription activation. In
addition it abolished synergistic activation by MEF2A and by transcriptional factor GATAbinding protein which involved in cell growth, with which MEF2A interact to regulate the
expression of the downstream target genes, by dominant –negative mechanism (Wang et
al.,2003). One study was dealing with large family with 13 patients who had an autosomal
dominant patterns of CAD. Nine of 13 patients later developed acute myocardial infarction.
Further genome wide association study linked data to chromosome 15q26. MEF2A also
demonstrate its relevance to expression of coronary arteries endothelium (Wang et al.,2003).
Another independent case-control studies was performed from 2003 to 2007 involving 726
individuals in China (Han et al.,2007). The results of that study suggested the disease-causing
relationship between MEF2A and coronary artery disease. In subsequent study, Weng et al who
report sequencing MEF2A in 300 patients with premature coronary artery disease and control,
only 1 CAD patient was reported to have the mutation that wasn’t found in the control group
(Altshuler & Hirschhorn, 2005). Also another study in large Irish population showed no
association between variation in the MEF2A gene and coronary artery disease (Horan et
al.,2006).However, the absence of CAD in a control group wasn’t confirmed by angiography. As
science progresses it is becoming much easier to collect data but it also causes many controversy
in its analysis. MEF2A plays an important role in cardiovascular biology, but its genetic
variation contribution to pathophysiology in CAD should be further validated in order to make it
the criteria for genetic testing for CAD.
Susceptability genes are those that increase or decrease the risk of developing disease and in
combination with environmental factors and other genetic factors may contribute to pathogenesis
of a disease. These genes might have less predictive values for developing a disease, but
contribute a lot to understanding of pathophysiology process.
eNOS gene.
Nitric oxide (NO) is gas and is identified as endothelium derived relaxant factor. NO is
synthesized from substrate L-arginine by endothelial cell nitric oxide synthase (eNOS) which
encoded by nitric oxide synthase 3 gene (NOS3) that is located on 26-exon on chromosome 7.
NO plays a few important roles in healthy endothelium such as regulation of vascular tone in
coronary arteries, prevents leukocytes adhesion and platelets aggregation and inhibits vascular
smooth muscle migration and proliferation. Biochemical and/or physical shear stress damages
endothelium and impairs production of mediator such as nitric oxide. This might lead to
vasoconstriction, loss of elasticity and promote platelets activation. Indirectly decrease in nitric
oxide activity affect conditions such as hypertension and hypercholesterolemia which predispose
to atherosclerosis [Dzau.2007]. Few clinical studies indicated relationship between different
61

eNOS gene polymorphism and atherosclerosis development. The most commonly studied variant
is Glu298Asp which is conversion of glutamate to aspartate at the position 298 that results from
G894T substitution within exon 7. In English study sample Glu298T variance has been reported
to be associated with atherosclerotic coronary arteries. The mechanism is unknown but by
altering mature protein activity can affect enzyme activity and decreased local nitric oxide
synthesis. As a result of case-control study involve Iranian population (Salimi et al., 2006), we
observed that the genotype frequencies differ from allele frequencies significantly between
control and CAD patients. However, controversy brought up by other small studies that do not
support these findings. Therefore the relevance of this data remains unclear. It might be because
of subjects were picked from different ethnicity and genetic background. Further larger studies
are needed in order to prove major effect of Glu298Asp polymorphism on disease development
but for now it can be considered as indirect genetic marker associated with the disease.
TNF-alpha
Tumor necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine that plays a role in
pathogenesis of CAD. It was localized in atherosclerotic plaque in pathological studies.
Macrophage derived TNF-alpha has important pro-inflamatory autocrine and paracrine effect.
Stimulation of the cells by TNF-alpha, activate the cascade of events that lead to upregulation of
various adhetion molecules. Overall contribution of TNF-alpha believed to be activation of
influx of additional inflammatory cells and involvement in endothelial dysfunction (Dzau 2007).
TNF-alpha has two receptors through which it exerts its effect TNFR1 and TNFR2.
Polymorphisms in TNF-alpha and TNF receptor genes are hypothesized to affect secretion of
this cytokine and relate to presence or severity of CAD. To investigate this matter scientist
conducted a study 259 patients with angiographiclly confirmed CAD and control group (Allen et
al., 2001). As a result of the statistical analysis no significant differences were found between
polymorphism frequencies. Another European study was performed to investigate association of
TNF-alpha gene polymorphism and its relationship with CAD via polymerase chain reactionsingle-strand confirmation polymorphism and sequencing (Herrman et al.,1998). Although,
TNF-alpha gene polymorphism have been associated with number of inflammatory diseases it is
unlikely to contribute to development of CAD
Diseased-linked genes are those genes whose expression is linked or connected to the disease but
the cause and effect relationship is not established. They might serve as biomarkers for the
disease. A big chunk of genes were newly identified as disease-linked genes for CAD. The most
studied include intracellular adhesion molecules-2, E-selectine gene, ect. The reason for interest
in studying disease-linked genes is the fact that about half of the patients who are diagnosed with
CAD do not have traditionally established risk factors. Therefore, the search for other
biomarkers was proposed in order to help identify individuals who might be at risk.
Cellular adhesion molecules.
Cell adhesion molecules (CAMs) are transmembrane proteins that involve in binding of cells
with other cells or extracellular matrix. In healthy endothelium, expression of adhesion
molecules is very limited. In diseased coronary artery, transendothelial T-cells and monocytes
migration are mediated by these molecules (figure4) Transendothelial migration.
62

www.medcellbiol.uu.se/.../mp_figure1.jpg

One of
the CAMs category belong to Immunoglobulin superfamily. They are intracellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Animal and human
studies earlier show that overexpression of adhesion molecules and endothelial cell activation
causes accumulation of leukocytes in coronary tunica intima. According to latest reports,
expressions of cellular adhesion molecules is stimulated by cytokins such as interleukin-1,
tumour necrosis factor (TNF) and interferons-gamma (INF) (Ohta et al., 1999) Furthermore, the
increased expression of cellular adhesion molecules in atherosclerosis shows in early stages of
atherosclerotic development which presented by fatty streaks in inner layer of an artery as well
as the latest fibro-fatty lesions. Linkage of levels of ICAM-1 and VCAM-1 to coronary artery
disease that was established by study and can be considered as an independent risk predictor
(Hajilooi et al.,2003).Although, genetic aspect of these molecules remain poorly known, recent
multi-ethnic study was conducted to investigate relationship of 12/ICAM-1 and 7/VCAM-1
single nucleotide polymorphism (SNP) and coronary artery calcium and ICAM-1 SNP and
circulating levels of soluble ICAM-1. It showed no significant association of ICAM-1 and
VCAM-1 and coronary artery calcium in any ethnic groups, but polymorphism in ICAM-1
showed significant association with soluble ICAM-1 levels and was identified as a marker for
atherosclerosis (Bielinski et al ., 2008).
Other family of cell adhesion molecules consists of E-selectin and P-selectin. Both of
them suggested to play an important role in early and advance stages of coronary arthrosclerosis
from earlier double-knockout mouse experiment. P-selectine is important in the transient
attachment of leucocytes to endothelial cells and platelets (Carter et al., 2003). When endothelial
cells get activated via mediators such as histamine and thrombin in inflammatory process, Pselectine translocates from internal to endothelial cell surface. Just like prior mentioned cell
adhesion molecules, P-selectine also contributes to development of atherosclerosis by facilitating
adhesion of leukocytes to injured endothelium and platelets. Soluble P-selectins were found in
plasma in multiple conditions including heart disease. Number of polymorphism has been
identified in gene encoding P-selectin. THR715Pro polymorphism for example was reported to
be associated with myocardial infarction in previous studies. In 2003 the study was performed
that compared levels of soluble P-selectin in 249 individuals with CAD and 252 healthy control
group and investigated the relationship between polymorphism of P-selectin and circulated
soluble P-selectin levels and cardiovascular risk (Carter et al., 2003). It showed that levels of
soluble P-selectin were higher in affected individuals than control group after adjustment for age
sex and smoking status. Moreover, no significant association was found between P-selectin
polymorphism in CAD affected patients and healthy control group. This study suggested that the
relationship between Thr715Pro polymorphism and levels of soluble P-selectins exist but its
mechanism is still unclear.
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E-selectin also involved in adhesion of leukocytes to activated endothelium. Mutation
of E-selectin gene, due to G to T mutation (G98T) in untranslated region of exon 2, was found to
be significantly higher in frequency in patients with CAD than control group and thus suggests
association with premature coronary artery disease (Zheng et al.,2001).Even after adjustment for
other multifactor, mutation of G98T may be an independent risk factor for premature CAD.
Another study was performed in 2006 within Saudi Arab population. It attempted to investigate
amino acid change from serine to arginine at codon 128 (S128R), which corresponds toA>C
nucleotide change at the position 561 (A561C), in the epidermal growth factor-like domain of
the E-selectin gene that was previously implicated in pathogenesis of CAD in few ethnic groups
(Abu-Amero et al., 2006). The frequency of mutation in 128r allele was found to be much higher
in patients with CAD than control group, but lost association with adjustment for other CAD risk
factors. The most recent study that investigated Association of E-selectin gene (S128R)
polymorphism in patients with CAD within Indian population was consisted with previous
findings. It revealed the increased frequency of E-selectin polymorphism in CAD patients but its
interaction with other risk factors showed that in fact the significant determinant of coronary
artery disease were presents of diabetes, hypertension, smoking habit, elevated serum
triglycerides and low HDL level.
The involvement of cell adhesion molecules was established to play an important role in
development of atherosclerosis. Overall studies suggest that neither the measurements of soluble
adhesion molecules, nor screening for their gene polymorphisms cannot be an independent
predictor of CAD. It may only offer some additional marker of atherosclerosis but cannot go
beyond the assessment of conventional coronary artery disease risk factors.
Conclusion:
Throughout last decade significant advances in genetic studies were made which gave us a fair
insight on pathogenesis of coronary artery disease. It no longer viewed as a simply degenerative
disease or gradually accumulating lipid disease. Current views regard CAD as complex disease
that involved in active process of alteration in cell intercommunication and cell signaling. At this
point in time we can only speculate on assumed biological role of genetic polymorphisms that
has been identified in relationship with CAD. Field in genetic studies is promising and expects to
accelerate as future studies will focus on identifying new genetic polymorphism in connection to
CAD. However, at this time coronary artery disease can’t be simply diagnosed through genetic
testing, but can only look for variants that increase the risk of developing it. Prediction of CAD
via genetic polymorphism may eventually lead to clinical utilization, but now only physician can
diagnose the disease based on a medical history, family history, risk factors and the results of
medical tests. Genetic testing can not clearly tell if disease is going to develop or not, but if
certain genetic markers are present, it may help us to modify our estimated risk of developing it.
When considered genetics along with other individual’s information including other risk factors
may help individual to reduce the risks that we can control such as lifestyle, diet and exercise.
Moreover, if clinician knows about increased genetic predispositions, they may stronger
recommend lifestyle changes. In addition, high index of suspicion might result in early
diagnostic application and close monitoring of patient with marked genetic polymorphism by
their doctors. Currently a few of screening tests are available for asymptomatic individuals who
are at risk for premature atherosclerosis and CAD such as computed tomography, ultrasound ect.
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Hopefully in near future genetic studies will lead us to revolutionary changes in further
understanding, ability to diagnose, prevent and treat the wold’s biggest killer.
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Vitamin D3
Aryeh Grossman
Introduction
Vitamin D is the only vitamin that is free. It can be easily obtained from exposure to sunlight and
yet more than 60% of Americans are Vitamin D deficient (Ginde et al., 2009; Bones, Vitamin D,
and Calcium, n.d). The significance of Vitamin D can’t be emphasized enough and is often
overlooked. Some its profound effects are apparent in the prevention of various diseases such as
cancer, multiple sclerosis, and cardiovascular disease et cetera. Many lives can be spared each
year just by taking Vitamin D. From cancer alone, 23,000 deaths can be attributed each year to a
lack of Vitamin D (Grant, 2002; Reichrath, 2008). Vitamin D deficiency in America is an
epidemic that needs to be addressed.
Vitamins:
Vitamins are required for the well being of the human body, in essence in achieving homeostasis.
Vitamins are organic substances (coenzymes) that can’t be synthesized by the human body.
Vitamins are divided into two discrete categories: water-soluble and lipid-soluble vitamins.
Water soluble vitamins can be eliminated easily from the body in the form of urine and sweat.
On the other hand, an excess intake of lipid soluble vitamins can be fatal. They can’t be easily
excreted as a waste, due to their hydrophobic properties. Vitamin D is one such lipid soluble
vitamin that is stored in adipose tissue.
Vitamin D3 Background
Vitamin D is a steroid hormone despite it being classified as a vitamin. The molecular structure
of Vitamin D closely resembles typical steroid hormones, which have the same cyclopentanoperhydrophenanthrene root carbon ring structure. This suggests that Vitamin D reacts similarly to
other steroid hormones. There are various forms of Vitamin D, but the naturally occurring form
is cholecalciferol, also known as Vitamin D3. The primarily and most abundant source of
Vitamin D is obtained during the presence of sunlight. It can also be naturally obtained from
several food sources, however, in minute amounts.
BiochemistryA cholesterol molecule, 7-Dehydrocholesterol functions as a precursor to
Vitamin D. The highest concentrations are found in the epidermis, particularly the stratum basale
and stratum spinosum layers. In conjunction with sunlight, in the form of Ultra-violet B
radiation, cholecalciferol is synthesized. The most effective wavelength is found between the
range of 270-290 nm. This absorption excites the double bonds, allowing the B-ring to open,
thereby making it into a more flexible structure. Once produced, cholecalciferol (D3) the inactive
form of Vitamin D3 is then transported to the liver by the
plasma transport protein, Vitamin D–binding protein
(DBP) or also known as transcalciferin (TC). In the
endoplasmic reticulum of hepatocytes, cholecalciferol is
hydroxylated at the Carbon-25 position to yield 2570
Figure 1. 1α,25-dihydroxycholecalciferol
[1,25-(OH)2D3] also known as Vitamin D 3.
Source: IUPAC. (Dixon, 1982)

hydroxycholecalciferol (Calcidiol) by the enzyme 25-hydroxylase. It is then successively
transported by DBP to the proximal tubules of the kidney where it is catalyzed by the enzyme
1α-hydroxylase. The hydroxyl is placed on Carbon 1 or 24 to yield the following, 1α,25dihydroxycholecalciferol [1,25-(OH)2D3] and 24R,25-dihydroxyvitamin D3 [24,25(OH)2D3]
respectively (Dixon, 1982). Finally, by a means of diffusion (Hollis et al., 2008), DBP transports
both steroids to their target tissues, where 1α,25-dihydroxycholecalciferol or also known as
calcitriol, is considered to be the hormonally active form of Vitamin D3 (Figure 1). The inactive
form 24, 25(OH)2D3 , is chemically degraded and eventually excreted as either calcitroic acid or
as 23-carboxyl derivatives. In comparison to its inactive isomer 24,25(OH)2D3, the affinity of
calcitriol to Vitamin D3 receptor sites is over 1000 times more than to its isomer. (Norman, 1990;
1998; MacDonald & Sutton, 2003)
Vitamin D3 similarly to other steroid hormones, binds to intracellular ligand-dependent
transcription receptors. Being hydrophobic it is easily able to penetrate the phospholipid
membrane of target cells. Once in the cytosol of the cell, Vitamin D3 binds to a receptor protein
known as the Vitamin D receptor (VDR), which prompts a cascade of macromolecular
interactions leading to the transcription of certain genes. Promoted by Vitamin D3 the Vitamin D
receptor forms a heterodimer complex with the retinoid-X receptor (RXR), a category of class II
nuclear receptors. Class II receptors are known as transcription factors which regulate the
expression of specific genes .In contrast to class I receptors, class II receptors are found in the
nucleus of the cell. With the correspondence of Vitamin D3 the active receptor protein complex
enters the nucleus and initiates a series of molecular interactions, where the activation and
suppression of specific modification of genes occurs. The specific sequences of genes that it
seeks are known as the Vitamin D-responsive elements. Finally the transcription of these genes
is executed and an mRNA strand is produced, where it is translated into specific proteins by
ribosomes (Norman, 1998; Campbell & Reece, 2001; Holick, 2004).
Regulation: Parathyroid Hormone
Parathyroid hormone (PTH) is necessarily mentioned here on the basis that it plays a crucial role
in the regulation of Vitamin D3. The rate limiting step of Vitamin D3 production occurs in the
kidney and is accomplished by the enzyme 1α-hydroxylase. The parathyroid hormone plays an
active role in directly either inhibiting or by the activation of the enzyme 1α-hydroxylase, which
in turn produces l,25(OH)2D3. Also to be noted the half-life of Vitamin D3 is only approximately
3-4 hours. Due to its short half life, its production is tightly regulated as a means of conserving it,
where PTH essentially serves as this control point in the production of Vitamin D3 (Bowen, n.d.).
Receptor Sites:
Calcitriol targets a wide range of tissues. Until recently VDR sites for l,25(OH)2D3 were only
known to be located on bones, intestines and in the kidneys. New research formulates that VDR
receptors are localized in cancer cell lines, the pituitary gland, the skin, hematopoietic cells,
leukocytes including T and B lymphocytes, reproductive organs, ß-islet cells of the pancreas, and
nerve cells. This suggests the additional roles and involvement of Vitamin D3 , in the functioning
and regulation of the immune system (Holick, 2004; Norman, 1990).
Roles:
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Vitamin D3 has been recognized for maintaining adequate levels of calcium in the serum.
Additionally, it has been associated with keeping bones strong, as we know drinking milk as a
source of Vitamin D3, has been highly encouraged over the past years by the statement “Got
Milk”. Vitamin D3 has been evident in preventing rickets in children and osteoporosis
(osteomalacia) in adults. Moreover, recent evidence has established that Vitamin D3 has
extraordinary properties that go beyond strong bones, to such an extent that it has been reputed
as a preventive medicine. It is apparent that it functions and is highly involved in the
immunological system. It has been proven to prevent an extensive range of diseases including,
multiple sclerosis, cardiovascular disease, diabetes, and most forms of cancer (Vitamin D
Science, n.d.; Zittermann, 2003).
Calcium
Calcium (Ca2+), a key element required for the human survival. A minor drop in calcium levels
can be fatal and lead to cardiac arrest. Calcium is associated with maintaining and keeping the
strength and rigidity of bones. Additionally, it is also responsible for the propagation of action
potentials across nerve synapses. Release of neurotransmitters (exocytosis) into the synaptic cleft
is prompted by calcium ions, which consecutively are transmitted along and received by adjacent
dendritic cells in the post synaptic region. In addition, calcium plays a pivotal role in muscle
contraction such as of the skeletal and cardiac muscles (Tortora, Grabowski, & Roesch, 1996, p.
125).
One of the essential attributions of Vitamin D3 is for promoting calcium absorption. One way
this is achieved is by the absorption of calcium from the lumen of the small intestine, primarily
in the duodenum and jejunum. Calcitriol activates specific gene factors in DNA that translate into
carrier proteins known as Vitamin D-dependent calcium binding proteins .These act as a vector
for transporting proteins across the small intestine and into the blood. The most commonly
known of these calcium transporters is calbindin (Norman, 1990; Tortora et al., 1996, pp. 525527). Calcium absorption also occurs in the distal convoluted tubule (DCT) of the nephron. In
concert with parathyroid hormone, production of 1,25(OH)2D3 results in changes in gene
expression that eventually results in the re reabsorption of Ca2+in the tubule (Lajeunesse &
Brunette, 1991).
A drop in serum calcium levels (normal reference range is 8.5 - 10.5 mg/dL), induces the
parathyroid gland to secrete parathyroid hormone (PTH) in an attempt to restore normal calcium
levels back to normal. PTH brings about the release of calcium from the bones by osteoclast
formation, thereby reducing bone density. Excess PTH can lead to fragile bones, a condition
known as osteoporosis. However, when Vitamin D is present, calcium is obtained by the
alternative means such discussed above, conserving bone density by leaving bones intact and
strong. Additionally, Vitamin D has been shown to interact with PTH, activating osteoclasts and
subsequently the release of calcium. However, Vitamin D stimulates intestinal calcium uptake
and excess calcium is restored to bones by osteoblast formation. Therefore, this accounts for a
net gain of calcium, strengthening and maintaining the bone matrix (Tortora et al., 1996).
Cellular Differentiation
All cells originate from pluripotent stem cells, as they divide and mature they reach a climax
state, where differentiation isn’t possible anymore. In contrast to differentiated cells, immature
cells proliferate rapidly, as evident in embryos and infants. Alternatively, aging accounts for the
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lack of stem cells, brought about by terminal differentiation (Cell Differentiation, n.d; Oberley et
al., 1980). Being that cancer cells are similar to embryonic tissues, and are relatively
undifferentiated, they have a high growth rate potential (Sell, 2004). Furthermore, stem cells are
present in malignant tumors, this evidently substantiates their similarity in their differentiation
state and growth pattern (Farkas et al., 2009; Kopper & Hajdú, 2004; Tumor Stem Cells, n.d).
Vitamin D3 via gene expression factors induces the differentiation of osteoblasts. Osteoblasts,
derived from osteoprogenitor cells, secrete collagen and other essential organic components
required in bone formation and maintenance. Additionally, many genes are directly involved in
the cell cycle and influence proliferation, differentiation, and apoptosis in distinctively every
cell. This speculates that Vitamin D3 deficiency can consequently result in a low degree or lack of
cellular differentiation (Kadakia et al., 2010; Samuel & Sitrin, 2008; Tortora et al., 1996, p. 144).
Immunology
Vitamin D3 plays an exceptional role in the immune system. Vitamin D deficiency is an
unrecognized epidemic among both children and adults in the United States. Vitamin D
deficiency not only accounts for rickets among children and osteoporosis among adults but is
also highly associated with increased risks for Multiple Sclerosis (MS), malignant cancers,
cardiovascular disease, and both types of diabetes mellitus but primarily type 1 (Holick, 2004).
Multiple Sclerosis
Multiple Sclerosis, also known as MS, is a chronic autoimmune disease that affects the central
nervous system (CNS). The CNS consists of the brain and the spinal cord. On a cellular level,
neurons continuously transmit and receive signals, each being a minute, yet a necessary part of
the intricate CNS orchestration, that culminate in the actions, sensations, thoughts and emotions
that comprise the human experience. Normally, the path over which a nerve signal or action
potential travel is protected by an insulation of fibrous material known as the myelin sheath or
white matter. This is essential for efficient nerve conduction and propagation. In MS, the myelin
sheath is eroded, which diminishes the ability of neurons to properly transmit signals.
It is believed that the loss of myelin is the result of mistaken attack of white blood cells. In MS
something goes awry; white blood cells infiltrate the CNS, cross the blood brain barrier, seek out
and destroy the myelin. As an ongoing inflammation of nerve tissue occurs, nerve signals are
disrupted, leading to an array of symptoms; ranging from numbness or tingling to blindness and
paralysis (Multiple Sclerosis, n.d.).
In MS an unknown trigger activates helper T cells (CD-4), which correspondingly recognize
myelin as an antigen. Once activated, helper T cells reproduce and release cytokines such as
interleukin-2. Subsequently B cells and cytotoxic T cells (CD-8) become stimulated, enabling
them to cross the blood brain barrier. Once in the cerebrospinal fluid (CSF), B-cells produce
immunoglobulins or antibodies that bind to myelin and oligodendracytes (cells of CNS that
synthesis myelin). Cytotoxic T cells and macrophages are involved in the destruction of myelin.
(Hellings, 2008)
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Currently about 350,000 people in the United States and over 2 million people worldwide are
affected by MS
(Dangond, n.d.).
Statistics have revealed
that there is a higher
incidence of MS in
regions where inadequate
sunlight exists. As a
trend, the risk of
developing multiple
sclerosis usually increases
with the distance from the
equator (Figure 2).
Astonishingly, regions
near the equator are risk
free or have a 0 MS risk
coincidence. The risk of
Figure 2. Epidemiology of Multiple Sclerosis: World map showing
acquiring MS increases
that risk (incidence) for MS increases with greater distance from the
dramatically with latitude
equator. Source: Multiple Sclerosis International Federation. (Atlas of
and is inversely related to
MS Database, n.d).
sunlight. For instance, in
Canada 240 out of 100,000 people have MS, compared to a mere of 9 in Mexico (Atlas of MS
Database, n.d.). In the United States, the prevalence rate of MS below the 37th parallel is 57 to
78 out of 100,000 people. On the other hand, above the 37th parallel, the prevalence rate of MS
is 110 to 140 per 100,000 people, approximately twice the rate as below the 37th parallel. An
insufficient level of Vitamin D transpires under low sunlight conditions, which make one more
susceptible to MS (Nursing Home Care, n.d.).
In a case conducted study, a group of researchers at the Harvard School of Public Health
accessed serum samples of more than 7 million military personnel. Two hundred and fifty seven
of them were diagnosed with MS and had blood samples taken prior to diagnoses. Each had their
serum level compared to at least two other control subjects that were disease free. They were
matched on the basis of common characteristics such as age, serum collection date etc. They
were then ranked into five groups based on their Vitamin D levels. Predictability, those with MS
fell disproportionately into the lowest-ranking groups. Those in the highest compared to the
lowest-ranking group, had a lower risk of developing MS by a staggering rate of 62 percent.
(Munger et al., 2006)
Based on a study, pregnant women are encouraged to obtain
Vitamin D. In this study the mothers of approximately
35,000 nurses provided information regarding their diet
during pregnancy. After a span of 16 years, 199 out of these
nurses developed MS. It was concluded that the mothers that
consumed Vitamin D during pregnancy, gave birth to
daughters with a 45 percent less risk of developing MS in
years to come (Langer-Gould et al., 2010). Additionally,
babies born in northern countries during the month of
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Figure 3. Pooled analysis of observed
births in people with multiple sclerosis.
Source: British Medical Journal. (Willer
et al., 2005)

November have shown a decreased risk of developing multiple sclerosis later on in life (Figure
3). This study was based on 42,000 people and those that were born in November had a 19%
decreased risk of developing multiple sclerosis over those that were born in May. Mothers
pregnant during sunny months have higher levels of Vitamin D in their serum, which apparently
is gets passed on to their developing baby (Willer et al., 2005).
MS patients often experience and/or are prone to bone fractures. MS is also associated with a
high frequency of osteoporosis. The bone mass density (BMD) of the lumbar spine and femoral
neck was found to be one to twofold lower in women with MS against controls. Low circulating
levels of Vitamin D that were found in MS patients, can account for this direct relationship.
(Siokaa et al., 2009; Van der Mei et al., 2007; Correale et al., 2009; Nieves et al., 1994)
.Additionally, MS patients with a high Vitamin D level has shown a lesser relapse rate than
controls. A dosage of 15 ng per mL, which is equivalent to 2000 international units (IU) has
been shown to cut the relapse rate by half (Correale et al., 2009; Mowry et al., 2010).
Cancer
In between 1970 to 1994, cancer mortality rates in the US were approximately twice as high in
the northeast compared with the southwest. An
examination of 506 regions found a close inverse
relationship between cancer mortality rates and
levels of sunlight in the form of UV-B radiation.
Annually, 21,700 premature deaths result due to a
lack of Vitamin D. These results were obtained by
comparing UV-B data in various regions and by
using regression analysis based methods (Figure 4).
This study surveyed and concluded that Vitamin D
is associated with the prevention of most forms of
cancers, including breast, colon, ovarian, prostate,
lung, pancreatic, stomach, non-Hodgkin lymphoma, et
cetera (Grant, 2002; Reichrath, 2008).

Figure 4. Annual mortality rates for
breast carcinoma in white females (19701994) versus DNA-weighted ultraviolet
(UV) radiation for July 1992. Source:
American Cancer Society (Grant, 2002)

A four year randomized study conducted by the
Creighton University School of Medicine revealed that
Vitamin D can reduce cancer risks by a dramatic 60 to 77 percent. The subjects were 1,179
randomly selected healthy women over the age of 55. Participants were free of known cancers
for a minimum of ten years prior to entering the study. Each group was either given 1,400-1,500
mg supplemental calcium, 1,400-1,500 mg supplemental calcium plus 1,100 IU of Vitamin D3
(nearly three times the Recommended Daily Amount) or just placebos. Over the course of four
years there was no statistically significant difference in cancer incidence between participants
taking placebos and those just taking calcium supplements. However, those in the Vitamin
D3/Calcium group demonstrated a remarkable 60 percent cancer risk reduction, than to the
placebo group alone.
On the premise that some women entered the study with undiagnosed cancers, the first year was
eliminated from the study. During the last three years, the results became even more apparent in
signifying the effects of Vitamin D3 on Cancer. In those three years alone, the calcium/Vitamin
D3 group exhibited a startling 77 percent cancer-risk reduction. These results were based on the
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notion that calcium intervention had no significant difference in cancer reduction and were
primarily due to the positive effects of Vitamin D3. The significance of this study was that it was
population based and subjects were randomly selected. Additionally, the study had a low dropout
rate of less than 3.5 percent, due to the high level of treatment adherence, which applauds to the
positive effects of Vitamin D3. This provides strong evidence that Vitamin D3 is the most
effective medicine against cancer, far more than any other drug (Lappe, 2007).
There has been some controversy, however, in the role of Vitamin D3 in the prevention of
cancer. In a study conducted between 1995 and 2005, the Women's Health Initiative (WHI)
gathered over 36 thousand participants, making it the largest randomized clinical trial of calcium
and Vitamin D ever done. The subjects were divided into two groups and were administered
twice daily either, 500 mg of calcium plus 200 IU Vitamin D3 or just placebo alone. Participants
were required to make clinical visits annually and answer a series of questions every six months,
in order to determine the effects of the pills. Over an average span of seven years, a total of 322
women were diagnosed with invasive colorectal cancer. In comparison to participants who took
the active Ca-D supplements with those who took placebo pills, there was no substantial
difference in the rate of colorectal cancer diagnoses, prompting evidence that Vitamin D3 may
not play a role in cancer prevention (Wactawski-Wende et al., 2006).
However there are many flaws in this study, considering scientists’ estimate that it may take at
least 10 to 20 years for colorectal cancer to develop and the study was limited to an average of 7
years. Additionally, the WHI based its report on colorectal cancer incidence but failed to account
for the many other predominant forms of cancers. The highly significant inverse relationship
between Vitamin D3 and the risk incident for all cancers was reported in the Creighton study.
Nevertheless, it was observed in the WHI study that the participants with lowest quartile of
serum had an overall colorectal cancer incidence that was 253 percent of the incidence in the
highest quartile. Furthermore, a much lower dose of Vitamin D3 was used in the study than in
the Creighton study. A dose of 400 IU was administered, which is inadequate in promoting the
health benefits of Vitamin D3 to the full potential. It is now generally recommended that 1000 IU
of Vitamin D3 daily is necessary to attain proper levels in order to achieve optimal prevention of
cancer and other crucial benefits such as calcium absorption and bone strength (Holick et al.,
2003). Finally, all the subjects in the study had Vitamin D insufficiency prior to the start of the
trial and also during the trial based on the criterion given above (Holick, 2006).
The best source of evidence that significantly demonstrates that a higher dose of 1000 IU of
Vitamin D3 is advisable for preventing colorectal cancer, besides for other cancers, is based on a
Quantitative meta-analysis pool of data from an extensive range of studies that were conducted
between January 1966 and December 2004. The five studies that were surveyed contained serum
collections from a wide variety of healthy volunteers who were closely monitored for periods
ranging from two to twenty five years. There were a total of 1,448 total participants, 535 in the
pooled analysis and 913 controls. The researches established that 1000 IU of Vitamin D3 is
associated with a 50 percent, or half of a risk reduction, of developing colorectal cancer, rather
than the 400 IU of D3 that was seen in the WHI study. The results were obtained by dividing the
pooled results into quintiles with median values. Odds ratios were calculated by quintile, with the
lowest as the reference group. Based on the odds for each quintile of the pooled data, a dose
response curve was plotted. Data were abstracted and analyzed in 2006. It has also concluded
that public awareness is needed to increase the Vitamin D3 intake of to 1000 IU per day (Holick
et al., 2007; Holick et al., 2005).
76

To validate the effects of Vitamin D3 deficiency and cancer, mice with lacking VDR receptor
sites were assessed. Vitamin D effects are mediated through VDR receptors, a ligand-dependent
transcription factor. In comparison to normal wild type mice, the VDR knockout mice exhibited
accelerated growth and heavier mammary glands. This supported the hypothesis that Vitamin D3
inhibits proliferation and induces differentiation. Additionally, this study demonstrated that
VDR absent mice were more prone and sensitive to mammary tumors that were induced due to a
disruption of Vitamin D3 (Welsh, 2004). To further determine the effects of Vitamin D and
cancer proliferation, two groups of mice were fed different diets. The first group was fed a
Vitamin D deficient diet for three months.
The other was fed the same diet but with
supplemental Vitamin D for the same
duration. The mice were then injected with
MC-26, a colon cancer cell line. The tumors
were measured daily for an interval of
twenty days. The result: the Vitamin D
sufficient mice had forty percent smaller
tumors than the Vitamin D deficient mice. In
the Vitamin D sufficient mice the expression
of the mRNA for the VDR and 1αhydroxylase were measured and found to be
37- and 6-fold higher, respectively, in
Figure 5. MC-26 tumor size in vitamin D–deficient (solid
comparison to the Vitamin D absent mice. These
line) vs. vitamin D–sufficient (dashed line) mice.Source:
results support the notion that Vitamin D3
Journal of Nutrition (Tangpricha et al., 2005)
inhibits the proliferation of cancer (Tangpricha
et al., 2005).
Cell Cycle
Human development and maintenance requires billions of rounds of the cell cycle. The cell cycle
is split into two stages, Interphase and Mitosis, respectively. Interphase
accounts for approximately 95 percent of the cell cycle, making it the
prominent stage in regards to cellular regulation. It consists of a sequence
of three distinct phases in the order of the G1, S, and G2 (Figure 6). Mitosis
is defined as the M phase. Depending on environmental and developmental
signals, cells in the G1 phase may temporarily or permanently cease
division and enter into an arrested phase known as the G0 resting phase
.Highly differentiated cells, such as, nerve cells exist in the G0 state
(Tortora et al., 1996, p. 80) .A mishap in the cell cycle is believed to be an attribution for cancer.
Simultaneously, Vitamin D is believed to be one of the crucial components Figure 6. The cell cycle.
responsible for cellular regulation and thus preventing cellular
Source: University of
Arizona. (The Cell
abnormalities that contribute for cancer.
Cycle, n.d.).

In transition to consecutive
phases, throughout the cell cycle there are several
regulatory checkpoints. A group of protein kinase
molecules known as Cyclin-dependent kinases
(CDK’s) trigger the transition of subsequent phases
in the cell cycle (Figure 7). CDK’s are in an active
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Figure 7. Model illustrating CDK regulation. Source:
Harvard Medical School (Van den Heuvel, 2005).

state when bound to Cyclin proteins and by direct phosphorylation. Cyclin molecules are
degraded as they progress through the cell cycle; in respect to time their concentration varies in a
cyclical fashion. This ensures that cells only proceed up to the subsequent cycle. CDK’s are kept
in an inactive state through association with CDK-inhibitory proteins (CKIs) and by Wee1,
inhibitory phosphorylation molecules. Activation requires ubiquitin-dependent proteolysis of the
CKI, phosphorylation of the CDK by a CDK-activating kinase (CAK), and removal of the
inhibitory phosphates by Cdc25 (cell division cycle) phosphatase.
Interphase consists of several regulatory checkpoints. They ensure proper cell development,
DNA replication and other critical processes that enable a cell to be error free. The G1
checkpoint (G1through S phase) is regulated by CDK-2, -4, and CDK6 proteins, which proper
entry into the S phase. The G2 checkpoint (G2 to mitosis) is regulated by the CDK-1 protein,
which promote M-phase progression. Identical DNA allows the cells to proceed through these
checkpoints. However, the unexpected can occur, damaged DNA are often recognized and
repaired. Nevertheless, unsuccessful repair attempts can result in cellular aptosis. Families of
CDK kinase inhibiters (CKI) include classes of p21, p27, and p57 proteins. Their function is to
inhibit a broad range of CDK’s, including CDK-1, 2, 4, and CDK-6. In breast cancer cells,
Vitamin D3 impeded proliferation by preventing entry into the S-phase. Vitamin D3 was
identified to up-regulate p21 inhibiters through analogues. One such analogue is EB1089, a
derivative of Vitamin D3 with modified side chains. This targets and inactivates CDK-2
complexes, thereby terminating DNA synthesis and cell replication (Jeffrey et al., 1995; Liu et
al., & Freedman, 1996; Jensen et al., 2001).
Sunscreens and Sunlight
People use sunscreen as a protective measure from the sun’s rays. According to evident studies,
sunscreens may do more harm than good. Sunscreens block Vitamin D production, which can
contribute to far greater cancer deaths than it prevents (Dennis, Freedman, & VanBeek, 2003).
Each year less than 1500 people die from skin related cancers while each day, 1500 people die
from other cancers (Cancer Facts & Figures, n.d.; Skin Cancer Facts, n.d.). Sunscreens with an
SPF of 8 or greater block both UVA and UVB rays (Hughes & Talbott, 2007). UVB rays are
necessary to synthesize Vitamin D in the skin. Sun block may prevent skin cancer but at the
same time, can be attributed to other major forms of cancer that are far more fatal.
Sunlight is often associated with promoting skin cancer but it has been demonstrated to the
contrary in a San Diego study. During 1974 to 1984, there were 176 confirmed cases of
melanoma that were identified in active-duty white male personnel enlisted in the US Navy.
Occupations were grouped in three categories based on sunlight exposure, as indoor, outdoor or a
combination of indoor/outdoor. Compared to the U.S. civilian population, those working indoor
had a higher melanoma occurrence of 10.6 per 100,000 people. Those who worked in
occupations that required spending time both indoors and outdoors had the lowest rate, of 7.0 per
100,000 people. Additionally, incidence rates of melanoma were higher on the trunk than on
more common sunlight exposed areas, such as the head and arms. This establishes that moderate
amounts of sunlight can prevent melanoma rather than cause it (Garland et al., 1990).
According to the CDC melanoma has been rising sharply for the last several decades ("Notice to
Readers:," 2000). Yet, concurrently, as year’s progress, less time is spent outdoors. In the
early1900’s more than 75% of the North American population worked outdoors compared to
only 10% by the 1970’s (Genius, 2006). This trend illustrates an inverse relationship between
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sunlight and melanoma. Furthermore, the greatest increase of melanoma occurred after the
introduction of sunscreens. Death rates in the US between the 1950’s and 1990’s doubled in men
and nearly tripled in women (Garland et al., 1992,).
Analytic studies were performed on articles published in between 1966 to 2003 relating to
melanoma and sunscreen use. Odds ratios were pooled across studies by using standard metaanalytic techniques. It was concluded however, that, no correlation was seen between melanoma
and sunscreen use (Dennis, Freedman, & VanBeek, 2003). In between 1978-1992, cancer
mortality rates were analyzed in Spanish provinces. The mortality rates of melanoma and other
forms of cancer were significantly correlated with latitude. This concluded that melanoma occurs
more frequently in northern latitudes versus lower latitude areas (Grant, 2007).
Although sun light has been proven to have positive effects, it has limits too. There is a common
rule that applies to everything; “too much of a good thing is bad”. There should always be a
healthy balance between things. The recommended optimal daily intake of Vitamin D for an
adult is approximately 1000 IU (international units). This can be achieved by spending
approximately, depending on the day, about 15-20 minutes in the sun. Obviously, prolonged
endurance in the sun requires one’s discretion and application of sunscreen may be necessary
(Vitamin D, n.d.).
Toxicity
In healthy individuals, Vitamin D blood levels are normally found in the range of 32 to 70 ng per
mL. Vitamin D is a fat soluble molecule, making elimination difficult. An advantage to sunlight
obtained Vitamin D is that it is automatically regulated by a negative feedback loop. An adequate
threshold level of Vitamin D prompts the shutdown of further synthesis. This makes overdosing
unattainable by regulating Vitamin D levels. However, Vitamin D obtained in supplemental form
can pose a serious threat. Toxicity results from overdosing, which is about over 1,500
micrograms or 10,000 IU, ten times the recommended FDA daily dosage. Symptoms of
overdosing include nausea, poor appetite, constipation, weakness, weight loss, confusion, heart
rhythm abnormalities and Kidney stones.
Conclusion
The enormous positive effects of Vitamin D are vividly apparent. Its functions range from
Calcium absorption to the suppression of tumors. A diet rich in Vitamin D is extremely
encouraged. On the other hand, a deprivation of Vitamin D results in a multitude of
consequences. It is no coincidence that in recent years Vitamin D emerged in the spot light of
research, involving the formulation of numerous exceptional works.
Unfortunately, modern society encourages low levels of Vitamin D. People do not go out often
and when they do are in cars. Pollution obscures some of the sun’s beneficial rays. Furthermore,
spending time in the sun is associated with significant sun block use. Sunlight shouldn’t be
averted; it is a benefactor to humans. As mentioned in the Bible of Genesis, when redemption
will arrive, G-d will use the magnificent powers of the sun to heal the righteous.
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The Peanut Allergy Epidemic
Rivky Sachs

ABSTRACT
Peanut allergy is one of the most predominant food allergies. It accounts for
majority of the highly severe and fatal allergic reactions to food. Peanut allergy is generally
detected early in life and is commonly associated with other atopic disorders such as asthma,
eczema, and rhinitis. The prevalence and pervasiveness of peanut allergies is increasing
worldwide, and most peanut allergic patients have lifelong sensitivities to peanuts (de Leon et al,
2008).
Patients with severe allergies must stringently avoid any contact with peanuts and depend
on intramuscular epinephrine (EpiPen) to counteract the reaction caused by intake of peanuts.
Much research is dedicated to developing new treatments that may be able to induce tolerance in
peanut allergic individuals without adverse side effects. This paper reviews the current
understanding of clinical characteristics, pathogenesis, and hypothetical causes for the rise in
prevalence of peanut allergies. It also discusses genetic risks and environmental effects of peanut
allergy. Furthermore, it presents emergent future therapies and methods to prevent the
development of peanut allergies in infants.
INTODUCTION
Allergy is defined as an adverse immune response to food (Sicherer and Sampson, 2010).
Such responses can be mediated by IgE antibodies aimed at specific allergens, or they can be
triggered by other cellular activities (Wood, 2009). IgE mediated reactions are immediate, and
symptoms can range from acute or chronic atopic reactions to fatal anaphylaxis. Non- IgE
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mediated allergy occurs gradually and is evident by chronic skin conditions and gastrointestinal
discomfort (Eigenmann, 2009). Peanut allergy is an IgE mediated response.
EXPOSURE TO THE FOOD ALLERGEN
Peanut allergens are introduced to the body through one of three particular ways:
ingestion, skin contact, or inhalation of airborne particles. In the most prevalent form of the
allergy, peanuts must be consumed for an allergic reaction to ensue since the allergic reaction is
not frequently activated by skin or air contact with the peanut allergen. Food enters the digestive
system through the mouth and the food allergen is first introduced at the mucosal surface of the
gastrointestinal tract (Burks, 2008).
PATHOGENESIS
At the mucosal surface of the gut, food proteins are digested by specialized epithelial
cells that transfer them to antigen presenting cells such as dendritic cells which then process
them into peptide fragments. These peptide fragments are presented on the cell surface by class
II major histocompatibility complex (MHC) molecules. As the antigen presenting cell presents
the antigen to T helper cells through MHC/T cell receptor interaction it activates the T helper
cells. This process instigates humoral and cellular mediated responses that are associated with
peanut allergy (de Leon et al, 2008).
In peanut allergic individuals, the activation of T helper 2 (TH2) cells causes the
production of cytokines such as interleukins including IL-4, IL-5, IL-9, and IL-13. These
interleukins are released in increased amounts as compared to individuals that are not allergic to
peanuts, thus exciting B cells to synthesize IgE antibodies. These peanut specific IgE antibodies
are attached to mast cells in the gastrointestinal tract mucosa, skin, and respiratory tract mucosa
and to basophils (Burks, 2003, Burks, 2008).
Upon ingestion of peanuts, the peanut proteins bind with the specific IgE antibodies on
mast cells and basophils thereby secreting inflammatory mediators such as histamine. TH2 cells
and mast cells also produce tumour necrosis factor- a (TNF-a), IL-5, and chemokines, which
cause eosiniphils to accumulate at the site inflammation. Eosiniphils stimulate the release of
other inflammatory mediators which lead to clinical symptoms that will immediately develop (de
Leon et al, 2008).
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Allergic reaction to peanut (Burks, 2008)
CLINICAL SYMPTOMS
Clinical symptoms can be triggered by ingesting ten milligrams of peanut protein. The
time it takes for symptoms to develop ranges from seconds up to two hours after ingestion. The
majority of reactions of IgE mediated disorders include skin, respiratory, and gastrointestinal
symptoms. Local symptoms include itching, swelling, nausea, vomiting, cramping, and diarrhea
(Burks, 2008).
Anaphylaxis, a systemic symptom, can often be fatal. The early symptoms of anaphylaxis
include oral and pharyngeal pruritus and chest tightness. Further symptoms of wheezing,
hypotension, arrythema, and unconsciousness can develop into fatal and near fatal reactions (Lee
et al, 2003). Anaphylaxis is a rapidly progressing multiple organ system reaction that can lead to
cardiovascular failure. This reaction is a result of a massive release of mediators such as
histamine (Sicherer and Sampson, 2010).
EPIDEMIOLOGY AND RISING PREVALENCE
Studies done in the United Kingdom and North America show peanut allergy prevalence
rates in children have increased, in fact, almost doubling. Peanut allergy affects more than 1% of
school aged children (Sicherer and Sampson, 2007). Grundy et al did two sequential cohorts in
the Isle of Wight, United Kingdom six years apart. Children at the age of 3 and 4 received skin
prick tests and those with positive results were given oral peanut challenges unless there was an
otherwise convincing history of peanut allergy. The study confirmed an increase in peanut
allergy from .5% to 1.0% between 1989 and 1995.
The same incidence was reported in the U.S. with rates similar to those received in the
previous study. In 1997, Sicherer, Munoz-Furlong, and Sampson performed a population based,
cross-sectional, random telephone survey in the United States using a standardized questionnaire.
In 2003, they conducted a five year follow up study to compare the results of the prevalence
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estimates. The study indicated a doubling in peanut allergy in children from 0.4% in 1997 to
0.8% in 2002.
Kagan and colleagues also confirmed the assumption of increasing prevalence of peanut
allergy using diagnostic testing. They assigned questionnaires regarding peanut ingestion to
parents of children in kindergarten through grade 3 in randomly selected schools in Montreal.
Respondents were grouped as follows: (1) peanut tolerant, (2) never-rarely ingest peanut, (3)
convincing history of peanut allergy, and (4) uncertain history of peanut allergy.
Groups 2, 3, and 4 received peanut skin prick tests (SPTs), and if responses in groups 2
and 4 were positive, measurement of peanut specific IgE was taken. Children in group 3 with a
positive SPT were considered to have peanut allergy without more testing. Children in groups 2
and 4 who had peanut specific IgE levels less than 15kU/L were administered oral peanut
challenges. These techniques ensured that only children who had real peanut allergic symptoms
were considered sensitive. Their estimate of 1.5% proves that the prevalence of peanut allergy
was even higher than what had previously been reported (Kagan et al, 2003).
However, five years later a follow up study was performed using the same methodology
and population to determine whether prevalence was increasing over time. The prevalence
estimate was 1.62%, indicating a .13% difference. They concluded that the prevalence has
remained stable among this population. Furthermore, they refuted the studies conducted by
Grundy et al and Sicherer et al by saying that the increasing prevalence estimates they reported
was a result of environmental changes during the period that they experimented and that
participation rates were lower at follow up, thus leading to an overestimate of prevalence. Also,
they claim that the .4% difference in estimates of the case study done by Sicherer et al is not
statistically significant (Ben Shoshan, et al 2003).
There are numerous problems with this follow up study done in Montreal and the
conclusions drawn from its results. This study was conducted in one small region with low
participation rates, as compared to the survey performed by Sicherer et al which covered the
entire United States with a census of over 13,000 individuals. Therefore, .4% estimate is in
actuality a large percentage of the population.
Moreover, they base their estimates on the assumption that peanut specific IgE levels of
15kU/L or greater indicate a peanut allergy. Consequently, they only presented peanut oral
challenges to children who had positive SPTs with less than 15kU/L peanut specific IgE levels;
even though there is no proof that a positive peanut specific IgE level implies that an individual
does indeed have a peanut allergy. According to recent studies, between 50% and 75% of
patients with specific IgE to food are not allergic to the food (Roberts et al 2005). On the
contrary, in the study done by Grundy et al, all children with positive skin prick tests, not
including those with a history of peanut allergy, underwent oral challenges regardless of their
peanut specific IgE level. They did not rely on peanut specific IgE levels to determine if the child
has a peanut allergy. Due to this and many other incorrect assumptions, this study loses its
credibility. In addition, their criticism and disapproval of other studies is inherently biased and
lacks evidence.
Over the past twenty years there has been a universal increase in children being
diagnosed with this allergy (Grundy et al, 2002). The rise in prevalence of peanut allergies has
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initiated much research in this field. There are numerous new hypotheses and theories to explain
the apparent peanut epidemic.
SPECIFIC PEANUT ALLERGENS
Antigens that involve an IgE response are referred to as allergens, which are the
glycoproteins found in food. Eight peanut allergens have been discovered and are classified as
Ara h 1 to Ara h 8 (Burks 2008). The three major peanut allergens are Ara h 1, Ara h 2, and Ara
h 3. Ara h 1 and Ara h 2 are known to be highly allergenic, because numerous peanut allergic
individuals have serum specific IgE for these allergens.
The classification of Ara h 3 has not yet been identified: one study showed serum IgE
reactivity in 44% of peanut allergic subjects while another found it in 95% of the patients. Ara h
4-7 are not as reactive with IgE in patient sera and have not yet been classified. Ara h 8 is
different than the others as it is established to be a major allergen in Central Europe in
individuals who display a co-allergy to peanut and birch pollen (de Leon et al, 2008).
BIOCHEMICAL PROPERTIES OF PEANUT ALLERGENS
According to Koppelman et al, many peanut allergens have specific physiochemical
properties that display resistance to digestive enzymes and heat processing. Their study proves
that Ara h1 is heat stable, although its structure is changed significantly when heated. The
resistance of some peanut allergens to heat and enzymes may be connected to their ability of
forming stable dimer and trimer complexes. This enables the peanut proteins to reach the
intestinal mucosa intact, thus increasing their allergenicity and effectiveness.

MAILLARD REACTION
A major reaction that happens during the browning or processing of foods is the Maillard
reaction. One of the main chemical modifications that peanut proteins undergo is the Maillard
reaction which reduces sugars and primary amine groups thus increasing the allergic properties
of peanuts. Maleki, Chung, Champagne, and Raufman proved this by conducting an in vitro
model copying the Maillard reaction. Ara h 1 heated in the presence of sugars exhibited
increased allergenicity, while Ara h 1 heated without sugars degraded and was barely
discernible. Roasted peanut extracts were found to bind to IgE serum of allergic individuals at
about 90- fold higher than raw peanuts. The Maillard reaction contributed to this effect. This
study supports the findings of Nordlee et al that roasted peanuts bind IgE at higher levels than
raw peanuts. It also shows that modification of proteins during the roasting process increases the
IgE binding sites and enhances other allergenic properties in peanuts (Maleki et al, 2000).
EFFECTS OF COOKING METHODS ON PEANUT PROTIENS
There is a much lower prevalence of peanut allergy in China than in the United States,
even though there is a higher rate of peanut consumption in China. Peanuts are fried and boiled
in China; whereas they are usually roasted in the U.S. In 2001, Beyer et al conducted a study to
examine whether the method of preparing peanuts could be a contributing factor to the difference
of allergy prevalence between China and the United States. The Chinese-American population
seems to have a similar prevalence of peanut allergy as the general U.S. population, so genes
cannot account for this difference.
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Two kinds of peanuts grown in the United States were roasted, boiled, and fried. Proteins
were examined using SDS-PAGE and immunoblotting. Reactions to the peanuts were compared
by using immunolabeling with sera from 8 individuals with peanut allergy. Frying and boiling
modified the proteins of both types of peanuts in a similar way. The roasted peanuts had more
Ara h1 which resulted in an increase in IgE binding intensity as compared to the boiled and fried
peanuts. Furthermore, in the fried and boiled peanuts there was less IgE binding to Ara h 2 and
Ara h 3 than there was in the roasted peanuts.
Beyer et al concluded that frying and boiling peanuts, as done in China, reduces the
allergenic property of peanuts as compared to the roasting method which is widely used in the
United States. Roasting uses higher temperatures that probably strengthen the allergenicity of
peanut proteins by causing permanent changes in the structure and may account for the
difference in prevalence of peanut allergy in the two countries (Beyer et al, 2001).
Although this study has strong supporting data, the tests performed are statistically
insignificant and do not prove its hypothesis. There were only 8 samples of patient sera taken to
compare the different reactions. This is a very small range with little diversity, and it does not
differentiate between age groups. Recent statistics confirm that there are in fact more children
with peanut allergies in China than what was initially thought (Burks, 2008). This does not
invalidate the studies that show that roasting enhances peanut allergenicity. More information is
needed about the prevalence of peanut allergy to better understand this subject matter.
ARA H 2 FUNCTIONS AS A TRYPSIN INHIBITOR
In their previous study, Maleki et al showed that the allergenicity of peanut proteins is
enhanced due to thermal processing. Because of the increasing prevalence of peanut allergy and
the severity of the symptoms, another study was performed by Maleki and his colleagues to find
out whether any specific functions are associated with the major peanut allergen, Ara h 2, and
whether these functions are affected by processing. Maleki et al conducted a protein domain
homology search to figure out the functions of Ara h 2. Reputed functions were tested via
enzyme assays and protein gel electrophoresis. Afterward, the structural properties of Ara h 2
from purified and roasted peanuts were compared.
According to their results, Ara h 2 purified from peanuts acts as a trypsin (digestive
protein) inhibitor and roasting increases the trypsin inhibitory activity by a 3.6-fold. Ara h 2 was
also found to protect Ara h 1, a second major allergen, from trypsin digestion. This characteristic
was improved in Ara h 2 purified from roasted peanuts.
The data indicates that thermal processing may play a significant role in increased
allergenicity of peanuts. Not only does roasting change the structure and stabilize peanut proteins
as has already been proven, but it also alters its functional properties which further contribute to
its increased allergenicity. Ara h 2 increases its resistance toward and provides Ara h 1 with extra
protection against trypsin digestive enzymes (Maleki et al, 2003).
GENETIC RISK FACTORS OF PEANUT ALLERGY
It is implausible that genetic factors contributed to the increase of peanut allergy in
certain parts of the world over the past decade. Nonetheless, it is probable there are genetic
predisposing factors that contribute to the development of food allergy, just like there are genetic
factors associated with other atopic diseases such as asthma and eczema. More research is
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needed to figure out which genetic polymorphisms are associated with specific allergies (Lack,
2008).
Peanut allergy has been associated with familial inheritance and genetics. Hourihane,
Dean, and Warner calculated rates of other atopic symptoms in people with peanut allergy and
the prevalence of the allergy in their families. They concluded that a child with a peanut allergic
sibling has a 7- fold increase of developing a peanut allergy (Hourihane et al, 1996).
A study was performed by Sicherer et al to determine if genetic factors influence peanut
allergy by comparing the rate of this allergy among monozygotic and dizygotic twins. The
method relies on the fact that monozygotic twins share all of the same genes, while dizygotic
twins share only half of their genes. They found that there was a considerably higher peanut
allergy association among monozygotic twin pairs than there was among dizygotic twin pairs. In
monozygotic twins, a child has a 64.3% chance of developing peanut allergy if his/her twin has
the allergy, while a dizygotic twin has only a 6.8% chance.
This data suggests that specific genes influence the development of peanut allergy in an
individual. However, there are limitations to the results received in Sicherer et al’s study. Firstly,
it was impossible to get a population based sample, because of the low population rate of twins
with peanut allergies. In addition, environmental factors affect gene expression and are also
responsible for the increasing prevalence of peanut allergy.
VITAMIN D HYPTHOSES
The vitamin D hypotheses have been developed to explain the increase of allergies and
asthma, and it involves two opposing studies. One is the vitamin D excess hypothesis which
proposes that increased Vitamin D level results in a higher prevalence of allergies. The vitamin
D deficiency hypothesis argues the opposite. Wjst, the first to work out the vitamin D excess
hypothesis, recognized that in German farming communities there was less vitamin D
supplementation in food and less allergies found in children. The theory was further advanced
when they found an increase in allergies in Bavaria which happened around the same time that
vitamin D supplementations were added to children’s diets to prevent rickets. Milner et al and
Hypponnen et al both performed studies which proved that infants who had vitamin D added to
their diets were at a greater risk for developing food allergies.
Those that support the vitamin D deficiency hypothesis say that people who do not get
enough vitamin D from sunlight have a greater prevalence of allergies. They proved that
countries further from the equator are less exposed to sunlight yet have higher rates of asthma
(Lack, 2008). One intriguing study performed by Camargo et al provides evidence for the
vitamin D deficiency hypothesis. They observed a strong north-south gradient for the
prescription of EpiPens in the United States. In the New England region 8-12 EpiPens per 1000
persons were being distributed, while the southern states had only 3 EpiPen prescriptions per
1000 persons. Their data supports the presumable association between low vitamin D rates and
allergies. There are proofs to substantiate both of these hypotheses, yet the vitamin D
controversy remains unresolved.
ORAL AND NONORAL EXPOSURE TO PEANUT ALLERGEN
Infants can be exposed to peanuts through ingestion or via environmental exposure such
as topical use of peanut derivatives. Other types of exposure can occur in utero or through breast
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milk (de Leon et al, 2007). The exposure route through which sensitization occurs remains
unknown, and there are various schools of thought on this subject (Fox et al, 2009).
PEANUT AVOIDANCE DURING PREGNANCY, LACTATION, AND INFANCY
In order to reduce the prevalence of peanut allergy, the UK health department advised
pregnant or nursing mothers to avoid eating peanut products if they themselves or other
immediate family members of the fetus are atopic (Ewan, 1998). Hourihane et al conducted a
study five years after the UK peanut avoidance advice which showed that the prevalence of
peanut allergy in the UK increased. The authors concluded that the government’s advice showed
no significant influence on the outcome (Hourihane et al, 2007).
Similarly, the American Academy of Pediatrics committee recommended avoiding
peanuts in the infant’s diet during the first three years of life in order to prevent peanut allergy
development (Baker et al, 2000). It was later confirmed that peanut allergy in children doubled
since the recommendation was put into effect (Burks, 2009). However, it still remains tentative
whether peanut avoidance during pregnancy and lactation has a positive, negative or no impact at
all on the prevalence of this allergy in children (Hourihane et al, 2007).
DUAL-ALLERGEN EXPOSURE HYPOTHESIS
Fox et al presented data substantiating a different theory in which low-dose early
environmental exposure increases the probability of developing a peanut allergy as opposed to
maternal consumption of peanuts. Since most children with peanut allergy react on their first oral
exposure to peanut, they hypothesized that cutaneous exposure is the route through which
allergic sensitization occurs. In a previous study, they showed that topical exposure to creams
containing peanut oil was a risk factor for the development of peanut allergy. Almost 91% of the
children with peanut allergy were exposed via use of peanut oil in the first six months of life.
Moreover, in households where peanut is consumed a lot, there are other forms of environmental
exposure that can occur such as cutaneous contact or inhalation of the allergen. For example,
there is always remaining peanut allergen on the hands or in the saliva of someone who
consumed peanuts. When an individual ingests peanuts and touches or kisses someone not yet
exposed, it can cause sensitization.
At first, it seems that the results of the study demonstrate a strong association between
increased maternal consumption of peanuts during pregnancy and lactation and children who
develop peanut allergy. This inconsistency was resolved by adjusting for household peanut using
logistic regression. They concluded that maternal consumption is irrelevant, since mothers in
households with high peanut consumption are more probable to eat peanut because of its
accessibility.
One group of children had high levels of environmental exposure and consumption of
peanuts during infancy, yet they were tolerant to peanuts. This data supports the hypothesis that
infant oral exposure to peanuts can induce tolerance and prevent development of peanut allergy
even where there is environmental exposure as well. This study demonstrates that high levels of
environmental exposure due to household consumption increases cutaneous sensitization to
peanuts. It also refutes the original hypothesis that peanut consumption during pregnancy and
lactation causes the development of peanut allergy in infants (Fox et al, 2009).
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This theory is known as the dual-allergen exposure hypothesis. Low-dose early
environmental exposure of peanut is taken up by Langerhan’s cells in the skin which leads to
TH2 responses and release of IgE by B cells resulting in allergic sensitization. On the contrary,
early infant consumption causes TH1 and regulatory T cell responses thereby inducing tolerance.
This hypothesis reveals the connection between the presence of infant eczema and the ensuing
development of food allergy. It also explains the rates of food allergies in different parts of the
world and changes over time (Lack, 2008).

(Lack, 2008)
EARLY CONSUMPTION OF PEANUT
In order to investigate the effect of early consumption of peanut, Du Toit et al, compared
peanut allergy prevalence among Jewish children in the UK and Israel. Israeli children consume
peanut in high quantities early in life, while UK Jewish children avoid it altogether. Nonetheless,
Jewish children in the UK had a peanut allergy prevalence of more than 10-fold higher than in
Israel. Their findings imply that early and frequent high dose peanut consumption may thwart the
development of peanut allergy (Du Toit et al, 2008). Furthermore, studies suggest that people in
African and Asian countries, where the peanut allergy rate is relatively low, consume peanuts
throughout pregnancy and infancy. Conversely, in the U.S., U.K., Australia and Canada peanut
consumption is higher, yet there is a much greater prevalence of peanut allergy. This is due to the
fact that there is a lot of environmental exposure accompanied by avoidance of peanuts during
infancy (Lack, 2008).

Food allergies among allergy clinic patients
Country

Peanut allergy
(%)

Dietary practice recommendations (infant peanut
consumption)
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Country

Peanut allergy
(%)

Dietary practice recommendations (infant peanut
consumption)

United Kingdom (n =
191)

25

Avoidance

United States (n =
300)

69

Avoidance

Israel (n = 992)

2.1

High infant consumption

Philippines (n = 184)

0

High infant consumption
(Lack, 2008)

The results from these studies suggest a possibility that high levels of environmental
exposure without oral exposure can result in peanut allergy, while elevated peanut ingestion can
induce peanut tolerance. Further study is needed to investigate the validity of this hypothesis. It
is extremely difficult to differentiate between the precise effects of maternal consumption and
household peanut exposure. Moreover, there are other factors that can explain the difference in
peanut allergy prevalence between Israel and England.
First, there may be a delayed increase in Israel since the prevalence of 0.17% that Du Toit
et al recorded is a 4- fold increase from what was originally recorded by Dalal et al in 2002.
Additionally, most peanuts in Israel are boiled which decreases its allergic properties as
compared to being roasted which increases its allergenicity. Nonetheless, this promising theory is
being investigated further by the Learning Early About Peanut Allergy study through a
randomized controlled trial to assess whether early peanut consumption in high risk infants will
prevent peanut allergy more effectively than avoidance during infancy (Burks, 2009).

FUTURE THERAPIES
Most of the clinical studies being performed on peanut allergy are devoted to finding an
effective treatment to help patients with severe reactions to peanuts (de Leon et al, 2007). The
standard subcutaneous immunotherapy has been eliminated because it resulted in many adverse
reactions. Immunotherapeutic approaches to food allergy in general, have recently been
categorized as food allergen-specific and food allergen-nonspecific. Presently, there is no cure
for food allergy. The only treatment for peanut allergy is stringent avoidance of all peanut
containing products. The immunotherapeutic approaches discussed below are tentative and
require further research (Sicherer and Sampson, 2007).
SUBLINGUAL AND ORAL IMMUNOTHERAPY
Sublingual immunotherapy (SLIT) and oral immunotherapy (OIT) are both allergen
specific therapeutic approaches. Both these therapies are designed based on the theory of induced
tolerance when an antigen is presented at the oral mucosa/ gut associated lymphoid system. In
SLIT and OIT, patients are introduced to small amounts of the allergen orally and the amount is
increased over time. Although these therapies do provide desensitization for many patients on
therapy, there is no proof that induces tolerance. Furthermore, there are risks of extreme side
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effects and anaphylaxis if the patient stops therapy for 1-3 weeks and then resumes with the same
dosage (Sicherer and Sampso, 2007).
MODIFIED PROTEIN VACCINE
The engineered recombinant protein strategy is an allergen-specific method which
attempts to minimize IgE activation by mutating IgE binding sites. The three major peanut
allergens are separated to identify their allergenic epitopes/ IgE binding sites (Nowak-Wegrzyn
et al, 2009).Then, mutations are made to the peanut allergen gene which makes these sites
nonreactive to IgE. When the mutated peanut allergen is expressed, it will result in
hypoallergenic variants which can be used for immunotherapy (de Leon et al, 2007). This
method is much safer than standard subcutaneous which injected the native protein into the skin.
This approach looks very promising in murine models and human studies are being planned for
further testing (Sicherer et al, 2010).
CHINESE HERBAL MEDICINE
Li and colleagues developed a 9-herb preparation known as Food Allergy Herbal
Formula (FAHF-2), which is an allergen-nonspecific approach that prevents peanut inducedanaphylaxis (Sicherer and Sampson, 2007). In one experiment, peanut allergic mice treated with
FAHF-2 for 7 weeks were challenged 1, 3, or 5 weeks after therapy. They recorded that IgE
levels were particularly reduced by FAHF-2 and remained that way as long as 5 weeks after
therapy was completed. This result seems to be connected to the suppression of TH2 cytokines by
the FAHF-2. The full protection that FAHF-2 demonstrated was replicated in many experiments
and always showed a consistent response. This herbal formula might prove to be a valuable and
harmless treatment for peanut allergy (Srivastava et al, 2005)
ADDITIONAL IMMUNOTHERAPEUTIC METHODS
Other types of food allergen-specific therapies include cytokine-modulated
immunotherapy, immunostimulatory sequence-conjugated protein-modulated immunotherapy,
plasmid DNA-based immunotherapy, and allergen peptide immunotherapy. All these treatments
try to lessen the TH2 response or induce tolerance to a specific food allergen (Burks, 2008). One
study shows that similar proteins found in soybeans can be used for immunotherapy to
desensitize peanut allergic mice (Pons et al, 2004). Another allergen non-specific approach is
anti IgE therapy which does not cure the allergy but rather reduces fatal reactions in patients
(Burks, 2008). The responses to this therapy turned out to be inconsistent, and this method has
been suspended due to safety issues (Nowak-Wegrzyn et al, 2009).
Selected immunotherapeutic strategies:
Therapy

Immune rationale

Benefits

Observations to date

Standard
subcutaneous
immunotherapy
(native allergens)

Antigen presentation Proved for venom and
Primarily avoided for
in nonmucosal site
respiratory allergy,
risk of anaphylaxis
results in TH1 skewing possible benefit (pollen) (eg, peanut)
for oral allergy
syndrome

Sublingual/OIT

Antigen presentation
to mucosal site
provides
desensitization and

Natural foods, reduced
risk of systemic
anaphylaxis compared
with injections

Mounting evidence
for desensitization
and relative safety;
unclear effect on
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Therapy

Immune rationale

Benefits

might induce tolerance
Modified protein
vaccine

Reduced IgE
activation by mutation
of IgE-binding
epitopes

Observations to date
tolerance

A safer form of
Murine models show
immunotherapy
promise, human
compared with injection studies are planned
of native protein

Peptide vaccine
Peptides are less likely No requirement for IgE
(overlapping peptides) to cross-link IgE,
epitope
avoiding mast cell
mapping/mutation
activation

Limited

Conjugation of
immune stimulatory
sequences to allergen
and additional
adjuvant methods

Enhance TH2 response Increased efficacy,
Preclinical studies
by activating innate
possibly improved safety
immune receptors
(using specific
sequences or whole
bacteria)

Plasmid DNAencoded vaccines

Endogenous
Possible 1-dose
production of allergen treatment
might result in
tolerance

Murine models
reveal strain-specific
response

Anti-IgE antibodies

Targeted toward Fc
portion of antibody,
can inactivate IgE with
reduced risk for
activating mast cells

Not food specific Some
response in eosinophilic
gastroenteropathy (pilot
study)

Preliminary study
showed improved
threshold overall but
did not show uniform
protection

Chinese herbal
medicine

Mechanism unknown

Not food specific

Murine models show
efficacy Human
safety studies are
underway

Might allow directed
interruption of
inflammatory processes
without need for food
restriction

Preliminary study
shows benefit for
eosinophilic
esophagitis.

Cytokine/antiTo interrupt
cytokine (eg, anti–IL- inflammatory signals
5)

(Sicherer et al, 2010)
CONCLUSION
It has been proven that peanut allergy is becoming increasingly prevalent and poses a
health threat worldwide, specifically in developed countries. In peanut allergic individuals, the
exposure of peanut allergens via the gut, skin, or air can lead to clinical symptoms ranging from
mild skin conditions to fatal anaphylaxis. Much research has been done to investigate the
immunologic, environmental, and genetic affects on the development of peanut allergy. Studies
94

show that peanut proteins undergo the Maillard reaction during thermal processing, thus
increasing the allergenicity of peanuts. Furthermore, roasting uses elevated temperatures that
strengthen the allergic properties of peanut proteins by causing permanent changes in its
structure. Another study suggests that Ara h 2 purified from peanuts acts as a trypsin inhibitor
and roasting increases the trypsin inhibitory activity.
Some studies propose that genetic factors are linked to the development of peanut allergy,
while the vitamin D hypotheses suggest that either increased or decreased levels of vitamin D
leads to increasing allergy prevalence. Furthermore, it was originally thought that avoidance of
peanuts during pregnancy and lactation can prevent development of peanut allergy in the
fetus/infant. However, this was disproven, and the dual allergen exposure hypothesis, which
states that low-dose early environmental exposure increases the probability of developing a
peanut allergy, is the newest proposition. There are some allergen specific and allergen
nonspecific therapies available to reduce fatal peanut allergic reactions. Research is being done
to provide a therapy that induces tolerance to peanut without adverse side effects.
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